复方苦参全人群不良反应分析

完成时间：2022-12-10

# 一、概述

## 1.数据来源

  本研究监测2014年09月至2016年08月期间国内29家医疗机构中所有使用复方苦参注射液的患者。主要收集了两个监测表信息，分别为复方苦参注射液集中监测观察表（A表），复方苦参注射液不良事件观察表（B表）。根据集中监测观察表（A表）的受试者唯一编号（变量USUBJID）与不良事件观察表（B表）的受试者唯一编号匹配后，得到本研究最终用于分析的数据共30130例。

## 2.数据说明

### 2.1 全人群药品不良反应（ADR）数据集说明

  根据复方苦参注射液研究方案中的研究设计，对于使用复方苦参注射液的全人群（30130例），不良事件与使用复方苦参注射液关联性评估分为肯定有关、很可能有关、可能有关、可能无关、待评价、无法评价6级。然后根据患者信息中回答的评估，将可能有关、很可能有关、肯定有关的关联性评估判定为发生ADR（Adverse Drug Reaction，药品不良反应）；其他关联性评估判定为未发生ADR。针对发生ADR人群（193例216例次）和未发生ADR人群（29937例）进行对比分析。

  全人群药品不良反应发生率为0.64%，发生严重不良反应的患者2例3例次，全人群严重不良反应发生率为0.0066%，发生ADR人群中严重不良反应发生率为1.04%；发生一般不良反应的患者191例213例次，全人群一般不良反应发生率为0.6339%，发生ADR人群中一般不良反应发生率为98.96%。

## 3.统计分析方法

  所有的统计分析检验均采用双侧假设检验。本研究最主要的统计分析是描述统计，连续变量采用中位数（四分位，IQR）表述，并进行Shapiro-Wilk正态性检验及方差齐性检验，在满足正态分布且方差齐的条件下，采用t检验进行组间比较，否则采用Wilcoxon秩和检验进行组间比较，并给出两组差值及其95%CI；分类变量采用频数及百分数表达，并采用卡方检验或Fisher精确概率法进行组间比较。组内前后比较，连续性变量采用配对t检验/符号秩检验，分类变量采用McNemar检验或McNemar-Bowker检验。

# 二、全人群ADR两组对比分析

  针对发生ADR（AdverseDrugReaction，药品不良反应）人群（193例）和未发生ADR人群（29937例）进行对比分析。患者是否发生药品不良反应是根据B表（不良事件记录表）中的不良事件与使用复方苦参注射液关联性评估来进行定义，当关联性评估为“肯定有关”，“很可能有关”，“可能有关”时，判定发生ADR；若关联性评估为“可能无关”，“待评价”与“无法评价”时，判定未发生ADR。

## 1. 中心分布

  本研究共完成复方苦参注射液监测病例数为30130例，分布在29个中心，其中发生ADR最多的前10个中心及相应的ADR例数分别为27(48例)、26(37例)、29(11例)、15(10例)、19(8例)、23(8例)、1(7例)、12(7例)、31(7例)、9(7例)。具体分布情况见表 1。表中第二列和第三列对应的百分比代表某个中心发生ADR和未发生ADR的比例，并按各中心的ADR发生率大小排序，总计列为对应中心人数占总人数的比例。

**表 1: 中心分布表**

| **变量** | **发生ADR (N=193)** | **未发生ADR (N=29937)** | **总计 (N=30130)** |
| --- | --- | --- | --- |
| 医院编号 |  |  |  |
| 2 | 4(6.45%) | 58 ( 93.55% ) | 62 (0.21%) |
| 31 | 7(5.60%) | 118 ( 94.40% ) | 125 (0.41%) |
| 20 | 2(3.51%) | 55 ( 96.49% ) | 57 (0.19%) |
| 16 | 4(2.63%) | 148 ( 97.37% ) | 152 (0.50%) |
| 26 | 37(2.40%) | 1503 ( 97.60% ) | 1540 (5.11%) |
| 1 | 7(2.33%) | 294 ( 97.67% ) | 301 (1.00%) |
| 19 | 8(2.32%) | 337 ( 97.68% ) | 345 (1.15%) |
| 6 | 6(2.18%) | 269 ( 97.82% ) | 275 (0.91%) |
| 29 | 11(1.95%) | 552 ( 98.05% ) | 563 (1.87%) |
| 28 | 4(1.55%) | 254 ( 98.45% ) | 258 (0.86%) |
| 4 | 4(1.38%) | 285 ( 98.62% ) | 289 (0.96%) |
| 13 | 4(1.22%) | 324 ( 98.78% ) | 328 (1.09%) |
| 9 | 7(0.97%) | 714 ( 99.03% ) | 721 (2.39%) |
| 23 | 8(0.91%) | 873 ( 99.09% ) | 881 (2.92%) |
| 27 | 48(0.69%) | 6885 ( 99.31% ) | 6933 (23.01%) |
| 15 | 10(0.50%) | 1998 ( 99.50% ) | 2008 (6.66%) |
| 12 | 7(0.31%) | 2258 ( 99.69% ) | 2265 (7.52%) |
| 7 | 2(0.26%) | 764 ( 99.74% ) | 766 (2.54%) |
| 17 | 6(0.17%) | 3555 ( 99.83% ) | 3561 (11.82%) |
| 14 | 3(0.14%) | 2111 ( 99.86% ) | 2114 (7.02%) |
| 21 | 1(0.13%) | 787 ( 99.87% ) | 788 (2.62%) |
| 18 | 1(0.12%) | 827 ( 99.88% ) | 828 (2.75%) |
| 11 | 1(0.07%) | 1493 ( 99.93% ) | 1494 (4.96%) |
| 25 | 1(0.05%) | 1865 ( 99.95% ) | 1866 (6.19%) |
| 22 | 0(0.00%) | 100 ( 100.00% ) | 100 (0.33%) |
| 24 | 0(0.00%) | 599 ( 100.00% ) | 599 (1.99%) |
| 3 | 0(0.00%) | 388 ( 100.00% ) | 388 (1.29%) |
| 5 | 0(0.00%) | 84 ( 100.00% ) | 84 (0.28%) |
| 8 | 0(0.00%) | 439 ( 100.00% ) | 439 (1.46%) |

## 2. 基本特征

### 2.1 性别

  全人群中发生ADR的患者，性别:男86(44.56%)、女107(55.44%)，未发生ADR的患者，性别:男14753(49.28%)、女15184(50.72%)，两组的分布不具有显著性差异(p=0.191)，详见表 2。注：本节中其余二分类变量统计描述与此结构一致。

**表 2: 性别分布表**

| **变量** | **发生ADR (N=193)** | **未发生ADR (N=29937)** | **总计 (N=30130)** | **检验方法** | **P值** |
| --- | --- | --- | --- | --- | --- |
| 性别 |  |  |  | Pearson's Chi-squared test | 0.191 |
| 男 | 86 (44.56%) | 14753 (49.28%) | 14839 (49.25%) |  |  |
| 女 | 107 (55.44%) | 15184 (50.72%) | 15291 (50.75%) |  |  |
| Missing | 0 | 0 | 0 |  |  |

**横向占比统计**

| **变量** | **发生ADR (N=193)** | **未发生ADR (N=29937)** | **总计 (N=30130)** | **检验方法** | **P值** |
| --- | --- | --- | --- | --- | --- |
| 性别 |  |  |  | Pearson's Chi-squared test | 0.191 |
| 男 | 86(0.58%) | 14753 ( 99.42% ) | 14839 (49.25%) |  |  |
| 女 | 107(0.70%) | 15184 ( 99.30% ) | 15291 (50.75%) |  |  |
| Missing | 0 | 0 | 0 |  |  |

### 2.2 BMI指数

  全人群中中发生ADR的患者，BMI指数:均数(标准差)为453.53(133.86),中位数(上下四分位数)为430.56(352.27,536.67)，未发生ADR的患者，BMI指数:均数(标准差)为451.04(134.49),中位数(上下四分位数)为428.95(353.06,531.25)，两组的分布不具有显著性差异(p=0.852)，详见表 3。注：本节中其余的数值型变量统计描述与此结构一致。

**表 3: BMI指数分布表**

| **变量** | **发生ADR (N=193)** | **未发生ADR (N=29937)** | **总计 (N=30130)** | **检验方法** | **P值** |
| --- | --- | --- | --- | --- | --- |
| BMI指数 |  |  |  | Wilcoxon rank sum tests | 0.852 |
| Mean (SD) | 453.53 (133.86) | 451.04 (134.49) | 451.05 (134.49) |  |  |
| Median (Q1, Q3) | 430.56 (352.27, 536.67) | 428.95 (353.06, 531.25) | 428.95 (353.06, 532.26) |  |  |
| Min - Max | 237.66 - 916.67 | 177.78 - 1081.25 | 177.78 - 1081.25 |  |  |
| Missing | 0 | 55 | 55 |  |  |
| 平均秩 | 15154.611 | 15037.247 | 15038 |  |  |
| 正态性检验P值 | < 0.001 | < 0.001 |  |  |  |

### 2.3 年龄

#### 2.3.1 全人群年龄整体描述

  全人群中中发生ADR的患者，年龄:均数(标准差)为58.90(13.02),中位数(上下四分位数)为60.00(51.00,67.00)，未发生ADR的患者，年龄:均数(标准差)为58.29(12.65),中位数(上下四分位数)为59.00(50.00,67.00)，两组的分布不具有显著性差异(p=0.385)，详见表 4。

**表 4: 总体年龄分布表**

| **变量** | **发生ADR (N=193)** | **未发生ADR (N=29937)** | **总计 (N=30130)** | **检验方法** | **P值** |
| --- | --- | --- | --- | --- | --- |
| 年龄 |  |  |  | Wilcoxon rank sum tests | 0.385 |
| Mean (SD) | 58.90 (13.02) | 58.29 (12.65) | 58.30 (12.65) |  |  |
| Median (Q1, Q3) | 60.00 (51.00, 67.00) | 59.00 (50.00, 67.00) | 59.00 (50.00, 67.00) |  |  |
| Min - Max | 6.00 - 86.00 | 2.00 - 98.00 | 2.00 - 98.00 |  |  |
| Missing | 0 | 312 | 312 |  |  |
| 平均秩 | 15446.096 | 14906.004 | 14909.5 |  |  |
| 正态性检验P值 | 0.002 | < 0.001 |  |  |  |

#### 2.3.2 全人群年龄分层描述

  全人群中发生与未发生ADR两组患者的年龄分布无显著性差异。

**表 5: 分层年龄分布表**

| **变量** | **发生ADR (N=193)** | **未发生ADR (N=29937)** | **总计 (N=30130)** | **检验方法** | **P值** |
| --- | --- | --- | --- | --- | --- |
| 年龄 |  |  |  | Pearson's Chi-squared test | 0.666 |
| <18 | 1 (0.52%) | 62 (0.21%) | 63 (0.21%) |  |  |
| 18-40 | 12 (6.22%) | 2252 (7.60%) | 2264 (7.59%) |  |  |
| 41-65 | 121 (62.69%) | 18778 (63.39%) | 18899 (63.38%) |  |  |
| >65 | 59 (30.57%) | 8533 (28.80%) | 8592 (28.81%) |  |  |
| Missing | 0 | 312 | 312 |  |  |

### 2.4 吸烟、饮酒、体育锻炼情况

  发生不良反应的患者人群存在吸烟、饮酒、体育锻炼情况相关信息记录，此处通过表 6展示发生ADR人群关于这三个特征的描述。

**表 6: 发生ADR人群的吸烟、饮酒、体育锻炼情况描述**

| **变量** | **总计 (N=193)** |
| --- | --- |
| 吸烟情况 |  |
| 是 | 46 (23.83%) |
| 否 | 147 (76.17%) |
| Missing | 0 |
| 饮酒情况 |  |
| 经常 | 11 (5.70%) |
| 偶尔 | 20 (10.36%) |
| 未知 | 154 (79.79%) |
| 已戒 | 8 (4.15%) |
| Missing | 0 |
| 体育锻炼 |  |
| 偶尔 | 148 (76.68%) |
| 无 | 45 (23.32%) |
| Missing | 0 |

### 2.5 心率、收缩压、舒张压

  发生与未发生ADR两组人群的心率、收缩压、舒张压都不存在显著性差异。

**表 7: 发生ADR人群的心率、收缩压、舒张压描述**

| **变量** | **发生ADR (N=193)** | **未发生ADR (N=29937)** | **总计 (N=30130)** | **检验方法** | **P值** |
| --- | --- | --- | --- | --- | --- |
| 心率 |  |  |  | Wilcoxon rank sum tests | 0.530 |
| Mean (SD) | 81.38 (8.69) | 80.84 (8.88) | 80.84 (8.88) |  |  |
| Median (Q1, Q3) | 80.00 (78.00, 84.00) | 80.00 (76.00, 84.00) | 80.00 (76.00, 84.00) |  |  |
| Min - Max | 54.00 - 114.00 | 50.00 - 130.00 | 50.00 - 130.00 |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 平均秩 | 15451.653 | 15063.011 | 15065.5 |  |  |
| 正态性检验P值 | < 0.001 | < 0.001 |  |  |  |
| 收缩压 |  |  |  | Wilcoxon rank sum tests | 0.519 |
| Mean (SD) | 122.09 (13.95) | 122.93 (14.05) | 122.93 (14.05) |  |  |
| Median (Q1, Q3) | 120.00 (111.00, 130.00) | 120.00 (116.00, 130.00) | 120.00 (116.00, 130.00) |  |  |
| Min - Max | 90.00 - 180.00 | 59.00 - 233.00 | 59.00 - 233.00 |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 平均秩 | 14667.117 | 15068.068 | 15065.5 |  |  |
| 正态性检验P值 | < 0.001 | < 0.001 |  |  |  |
| 舒张压 |  |  |  | Wilcoxon rank sum tests | 0.627 |
| Mean (SD) | 77.17 (8.11) | 77.33 (9.05) | 77.33 (9.04) |  |  |
| Median (Q1, Q3) | 78.00 (70.00, 80.00) | 80.00 (70.00, 80.00) | 80.00 (70.00, 80.00) |  |  |
| Min - Max | 58.00 - 100.00 | 30.00 - 137.00 | 30.00 - 137.00 |  |  |
| Missing | 0 | 1 | 1 |  |  |
| 平均秩 | 14765.741 | 15066.929 | 15065 |  |  |
| 正态性检验P值 | 0.001 | < 0.001 |  |  |  |

## 3.省份

  在使用复方苦参注射液的30130例患者中，各省份发生ADR的比例从高到低排列见表 8所示。表中第二列和第三列对应的百分比代表省份发生ADR和未发生ADR的比例，总计列为对应省份人数及占总人数的比例。

**表 8: 省份分布表**

| **变量** | **发生ADR (N=193)** | **未发生ADR (N=29937)** | **总计 (N=30130)** |
| --- | --- | --- | --- |
| 省份 |  |  |  |
| 新疆 | 1(4.17%) | 23 ( 95.83% ) | 24 (0.08%) |
| 山西 | 14(2.38%) | 575 ( 97.62% ) | 589 (1.95%) |
| 天津 | 4(1.74%) | 226 ( 98.26% ) | 230 (0.76%) |
| 四川 | 19(0.92%) | 2036 ( 99.08% ) | 2055 (6.82%) |
| 河南 | 112(0.65%) | 16998 ( 99.35% ) | 17110 (56.79%) |
| 山东 | 19(0.48%) | 3907 ( 99.52% ) | 3926 (13.03%) |
| 河北 | 24(0.40%) | 5931 ( 99.60% ) | 5955 (19.76%) |
| 安徽 | 0(0.00%) | 31 ( 100.00% ) | 31 (0.10%) |
| 北京 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 福建 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 甘肃 | 0(0.00%) | 7 ( 100.00% ) | 7 (0.02%) |
| 广东 | 0(0.00%) | 7 ( 100.00% ) | 7 (0.02%) |
| 广西 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 贵州 | 0(0.00%) | 13 ( 100.00% ) | 13 (0.04%) |
| 海南 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 黑龙江 | 0(0.00%) | 33 ( 100.00% ) | 33 (0.11%) |
| 湖北 | 0(0.00%) | 21 ( 100.00% ) | 21 (0.07%) |
| 湖南 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 吉林 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 江苏 | 0(0.00%) | 6 ( 100.00% ) | 6 (0.02%) |
| 江西 | 0(0.00%) | 12 ( 100.00% ) | 12 (0.04%) |
| 辽宁 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 内蒙古 | 0(0.00%) | 11 ( 100.00% ) | 11 (0.04%) |
| 宁夏 | 0(0.00%) | 4 ( 100.00% ) | 4 (0.01%) |
| 青海 | 0(0.00%) | 5 ( 100.00% ) | 5 (0.02%) |
| 陕西 | 0(0.00%) | 8 ( 100.00% ) | 8 (0.03%) |
| 上海 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 西藏 | 0(0.00%) | 5 ( 100.00% ) | 5 (0.02%) |
| 云南 | 0(0.00%) | 7 ( 100.00% ) | 7 (0.02%) |
| 浙江 | 0(0.00%) | 18 ( 100.00% ) | 18 (0.06%) |
| 重庆 | 0(0.00%) | 36 ( 100.00% ) | 36 (0.12%) |

## 4.就医科室

  使用复方苦参注射液的30130例患者中，就诊科室发生ADR的比例从高到低排列见表 9所示。

**表 9: 科室分布表**

| **变量** | **发生ADR (N=193)** | **未发生ADR (N=29937)** | **总计 (N=30130)** |
| --- | --- | --- | --- |
| 科室 |  |  |  |
| 淋巴综合内科3病区 | 1(100.00%) | 0 ( 0.00% ) | 1 (0.00%) |
| 肝病科 | 2(28.57%) | 5 ( 71.43% ) | 7 (0.02%) |
| 消二 | 1(25.00%) | 3 ( 75.00% ) | 4 (0.01%) |
| 肝病一科 | 2(18.18%) | 9 ( 81.82% ) | 11 (0.04%) |
| 内二 | 1(16.67%) | 5 ( 83.33% ) | 6 (0.02%) |
| 中西医病区 | 1(16.67%) | 5 ( 83.33% ) | 6 (0.02%) |
| 呼吸科 | 4(8.00%) | 46 ( 92.00% ) | 50 (0.17%) |
| 血液科 | 2(7.14%) | 26 ( 92.86% ) | 28 (0.09%) |
| 骨科一 | 1(6.67%) | 14 ( 93.33% ) | 15 (0.05%) |
| 呼吸内科一病区 | 1(5.26%) | 18 ( 94.74% ) | 19 (0.06%) |
| 泌尿外科 | 1(4.35%) | 22 ( 95.65% ) | 23 (0.08%) |
| 肝胆外科 | 1(3.85%) | 25 ( 96.15% ) | 26 (0.09%) |
| 乳五病区 | 6(3.39%) | 171 ( 96.61% ) | 177 (0.59%) |
| 呼吸内科三病区 | 2(3.28%) | 59 ( 96.72% ) | 61 (0.20%) |
| 消化内二 | 1(3.23%) | 30 ( 96.77% ) | 31 (0.10%) |
| 妇科七 | 2(3.12%) | 62 ( 96.88% ) | 64 (0.21%) |
| 肿瘤科二病区 | 2(2.99%) | 65 ( 97.01% ) | 67 (0.22%) |
| 肿瘤三科 | 2(2.82%) | 69 ( 97.18% ) | 71 (0.24%) |
| 介入放疗科 | 1(2.70%) | 36 ( 97.30% ) | 37 (0.12%) |
| 中西二 | 1(2.50%) | 39 ( 97.50% ) | 40 (0.13%) |
| 胸外一科 | 5(2.49%) | 196 ( 97.51% ) | 201 (0.67%) |
| 消化科 | 1(2.44%) | 40 ( 97.56% ) | 41 (0.14%) |
| 肿瘤科一病区 | 2(2.44%) | 80 ( 97.56% ) | 82 (0.27%) |
| 乳五 | 9(2.43%) | 361 ( 97.57% ) | 370 (1.23%) |
| 呼吸二科 | 1(2.22%) | 44 ( 97.78% ) | 45 (0.15%) |
| 普外五B | 1(2.22%) | 44 ( 97.78% ) | 45 (0.15%) |
| 妇产科 | 1(2.08%) | 47 ( 97.92% ) | 48 (0.16%) |
| 淋巴综合内科 | 5(2.05%) | 239 ( 97.95% ) | 244 (0.81%) |
| 普外二病区（肿瘤科） | 1(1.89%) | 52 ( 98.11% ) | 53 (0.18%) |
| 中西五病区 | 1(1.82%) | 54 ( 98.18% ) | 55 (0.18%) |
| 外六 | 2(1.79%) | 110 ( 98.21% ) | 112 (0.37%) |
| 肿瘤科 | 46(1.73%) | 2613 ( 98.27% ) | 2659 (8.83%) |
| 妇科六 | 1(1.64%) | 60 ( 98.36% ) | 61 (0.20%) |
| 呼吸内科三 | 2(1.54%) | 128 ( 98.46% ) | 130 (0.43%) |
| 肿瘤二科 | 2(1.52%) | 130 ( 98.48% ) | 132 (0.44%) |
| 肿瘤 | 1(1.43%) | 69 ( 98.57% ) | 70 (0.23%) |
| 乳腺外科 | 8(1.42%) | 557 ( 98.58% ) | 565 (1.88%) |
| 胸外二科 | 1(1.39%) | 71 ( 98.61% ) | 72 (0.24%) |
| 血液内科 | 5(1.38%) | 358 ( 98.62% ) | 363 (1.20%) |
| 呼吸内科二 | 3(1.38%) | 215 ( 98.62% ) | 218 (0.72%) |
| 新乡医学院第一附属医院肿瘤科 | 1(1.33%) | 74 ( 98.67% ) | 75 (0.25%) |
| 消化内科二 | 3(1.19%) | 250 ( 98.81% ) | 253 (0.84%) |
| 生物治疗二 | 1(1.18%) | 84 ( 98.82% ) | 85 (0.28%) |
| 中西医结合科 | 4(1.16%) | 341 ( 98.84% ) | 345 (1.15%) |
| 肿瘤一科 | 2(1.12%) | 176 ( 98.88% ) | 178 (0.59%) |
| 淋巴综合内科病区 | 1(1.11%) | 89 ( 98.89% ) | 90 (0.30%) |
| 介入科 | 2(1.09%) | 182 ( 98.91% ) | 184 (0.61%) |
| 肿瘤内科 | 15(1.03%) | 1444 ( 98.97% ) | 1459 (4.84%) |
| 中西五 | 1(0.93%) | 107 ( 99.07% ) | 108 (0.36%) |
| 中西六病区 | 1(0.81%) | 123 ( 99.19% ) | 124 (0.41%) |
| 消化内科 | 2(0.74%) | 269 ( 99.26% ) | 271 (0.90%) |
| 呼吸内科二病区 | 1(0.72%) | 137 ( 99.28% ) | 138 (0.46%) |
| 放疗科 | 5(0.61%) | 821 ( 99.39% ) | 826 (2.74%) |
| 消化内科二病区 | 1(0.60%) | 167 ( 99.40% ) | 168 (0.56%) |
| 肿瘤放疗科 | 2(0.59%) | 336 ( 99.41% ) | 338 (1.12%) |
| 河南省肿瘤医院 | 1(0.50%) | 201 ( 99.50% ) | 202 (0.67%) |
| 呼吸内科 | 1(0.45%) | 220 ( 99.55% ) | 221 (0.73%) |
| 胸外科 | 3(0.44%) | 680 ( 99.56% ) | 683 (2.27%) |
| 肿内二 | 2(0.34%) | 594 ( 99.66% ) | 596 (1.98%) |
| 放疗三科 | 4(0.32%) | 1264 ( 99.68% ) | 1268 (4.21%) |
| 普外六科 | 1(0.31%) | 322 ( 99.69% ) | 323 (1.07%) |
| 放疗二科 | 2(0.24%) | 830 ( 99.76% ) | 832 (2.76%) |
| 放疗一科 | 1(0.16%) | 625 ( 99.84% ) | 626 (2.08%) |
| 新乡市中心医院肿瘤内科二 | 3(0.14%) | 2111 ( 99.86% ) | 2114 (7.02%) |
| f放疗一 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| ICU | 0(0.00%) | 4 ( 100.00% ) | 4 (0.01%) |
| LGMI | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| LX二 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| RICU | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| X消化内科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 癌痛科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 鼻科 | 0(0.00%) | 4 ( 100.00% ) | 4 (0.01%) |
| 鼻科一 | 0(0.00%) | 12 ( 100.00% ) | 12 (0.04%) |
| 肠二病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肠外科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肠一病区 | 0(0.00%) | 4 ( 100.00% ) | 4 (0.01%) |
| 成都市第二人民医院 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 成都市第二人民医院呼吸内科一病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 成都市第二人民医院介入科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 成都市第二人民医院消化内科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 成都市第二人民医院胸心外科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 成都市第二人民医院肿瘤科 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 成都市建设北路2段 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 创伤骨科 | 0(0.00%) | 13 ( 100.00% ) | 13 (0.04%) |
| 创伤外科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 耳鼻喉 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 耳鼻喉保健科 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 耳鼻喉科 | 0(0.00%) | 4 ( 100.00% ) | 4 (0.01%) |
| 耳鼻喉头颈外科 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 耳鼻咽喉科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 耳鼻咽喉头颈外科 | 0(0.00%) | 5 ( 100.00% ) | 5 (0.02%) |
| 耳科 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 防一科 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 放二 | 0(0.00%) | 6 ( 100.00% ) | 6 (0.02%) |
| 放二科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 放疗 | 0(0.00%) | 29 ( 100.00% ) | 29 (0.10%) |
| 放疗二 | 0(0.00%) | 17 ( 100.00% ) | 17 (0.06%) |
| 放疗二病区 | 0(0.00%) | 4 ( 100.00% ) | 4 (0.01%) |
| 放疗法 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 放疗科二病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 放疗三 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 放疗室 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 放疗四科 | 0(0.00%) | 383 ( 100.00% ) | 383 (1.27%) |
| 放疗五 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 放疗一 | 0(0.00%) | 31 ( 100.00% ) | 31 (0.10%) |
| 放疗一病区 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 放疗综合病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 放射科 | 0(0.00%) | 6 ( 100.00% ) | 6 (0.02%) |
| 放一 | 0(0.00%) | 11 ( 100.00% ) | 11 (0.04%) |
| 放一科 | 0(0.00%) | 57 ( 100.00% ) | 57 (0.19%) |
| 肺癌综合治疗科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肺瘤内科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肺内一 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肺一科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 风湿免疫科 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 妇科 | 0(0.00%) | 30 ( 100.00% ) | 30 (0.10%) |
| 妇科3病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 妇科4 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 妇科二 | 0(0.00%) | 5 ( 100.00% ) | 5 (0.02%) |
| 妇科二病区 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 妇科六病区 | 0(0.00%) | 39 ( 100.00% ) | 39 (0.13%) |
| 妇科七病区 | 0(0.00%) | 34 ( 100.00% ) | 34 (0.11%) |
| 妇科三 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 妇科三病区 | 0(0.00%) | 6 ( 100.00% ) | 6 (0.02%) |
| 妇科五 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 妇科五病区 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 妇科一 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 妇科一病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 妇瘤科 | 0(0.00%) | 5 ( 100.00% ) | 5 (0.02%) |
| 妇六 | 0(0.00%) | 7 ( 100.00% ) | 7 (0.02%) |
| 妇七 | 0(0.00%) | 12 ( 100.00% ) | 12 (0.04%) |
| 妇七科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 妇三 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 腹腔镜内分泌 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 腹腔镜内分泌科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 腹腔镜内分泌外科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肝癌综合科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肝病 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 肝病二 | 0(0.00%) | 49 ( 100.00% ) | 49 (0.16%) |
| 肝病二区 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 肝病科二病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肝病科一病区 | 0(0.00%) | 4 ( 100.00% ) | 4 (0.01%) |
| 肝病外科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肝肠外科 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 肝胆科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肝胆外科病区 | 0(0.00%) | 15 ( 100.00% ) | 15 (0.05%) |
| 肝胆胰二 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 肝胆胰二病区 | 0(0.00%) | 4 ( 100.00% ) | 4 (0.01%) |
| 肝胆胰三 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 肝胆胰三病区 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 肝胆胰一病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肝瘤内科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肝脏外科 | 0(0.00%) | 83 ( 100.00% ) | 83 (0.28%) |
| 感染科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 感染性疾病 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 感染性疾病科 | 0(0.00%) | 29 ( 100.00% ) | 29 (0.10%) |
| 干部病房二病区 | 0(0.00%) | 4 ( 100.00% ) | 4 (0.01%) |
| 干部病房五病区 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 干部病房一病区 | 0(0.00%) | 6 ( 100.00% ) | 6 (0.02%) |
| 干二 | 0(0.00%) | 4 ( 100.00% ) | 4 (0.01%) |
| 干一 | 0(0.00%) | 5 ( 100.00% ) | 5 (0.02%) |
| 干一病区 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 肛肠外科 | 0(0.00%) | 86 ( 100.00% ) | 86 (0.29%) |
| 骨病二病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 骨二 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 骨科 | 0(0.00%) | 7 ( 100.00% ) | 7 (0.02%) |
| 骨科二 | 0(0.00%) | 31 ( 100.00% ) | 31 (0.10%) |
| 骨科二病区 | 0(0.00%) | 13 ( 100.00% ) | 13 (0.04%) |
| 骨科三 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 骨科一病区 | 0(0.00%) | 14 ( 100.00% ) | 14 (0.05%) |
| 骨科一区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 骨三科 | 0(0.00%) | 8 ( 100.00% ) | 8 (0.03%) |
| 骨外 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 骨外科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 骨一 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 骨一科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 邯郸市医院放疗三科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 邯郸市中西医院放疗一科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 邯郸市中心医院放疗二科 | 0(0.00%) | 120 ( 100.00% ) | 120 (0.40%) |
| 邯郸市中心医院放疗科 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 邯郸市中心医院放疗三科 | 0(0.00%) | 207 ( 100.00% ) | 207 (0.69%) |
| 邯郸市中心医院放疗四科 | 0(0.00%) | 63 ( 100.00% ) | 63 (0.21%) |
| 邯郸市中心医院放疗一科 | 0(0.00%) | 93 ( 100.00% ) | 93 (0.31%) |
| 邯郸市中心医院之放疗四科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 邯郸市中医医院放疗一科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 河北省邯郸市放疗一科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 河科大一附院肿内二 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 河南大学淮河医院放疗科 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 河南大学淮河医院干一 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 河南大学淮河医院内二（二） | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 河南大学淮河医院内四 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 河南大学淮河医院中医科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 河南大学淮河医院肿瘤内科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 河南科技大学第一附属医院肿瘤放疗二病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 河南科技大学第一附属医院肿瘤一科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 河南科技大学第一附属医院肿瘤一区 | 0(0.00%) | 6 ( 100.00% ) | 6 (0.02%) |
| 河南科技大学第一附属医院肿内二 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 河南省滦县三川镇小红村 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 河南省肿瘤医院呼吸内科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 河南省肿瘤医院呼吸内科三 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 河南省肿瘤医院介入一病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 河南省肿瘤医院乳七病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 河南省肿瘤医院乳一 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 河南省肿瘤医院消化内科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 河南省肿瘤医院消化内科二 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 河南省肿瘤医院胸一 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 河南省肿瘤医院中西五 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 呼二 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 呼放二 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 呼内二 | 0(0.00%) | 34 ( 100.00% ) | 34 (0.11%) |
| 呼内三 | 0(0.00%) | 17 ( 100.00% ) | 17 (0.06%) |
| 呼内一 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 呼三 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 呼吸1 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 呼吸2 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 呼吸病区 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 呼吸二 | 0(0.00%) | 5 ( 100.00% ) | 5 (0.02%) |
| 呼吸二病区 | 0(0.00%) | 15 ( 100.00% ) | 15 (0.05%) |
| 呼吸放疗2病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 呼吸放疗二 | 0(0.00%) | 11 ( 100.00% ) | 11 (0.04%) |
| 呼吸放疗二病区 | 0(0.00%) | 5 ( 100.00% ) | 5 (0.02%) |
| 呼吸放疗二科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 呼吸放疗三 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 呼吸放疗一 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 呼吸放疗一病区 | 0(0.00%) | 5 ( 100.00% ) | 5 (0.02%) |
| 呼吸放疗一科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 呼吸科二病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 呼吸内 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 呼吸内二 | 0(0.00%) | 23 ( 100.00% ) | 23 (0.08%) |
| 呼吸内二病区 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 呼吸内二科 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 呼吸内科2 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 呼吸内科2病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 呼吸内科病区 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 呼吸内科二病房 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 呼吸内科二病区护士站 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 呼吸内科三病房 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 呼吸内科三病区护士站 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 呼吸内科一 | 0(0.00%) | 38 ( 100.00% ) | 38 (0.13%) |
| 呼吸内科一病室 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 呼吸内三 | 0(0.00%) | 10 ( 100.00% ) | 10 (0.03%) |
| 呼吸内三病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 呼吸内一 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 呼吸三 | 0(0.00%) | 9 ( 100.00% ) | 9 (0.03%) |
| 呼吸一 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 呼吸一病区 | 0(0.00%) | 13 ( 100.00% ) | 13 (0.04%) |
| 呼吸一科 | 0(0.00%) | 73 ( 100.00% ) | 73 (0.24%) |
| 呼吸音粗 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 化2 | 0(0.00%) | 7 ( 100.00% ) | 7 (0.02%) |
| 化2科 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 化二 | 0(0.00%) | 235 ( 100.00% ) | 235 (0.78%) |
| 化二科 | 0(0.00%) | 153 ( 100.00% ) | 153 (0.51%) |
| 化疗二 | 0(0.00%) | 13 ( 100.00% ) | 13 (0.04%) |
| 化疗二科 | 0(0.00%) | 112 ( 100.00% ) | 112 (0.37%) |
| 化疗科 | 0(0.00%) | 11 ( 100.00% ) | 11 (0.04%) |
| 化疗三科 | 0(0.00%) | 49 ( 100.00% ) | 49 (0.16%) |
| 化疗三颗 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 化疗四科 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 化疗一 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 化疗一科 | 0(0.00%) | 259 ( 100.00% ) | 259 (0.86%) |
| 化七科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 化三 | 0(0.00%) | 20 ( 100.00% ) | 20 (0.07%) |
| 化三科 | 0(0.00%) | 18 ( 100.00% ) | 18 (0.06%) |
| 化一 | 0(0.00%) | 142 ( 100.00% ) | 142 (0.47%) |
| 急诊 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 急诊科 | 0(0.00%) | 4 ( 100.00% ) | 4 (0.01%) |
| 急诊科（北院） | 0(0.00%) | 5 ( 100.00% ) | 5 (0.02%) |
| 甲西五病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 节介入病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 介入 | 0(0.00%) | 43 ( 100.00% ) | 43 (0.14%) |
| 介入二 | 0(0.00%) | 37 ( 100.00% ) | 37 (0.12%) |
| 介入二病区 | 0(0.00%) | 38 ( 100.00% ) | 38 (0.13%) |
| 介入二区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 介入放化疗 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 介入放疗 | 0(0.00%) | 7 ( 100.00% ) | 7 (0.02%) |
| 介入放射科 | 0(0.00%) | 10 ( 100.00% ) | 10 (0.03%) |
| 介入放射科病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 介入三病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 介入一 | 0(0.00%) | 151 ( 100.00% ) | 151 (0.50%) |
| 介入一病区 | 0(0.00%) | 54 ( 100.00% ) | 54 (0.18%) |
| 介入一科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 介一 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 晋城大医普通外科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 晋城大医院二病区（肿瘤科） | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 晋城大医院普外二病区(肿瘤科） | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 晋城大医院普外二病区（肿瘤科） | 0(0.00%) | 5 ( 100.00% ) | 5 (0.02%) |
| 晋城煤业集团总医院呼吸内科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 康复科 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 康复医学科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 科大一附院 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 科大一附院肿瘤内科二 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 科大一附院肿瘤内科二病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 老年病科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 老年病一科 | 0(0.00%) | 4 ( 100.00% ) | 4 (0.01%) |
| 老年二病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 疗二 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 淋巴混合内科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 淋巴结内科病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 淋巴综合 | 0(0.00%) | 22 ( 100.00% ) | 22 (0.07%) |
| 淋巴综合病区 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 淋巴综合内 | 0(0.00%) | 6 ( 100.00% ) | 6 (0.02%) |
| 淋巴综合内科病区护士站 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 淋巴综合四科 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 洛阳市科大一附院肿瘤科一病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 洛阳市科大一附院肿瘤六 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 洛阳市科大一附院肿瘤六病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 洛阳市科大一附院肿瘤六科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 洛阳市科大一附院肿瘤六区 | 0(0.00%) | 7 ( 100.00% ) | 7 (0.02%) |
| 洛阳市科大一附院肿瘤外科一病区 | 0(0.00%) | 5 ( 100.00% ) | 5 (0.02%) |
| 洛阳市科大一附院肿内一 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 洛阳市科大一附院肿外一区 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 洛阳市中心医院 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 洛阳市中心医院肿病二区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 洛阳市中心医院肿瘤1病区 | 0(0.00%) | 4 ( 100.00% ) | 4 (0.01%) |
| 洛阳市中心医院肿瘤1区 | 0(0.00%) | 25 ( 100.00% ) | 25 (0.08%) |
| 洛阳市中心医院肿瘤科一病区 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 洛阳市中心医院肿瘤区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 洛阳市中心医院肿瘤一病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 洛阳市中心医院肿瘤一区 | 0(0.00%) | 16 ( 100.00% ) | 16 (0.05%) |
| 洛阳市中心医院肿内一 | 0(0.00%) | 6 ( 100.00% ) | 6 (0.02%) |
| 泌尿二病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 泌尿外科病区 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 南院区放疗一科 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 南院区放一科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 脑瘤科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 脑瘤科一病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 脑瘤内科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 内-西病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 内八 | 0(0.00%) | 7 ( 100.00% ) | 7 (0.02%) |
| 内八病区 | 0(0.00%) | 4 ( 100.00% ) | 4 (0.01%) |
| 内二（二） | 0(0.00%) | 37 ( 100.00% ) | 37 (0.12%) |
| 内二（二0 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 内二科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 内分泌 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 内分泌二病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 内分泌科 | 0(0.00%) | 5 ( 100.00% ) | 5 (0.02%) |
| 内分泌内科 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 内分泌一病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 内九 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 内九病区 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 内科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 内科七病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 内科综合 | 0(0.00%) | 4 ( 100.00% ) | 4 (0.01%) |
| 内科综合病区 | 0(0.00%) | 5 ( 100.00% ) | 5 (0.02%) |
| 内内二 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 内三 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 内四 | 0(0.00%) | 19 ( 100.00% ) | 19 (0.06%) |
| 内五 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 内一 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 内一西病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 排普外三区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 皮肤科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 普病六区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 普二 | 0(0.00%) | 6 ( 100.00% ) | 6 (0.02%) |
| 普二病区 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 普科一病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 普六 | 0(0.00%) | 146 ( 100.00% ) | 146 (0.48%) |
| 普六病区 | 0(0.00%) | 83 ( 100.00% ) | 83 (0.28%) |
| 普六外科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 普内 | 0(0.00%) | 14 ( 100.00% ) | 14 (0.05%) |
| 普七病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 普三 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 普三病区 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 普通内科 | 0(0.00%) | 94 ( 100.00% ) | 94 (0.31%) |
| 普通外科 | 0(0.00%) | 4 ( 100.00% ) | 4 (0.01%) |
| 普外 | 0(0.00%) | 55 ( 100.00% ) | 55 (0.18%) |
| 普外（二） | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 普外1 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 普外2科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 普外3科 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 普外5 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 普外5A科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 普外5B | 0(0.00%) | 4 ( 100.00% ) | 4 (0.01%) |
| 普外5科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 普外6 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 普外6科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 普外病一区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 普外大科 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 普外二 | 0(0.00%) | 4 ( 100.00% ) | 4 (0.01%) |
| 普外二病区 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 普外二科 | 0(0.00%) | 130 ( 100.00% ) | 130 (0.43%) |
| 普外科 | 0(0.00%) | 207 ( 100.00% ) | 207 (0.69%) |
| 普外科一病区 | 0(0.00%) | 22 ( 100.00% ) | 22 (0.07%) |
| 普外科一病室 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 普外刘科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 普外六 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 普外六科 乳腺外科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 普外六科(乳腺外科） | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 普外六科（乳腺外科） | 0(0.00%) | 12 ( 100.00% ) | 12 (0.04%) |
| 普外内科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 普外七科 | 0(0.00%) | 19 ( 100.00% ) | 19 (0.06%) |
| 普外七科（肛肠外科） | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 普外三科 | 0(0.00%) | 18 ( 100.00% ) | 18 (0.06%) |
| 普外三区 | 0(0.00%) | 436 ( 100.00% ) | 436 (1.45%) |
| 普外思科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 普外斯科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 普外四科 | 0(0.00%) | 44 ( 100.00% ) | 44 (0.15%) |
| 普外五 | 0(0.00%) | 14 ( 100.00% ) | 14 (0.05%) |
| 普外五A病区 | 0(0.00%) | 4 ( 100.00% ) | 4 (0.01%) |
| 普外五A科 | 0(0.00%) | 9 ( 100.00% ) | 9 (0.03%) |
| 普外五B科 | 0(0.00%) | 10 ( 100.00% ) | 10 (0.03%) |
| 普外五B科（胃肠外科） | 0(0.00%) | 8 ( 100.00% ) | 8 (0.03%) |
| 普外五病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 普外五科 | 0(0.00%) | 200 ( 100.00% ) | 200 (0.66%) |
| 普外五科B | 0(0.00%) | 24 ( 100.00% ) | 24 (0.08%) |
| 普外一 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 普外一病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 普外一科 | 0(0.00%) | 100 ( 100.00% ) | 100 (0.33%) |
| 普五 | 0(0.00%) | 7 ( 100.00% ) | 7 (0.02%) |
| 普五病区 | 0(0.00%) | 4 ( 100.00% ) | 4 (0.01%) |
| 普一 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 其他劳动者 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 乳4 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 乳5 | 0(0.00%) | 5 ( 100.00% ) | 5 (0.02%) |
| 乳病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 乳病五区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 乳病一区 | 0(0.00%) | 4 ( 100.00% ) | 4 (0.01%) |
| 乳二 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 乳二病区 | 0(0.00%) | 6 ( 100.00% ) | 6 (0.02%) |
| 乳六 | 0(0.00%) | 190 ( 100.00% ) | 190 (0.63%) |
| 乳六病区 | 0(0.00%) | 86 ( 100.00% ) | 86 (0.29%) |
| 乳七 | 0(0.00%) | 218 ( 100.00% ) | 218 (0.72%) |
| 乳七病区 | 0(0.00%) | 86 ( 100.00% ) | 86 (0.29%) |
| 乳七痛区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 乳三 | 0(0.00%) | 187 ( 100.00% ) | 187 (0.62%) |
| 乳三病区 | 0(0.00%) | 82 ( 100.00% ) | 82 (0.27%) |
| 乳三病区护士站 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 乳外 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 乳五病房 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 乳五病区护士站 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 乳腺癌淋巴瘤放疗 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 乳腺病科 | 0(0.00%) | 4 ( 100.00% ) | 4 (0.01%) |
| 乳腺科 | 0(0.00%) | 29 ( 100.00% ) | 29 (0.10%) |
| 乳腺科六病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 乳腺科五病区 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 乳腺淋巴 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 乳腺淋巴癌放疗 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 乳腺淋巴癌放疗病Ⅱ | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 乳腺淋巴癌放疗区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 乳腺淋巴放疗 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 乳腺淋巴瘤 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 乳腺淋巴瘤放化疗区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 乳腺淋巴瘤放疗 | 0(0.00%) | 64 ( 100.00% ) | 64 (0.21%) |
| 乳腺淋巴瘤放疗病区 | 0(0.00%) | 62 ( 100.00% ) | 62 (0.21%) |
| 乳腺淋巴瘤放疗区 | 0(0.00%) | 10 ( 100.00% ) | 10 (0.03%) |
| 乳腺淋巴瘤放射病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 乳腺六科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 乳腺内科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 乳腺外 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 乳腺五 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 乳腺一 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 乳一 | 0(0.00%) | 721 ( 100.00% ) | 721 (2.39%) |
| 乳一病区 | 0(0.00%) | 342 ( 100.00% ) | 342 (1.14%) |
| 乳一病区护士站 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 山东济南槐荫区前周王庄 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 山东省立医院 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 山东省立医院(西院)药剂科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 山东省立医院（西院）药剂科 | 0(0.00%) | 52 ( 100.00% ) | 52 (0.17%) |
| 山西晋城煤业集团总医院普外二病区(肿瘤科） | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 神经内科 | 0(0.00%) | 11 ( 100.00% ) | 11 (0.04%) |
| 神经内科二 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 神经内科六 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 神经内一科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 神经三科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 神经外二 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 神经外科 | 0(0.00%) | 27 ( 100.00% ) | 27 (0.09%) |
| 神内二科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 神内四科 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 神外 | 0(0.00%) | 4 ( 100.00% ) | 4 (0.01%) |
| 神外三 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 神外三科 | 0(0.00%) | 34 ( 100.00% ) | 34 (0.11%) |
| 神外一科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 神物治疗二病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肾病 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 生物化疗 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 生物免疫二 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 生物免疫治疗二 | 0(0.00%) | 7 ( 100.00% ) | 7 (0.02%) |
| 生物免疫治疗二病区 | 0(0.00%) | 4 ( 100.00% ) | 4 (0.01%) |
| 生物诊疗二病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 生物治疗 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 生物治疗二病区 | 0(0.00%) | 30 ( 100.00% ) | 30 (0.10%) |
| 生物治疗科 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 生物治疗一 | 0(0.00%) | 6 ( 100.00% ) | 6 (0.02%) |
| 生物治疗一病区 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 食管胸上段癌 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 疼痛 | 0(0.00%) | 16 ( 100.00% ) | 16 (0.05%) |
| 疼痛病区 | 0(0.00%) | 10 ( 100.00% ) | 10 (0.03%) |
| 疼痛病区护士站 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 疼痛肝病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 疼痛科 | 0(0.00%) | 89 ( 100.00% ) | 89 (0.30%) |
| 疼痛科病区 | 0(0.00%) | 34 ( 100.00% ) | 34 (0.11%) |
| 头颈放疗病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 头颈甲状腺 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 头颈甲状腺癌 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 头颈甲状腺二 | 0(0.00%) | 8 ( 100.00% ) | 8 (0.03%) |
| 头颈甲状腺二病区 | 0(0.00%) | 15 ( 100.00% ) | 15 (0.05%) |
| 头颈甲状腺一 | 0(0.00%) | 7 ( 100.00% ) | 7 (0.02%) |
| 头颈甲状腺一病区 | 0(0.00%) | 8 ( 100.00% ) | 8 (0.03%) |
| 头颈科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 头颈外科 | 0(0.00%) | 8 ( 100.00% ) | 8 (0.03%) |
| 外 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 外二 | 0(0.00%) | 4 ( 100.00% ) | 4 (0.01%) |
| 外五 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 威海立医院南院区放一科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 威海市立项医院 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 威海市立医院 | 0(0.00%) | 5 ( 100.00% ) | 5 (0.02%) |
| 威海市立医院放疗二科 | 0(0.00%) | 5 ( 100.00% ) | 5 (0.02%) |
| 威海市立医院放疗一科 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 威海市立医院放一科 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 威海市立医院化二 | 0(0.00%) | 4 ( 100.00% ) | 4 (0.01%) |
| 威海市立医院化二科 | 0(0.00%) | 6 ( 100.00% ) | 6 (0.02%) |
| 威海市立医院化疗二科 | 0(0.00%) | 18 ( 100.00% ) | 18 (0.06%) |
| 威海市立医院化疗三科 | 0(0.00%) | 6 ( 100.00% ) | 6 (0.02%) |
| 威海市立医院化疗一科 | 0(0.00%) | 20 ( 100.00% ) | 20 (0.07%) |
| 威海市立医院化三科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 威海市立医院肿瘤科综合治疗科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 威海市立医院肿瘤综合科 | 0(0.00%) | 5 ( 100.00% ) | 5 (0.02%) |
| 威海市立医院肿瘤综合治疗科 | 0(0.00%) | 5 ( 100.00% ) | 5 (0.02%) |
| 威海市立医院肿综 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 威海市荣成市港湾街道办事处 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 微创介入 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 微创介入二病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 微创介入一 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 微创介入一病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 胃肠外科 | 0(0.00%) | 20 ( 100.00% ) | 20 (0.07%) |
| 胃肠胸外科 | 0(0.00%) | 63 ( 100.00% ) | 63 (0.21%) |
| 胃肠胸外一科 | 0(0.00%) | 5 ( 100.00% ) | 5 (0.02%) |
| 胃肠胸腺外科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 胃二 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 无业 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 消化 | 0(0.00%) | 8 ( 100.00% ) | 8 (0.03%) |
| 消化二 | 0(0.00%) | 10 ( 100.00% ) | 10 (0.03%) |
| 消化二科 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 消化二内 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 消化放化疗一病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 消化放疗二 | 0(0.00%) | 9 ( 100.00% ) | 9 (0.03%) |
| 消化放疗二病区 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 消化放疗二病区护士站 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 消化放疗一 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 消化放疗一病区 | 0(0.00%) | 4 ( 100.00% ) | 4 (0.01%) |
| 消化科二病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 消化内 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 消化内二病区 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 消化内二科 | 0(0.00%) | 6 ( 100.00% ) | 6 (0.02%) |
| 消化内分泌-肾内科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 消化内科2 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 消化内科2病区 | 0(0.00%) | 4 ( 100.00% ) | 4 (0.01%) |
| 消化内科二病区护士部 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 消化内科二病区护士站 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 消化内科三 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 消化内科一 | 0(0.00%) | 10 ( 100.00% ) | 10 (0.03%) |
| 消化内科一病区 | 0(0.00%) | 16 ( 100.00% ) | 16 (0.05%) |
| 消化内一 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 消化内一科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 消化时间 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 消化四科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 消化一 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 消內二 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 消内2 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 消内二 | 0(0.00%) | 27 ( 100.00% ) | 27 (0.09%) |
| 消内三 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 消内一 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 消区内科二 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 消一 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 心肠外 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 心内二 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 心内二科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 心内科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 心内三科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 心内四科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 心内一科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 心外科 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 心胸外 | 0(0.00%) | 4 ( 100.00% ) | 4 (0.01%) |
| 心胸外病科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 心胸外病区 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 心胸外科 | 0(0.00%) | 74 ( 100.00% ) | 74 (0.25%) |
| 心胸外科病区 | 0(0.00%) | 17 ( 100.00% ) | 17 (0.06%) |
| 心胸一病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 心血管呼吸内科 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 心血管内科 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 心脏大血管外科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 新泰人民医院肿瘤科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 新泰市人民医院创伤骨科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 新泰市人民医院内十二科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 新泰市人民医院肿瘤科 | 0(0.00%) | 6 ( 100.00% ) | 6 (0.02%) |
| 新乡市学院第一附属医院肿瘤科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 新乡医学院第一附属医院肿瘤二科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 新乡医学院附属医院肿瘤科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 新乡医学院一附院 | 0(0.00%) | 20 ( 100.00% ) | 20 (0.07%) |
| 新乡医学院一附院肿瘤科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 新医附院肿瘤科 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 新医一附院肿瘤科 | 0(0.00%) | 8 ( 100.00% ) | 8 (0.03%) |
| 信阳市市中心医院 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 信阳市中七医院肿瘤内科二病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 信阳市中心医院 | 0(0.00%) | 46 ( 100.00% ) | 46 (0.15%) |
| 信阳市中心医院介入放射科 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 信阳市中心医院介入放射科病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 信阳市中心医院介入科 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 信阳市中心医院心外科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 信阳市中心医院肿瘤科 | 0(0.00%) | 25 ( 100.00% ) | 25 (0.08%) |
| 信阳市中心医院肿瘤科二B病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 信阳市中心医院肿瘤内科二 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 信阳市中心医院肿瘤内科二病区 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 信阳市中心医院肿瘤内科三病区 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 信阳市中心医院肿瘤内科一病区 | 0(0.00%) | 4 ( 100.00% ) | 4 (0.01%) |
| 信阳市中心医院肿瘤内衣一病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 信阳市中心医院肿内二 | 0(0.00%) | 8 ( 100.00% ) | 8 (0.03%) |
| 信阳市中心医院肿内二病 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 信阳市中心医院肿内二病区 | 0(0.00%) | 5 ( 100.00% ) | 5 (0.02%) |
| 信阳市中心医院肿内三 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 信阳市中心医院肿内一 | 0(0.00%) | 7 ( 100.00% ) | 7 (0.02%) |
| 信阳市中心医院肿内一病区 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 信阳中心医院肿瘤科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 信仰市中心医院肿瘤科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 信仰市中心医院肿内二 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 胸二 | 0(0.00%) | 11 ( 100.00% ) | 11 (0.04%) |
| 胸二病区 | 0(0.00%) | 10 ( 100.00% ) | 10 (0.03%) |
| 胸呼吸内科二 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 胸内科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 胸三 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 胸三病区 | 0(0.00%) | 5 ( 100.00% ) | 5 (0.02%) |
| 胸外 | 0(0.00%) | 5 ( 100.00% ) | 5 (0.02%) |
| 胸外二 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 胸外一 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 胸腺外 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 胸心二病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 胸心外 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 胸心外二 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 胸心外科 | 0(0.00%) | 29 ( 100.00% ) | 29 (0.10%) |
| 胸心外一 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 胸心外一病区 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 胸心血管二病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 胸心血管科外科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 胸心血管科一 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 胸心血管科一病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 胸心血管外二病区 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 胸心血管外科 | 0(0.00%) | 9 ( 100.00% ) | 9 (0.03%) |
| 胸心血管外科-病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 胸心血管外科（一） | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 胸心血管外科二病区 | 0(0.00%) | 12 ( 100.00% ) | 12 (0.04%) |
| 胸心血管外科一病房 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 胸心血管外科一病区 | 0(0.00%) | 9 ( 100.00% ) | 9 (0.03%) |
| 胸心血管外一 | 0(0.00%) | 5 ( 100.00% ) | 5 (0.02%) |
| 胸心血管外一病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 胸一 | 0(0.00%) | 226 ( 100.00% ) | 226 (0.75%) |
| 胸一病区 | 0(0.00%) | 102 ( 100.00% ) | 102 (0.34%) |
| 血管外科 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 血管外科病区 | 0(0.00%) | 7 ( 100.00% ) | 7 (0.02%) |
| 血外 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 血液病科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 血液内 | 0(0.00%) | 10 ( 100.00% ) | 10 (0.03%) |
| 血液七 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 血液七病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 血液四科 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 血液五病区 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 血液肿瘤科 | 0(0.00%) | 27 ( 100.00% ) | 27 (0.09%) |
| 血液肿瘤内科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 药剂科 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 右侧肾盂癌 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 郑州人民医院 | 0(0.00%) | 15 ( 100.00% ) | 15 (0.05%) |
| 郑州人民医院普外二科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 郑州人民医院乳腺外科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 郑州人民医院肿瘤放疗科 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 郑州人民医院肿瘤内科 | 0(0.00%) | 4 ( 100.00% ) | 4 (0.01%) |
| 郑州市人民医院 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 郑州肿瘤内科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 直肠腺癌 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 中内科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 中西二病区 | 0(0.00%) | 12 ( 100.00% ) | 12 (0.04%) |
| 中西结合区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 中西六 | 0(0.00%) | 193 ( 100.00% ) | 193 (0.64%) |
| 中西六病 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 中西六病区护士站 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 中西六结合 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 中西六科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 中西三 | 0(0.00%) | 10 ( 100.00% ) | 10 (0.03%) |
| 中西三病区 | 0(0.00%) | 15 ( 100.00% ) | 15 (0.05%) |
| 中西五病房 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 中西武病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 中西一 | 0(0.00%) | 42 ( 100.00% ) | 42 (0.14%) |
| 中西一病区 | 0(0.00%) | 20 ( 100.00% ) | 20 (0.07%) |
| 中西一科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 中西医 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 中西医二病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 中西医结合 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 中西医结合区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 中西医科 | 0(0.00%) | 9 ( 100.00% ) | 9 (0.03%) |
| 中西医六 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 中西医三 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 中西医一 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 中西医一病区护士站 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 中医 | 0(0.00%) | 37 ( 100.00% ) | 37 (0.12%) |
| 中医科 | 0(0.00%) | 85 ( 100.00% ) | 85 (0.28%) |
| 中医一病区 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 中肿内一 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肿病科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肿二 | 0(0.00%) | 40 ( 100.00% ) | 40 (0.13%) |
| 肿瘤（一） | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肿瘤（一）病区 | 0(0.00%) | 9 ( 100.00% ) | 9 (0.03%) |
| 肿瘤1病区 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 肿瘤1科病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肿瘤1区 | 0(0.00%) | 56 ( 100.00% ) | 56 (0.19%) |
| 肿瘤病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肿瘤二 | 0(0.00%) | 4 ( 100.00% ) | 4 (0.01%) |
| 肿瘤二病区 | 0(0.00%) | 4 ( 100.00% ) | 4 (0.01%) |
| 肿瘤二区 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 肿瘤放疗 | 0(0.00%) | 15 ( 100.00% ) | 15 (0.05%) |
| 肿瘤放疗1区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肿瘤放疗病区 | 0(0.00%) | 8 ( 100.00% ) | 8 (0.03%) |
| 肿瘤放疗病区一 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肿瘤放疗二 | 0(0.00%) | 8 ( 100.00% ) | 8 (0.03%) |
| 肿瘤放疗二病区 | 0(0.00%) | 7 ( 100.00% ) | 7 (0.02%) |
| 肿瘤放疗二区 | 0(0.00%) | 6 ( 100.00% ) | 6 (0.02%) |
| 肿瘤放疗一 | 0(0.00%) | 17 ( 100.00% ) | 17 (0.06%) |
| 肿瘤放疗一病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肿瘤放疗一科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肿瘤放疗一区 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 肿瘤放射科 | 0(0.00%) | 6 ( 100.00% ) | 6 (0.02%) |
| 肿瘤化疗科 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 肿瘤科二 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肿瘤科放疗室 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肿瘤科六病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肿瘤科内二病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肿瘤科三 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 肿瘤科一 | 0(0.00%) | 8 ( 100.00% ) | 8 (0.03%) |
| 肿瘤六科 | 0(0.00%) | 6 ( 100.00% ) | 6 (0.02%) |
| 肿瘤六区 | 0(0.00%) | 70 ( 100.00% ) | 70 (0.23%) |
| 肿瘤内 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肿瘤内二 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肿瘤内二病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肿瘤内二科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肿瘤内科1病区 | 0(0.00%) | 5 ( 100.00% ) | 5 (0.02%) |
| 肿瘤内科二 | 0(0.00%) | 63 ( 100.00% ) | 63 (0.21%) |
| 肿瘤内科二病区 | 0(0.00%) | 74 ( 100.00% ) | 74 (0.25%) |
| 肿瘤内科六病区 | 0(0.00%) | 43 ( 100.00% ) | 43 (0.14%) |
| 肿瘤内科三 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 肿瘤内科五病区 | 0(0.00%) | 108 ( 100.00% ) | 108 (0.36%) |
| 肿瘤内科一 | 0(0.00%) | 22 ( 100.00% ) | 22 (0.07%) |
| 肿瘤内科一病区 | 0(0.00%) | 35 ( 100.00% ) | 35 (0.12%) |
| 肿瘤内科一区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肿瘤内科主病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肿瘤内六 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肿瘤三 | 0(0.00%) | 11 ( 100.00% ) | 11 (0.04%) |
| 肿瘤四科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肿瘤外科 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 肿瘤外科二病区 | 0(0.00%) | 4 ( 100.00% ) | 4 (0.01%) |
| 肿瘤外科三病区 | 0(0.00%) | 4 ( 100.00% ) | 4 (0.01%) |
| 肿瘤外科一病区 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 肿瘤微疗科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肿瘤五 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肿瘤五病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肿瘤一 | 0(0.00%) | 23 ( 100.00% ) | 23 (0.08%) |
| 肿瘤一病区 | 0(0.00%) | 25 ( 100.00% ) | 25 (0.08%) |
| 肿瘤一区 | 0(0.00%) | 73 ( 100.00% ) | 73 (0.24%) |
| 肿瘤医院 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肿瘤综合 | 0(0.00%) | 23 ( 100.00% ) | 23 (0.08%) |
| 肿瘤综合放疗科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肿瘤综合科 | 0(0.00%) | 130 ( 100.00% ) | 130 (0.43%) |
| 肿瘤综合内科 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 肿瘤综合外科 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |
| 肿瘤综合治疗 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肿瘤综合治疗科 | 0(0.00%) | 66 ( 100.00% ) | 66 (0.22%) |
| 肿六 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肿內二 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肿內一 | 0(0.00%) | 22 ( 100.00% ) | 22 (0.07%) |
| 肿内 | 0(0.00%) | 49 ( 100.00% ) | 49 (0.16%) |
| 肿内1 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肿内1区 | 0(0.00%) | 9 ( 100.00% ) | 9 (0.03%) |
| 肿内2 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肿内二病区 | 0(0.00%) | 15 ( 100.00% ) | 15 (0.05%) |
| 肿内科二病区 | 0(0.00%) | 4 ( 100.00% ) | 4 (0.01%) |
| 肿内六 | 0(0.00%) | 164 ( 100.00% ) | 164 (0.54%) |
| 肿内六科 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 肿内区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肿内三 | 0(0.00%) | 71 ( 100.00% ) | 71 (0.24%) |
| 肿内无 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肿内五 | 0(0.00%) | 97 ( 100.00% ) | 97 (0.32%) |
| 肿内五病区 | 0(0.00%) | 5 ( 100.00% ) | 5 (0.02%) |
| 肿内一 | 0(0.00%) | 902 ( 100.00% ) | 902 (2.99%) |
| 肿内一病区 | 0(0.00%) | 3 ( 100.00% ) | 3 (0.01%) |
| 肿内一科 | 0(0.00%) | 20 ( 100.00% ) | 20 (0.07%) |
| 肿内一区 | 0(0.00%) | 4 ( 100.00% ) | 4 (0.01%) |
| 肿三 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肿外二 | 0(0.00%) | 18 ( 100.00% ) | 18 (0.06%) |
| 肿外三 | 0(0.00%) | 33 ( 100.00% ) | 33 (0.11%) |
| 肿外一 | 0(0.00%) | 35 ( 100.00% ) | 35 (0.12%) |
| 肿外一病区 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 肿外一科 | 0(0.00%) | 4 ( 100.00% ) | 4 (0.01%) |
| 肿外一区 | 0(0.00%) | 11 ( 100.00% ) | 11 (0.04%) |
| 肿一 | 0(0.00%) | 34 ( 100.00% ) | 34 (0.11%) |
| 肿一科 | 0(0.00%) | 9 ( 100.00% ) | 9 (0.03%) |
| 肿综 | 0(0.00%) | 15 ( 100.00% ) | 15 (0.05%) |
| 重症医学科 | 0(0.00%) | 4 ( 100.00% ) | 4 (0.01%) |
| 周围血管 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 周围血管科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 周围血管外科 | 0(0.00%) | 97 ( 100.00% ) | 97 (0.32%) |
| 周围血液外科 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 综合 | 0(0.00%) | 1 ( 100.00% ) | 1 (0.00%) |
| 综合内科 | 0(0.00%) | 157 ( 100.00% ) | 157 (0.52%) |
| 综合外科 | 0(0.00%) | 2 ( 100.00% ) | 2 (0.01%) |

## 5.西医诊断

### 5.1 主要诊断

#### 5.1.1 ADR人群诊断类别统计

  在193例ADR患者中，西医主要诊断1级系统分类中ADR发生例次降序排列，前5位的是，肿瘤152例(78.76%)，影响健康状态或与保健机构接触的因素21例(10.88%)，症状、体征或临床所见，不可归类在他处者7例(3.63%)，内分泌、营养或代谢疾病5例(2.59%)，呼吸系统疾病2例(1.04%)。

**表 10: ADR人群西医主要诊断系统分类统计表**

| 一级系统分类 | 例数 | 例数占ADR人群比 |
| --- | --- | --- |
| 肿瘤 | 152 | 78.76% |
| 影响健康状态或与保健机构接触的因素 | 21 | 10.88% |
| 症状、体征或临床所见，不可归类在他处者 | 7 | 3.63% |
| 内分泌、营养或代谢疾病 | 5 | 2.59% |
| 呼吸系统疾病 | 2 | 1.04% |
| 泌尿生殖系统疾病 | 2 | 1.04% |
| 某些感染性疾病或寄生虫病 | 2 | 1.04% |
| 消化系统疾病 | 1 | 0.52% |

#### 5.1.2 诊断名例次统计

*30130例研究人群中，肿瘤人群共23814例，非肿瘤人群6316例。*分别统计肿瘤与非肿瘤人群的诊断4级分类名称,详见表 11，表 12。

**表 11: 肿瘤4级分类名称统计**

| **X1级系统分类名称** | **肿瘤4级分类名称** | **全人群中发生例数** | **在全人群占比** | **AE人群中发生例数** | **在AE人群占比** | **ADR人群中发生例数** | **在ADR人群占比** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 肿瘤:例数23815(79.04%) | 中耳、呼吸器官或胸腔内器官的恶性肿瘤 | 6827 |  | 1038 | 23.452% | 44 | 22.798% |
| 乳房恶性肿瘤 | 3488 |  | 426 | 9.625% | 28 | 14.508% |
| 消化器官恶性肿瘤 | 7221 |  | 1097 | 24.785% | 27 | 13.990% |
| 唇、口腔或咽部恶性肿瘤 | 1484 |  | 215 | 4.858% | 13 | 6.736% |
| 女性生殖器官恶性肿瘤 | 1072 |  | 163 | 3.683% | 11 | 5.699% |
| 非霍奇金淋巴瘤 | 492 |  | 78 | 1.762% | 6 | 3.109% |
| 未知或未特指类型的脑原发性肿瘤 | 407 |  | 80 | 1.808% | 5 | 2.591% |
| 泌尿道恶性肿瘤 | 260 |  | 41 | 0.926% | 5 | 2.591% |
| 内分泌腺恶性肿瘤 | 617 |  | 79 | 1.785% | 3 | 1.554% |
| 髓系白血病 | 212 |  | 70 | 1.582% | 2 | 1.036% |
| 浆细胞肿瘤 | 59 |  | 11 | 0.249% | 2 | 1.036% |
| 恶性间叶细胞肿瘤 | 310 |  | 43 | 0.972% | 1 | 0.518% |
| 未特指部位原位癌 | 224 |  | 32 | 0.723% | 1 | 0.518% |
| 成熟T细胞或NK细胞淋巴瘤和淋巴增生性疾病，原发性皮肤特定类型 | 177 |  | 20 | 0.452% | 1 | 0.518% |
| 未特指的霍奇金淋巴瘤 | 149 |  | 27 | 0.610% | 1 | 0.518% |
| 间皮肿瘤，良恶性未确定 | 26 |  | 4 | 0.090% | 1 | 0.518% |
| 未特指的骨髓增生异常综合征 | 19 |  | 4 | 0.090% | 1 | 0.518% |
| 男性生殖器官恶性肿瘤 | 252 |  | 29 | 0.655% | 0 | 0.000% |
| 未特指的造血或淋巴组织肿瘤 | 165 |  | 24 | 0.542% | 0 | 0.000% |
| 皮肤恶性肿瘤 | 111 |  | 18 | 0.407% | 0 | 0.000% |
| 其他部位转移性恶性肿瘤 | 83 |  | 11 | 0.249% | 0 | 0.000% |
| 白血病，未特指 | 53 |  | 16 | 0.362% | 0 | 0.000% |
| 腹膜后、腹膜或网膜恶性肿瘤 | 52 |  | 2 | 0.045% | 0 | 0.000% |
| 淋巴细胞白血病，不可归类在他处者 | 23 |  | 7 | 0.158% | 0 | 0.000% |
| 乳腺良性肿瘤 | 8 |  | 0 | 0.000% | 0 | 0.000% |
| 良性平滑肌或骨胳肌肿瘤 | 6 |  | 2 | 0.045% | 0 | 0.000% |
| 淋巴结转移性恶性肿瘤 | 5 |  | 1 | 0.023% | 0 | 0.000% |
| 良性脂肪瘤样肿瘤 | 3 |  | 0 | 0.000% | 0 | 0.000% |
| 滤泡性淋巴瘤 | 3 |  | 0 | 0.000% | 0 | 0.000% |
| 不明部位的恶性肿瘤 | 3 |  | 0 | 0.000% | 0 | 0.000% |
| 非肥大细胞骨髓增殖性肿瘤 | 1 |  | 0 | 0.000% | 0 | 0.000% |
| 急性髓系白血病，采用其他标准不可归类在他处者 | 1 |  | 0 | 0.000% | 0 | 0.000% |
| 内分泌腺生物学行为未知的肿瘤 | 1 |  | 0 | 0.000% | 0 | 0.000% |
| 其他和未特指的脑或中枢神经系统肿瘤 | 1 |  | 0 | 0.000% | 0 | 0.000% |
| 未特指的骨髓增生异常和骨髓增殖性肿瘤 | 1 |  | 0 | 0.000% | 0 | 0.000% |

**表 12: 其他3级分类名称统计**

| **X1级系统分类名称** | **其他3级分类名称** | **全人群中发生例数** | **在全人群占比** | **AE人群中发生例数** | **在AE人群占比** | **ADR人群中发生例数** | **在ADR人群占比** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 影响健康状态或与保健机构接触的因素:例数4078(13.53%) | 其他特指的影响健康状态或与保健机构接触的因素 | 4077 | 13.531% | 584 | 13.195% | 21 | 10.881% |
| 为不涉及器械的非手术干预而与保健机构接触 | 1 | 0.003% | 1 | 0.023% | 0 | 0.000% |
| 症状、体征或临床所见，不可归类在他处者:例数672(2.23%) | 累及女性生殖系统的症状、体征或临床所见 | 447 | 1.484% | 51 | 1.152% | 6 | 3.109% |
| 累及消化系统或腹部的症状或体征 | 80 | 0.266% | 11 | 0.249% | 1 | 0.518% |
| 血液、造血器官或免疫系统的症状 | 56 | 0.186% | 7 | 0.158% | 0 | 0.000% |
| 肌肉骨骼系统的临床所见 | 30 | 0.100% | 3 | 0.068% | 0 | 0.000% |
| 神经系统的临床所见 | 30 | 0.100% | 5 | 0.113% | 0 | 0.000% |
| 全身症状 | 10 | 0.033% | 2 | 0.045% | 0 | 0.000% |
| 累及皮肤的症状或体征 | 8 | 0.027% | 0 | 0.000% | 0 | 0.000% |
| 呼吸系统的临床所见 | 4 | 0.013% | 0 | 0.000% | 0 | 0.000% |
| 累及呼吸系统的症状或体征 | 4 | 0.013% | 2 | 0.045% | 0 | 0.000% |
| 累及泌尿系统的症状、体征或临床所见 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 累及神经系统的症状或体征 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 其他特指的血液或造血器官疾病 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 呼吸系统疾病:例数545(1.81%) | 慢性阻塞性肺疾病 | 146 | 0.485% | 24 | 0.542% | 1 | 0.518% |
| 呼吸道感染，不可归类在他处者 | 54 | 0.179% | 7 | 0.158% | 1 | 0.518% |
| 支气管炎 | 164 | 0.544% | 16 | 0.362% | 0 | 0.000% |
| 其他特指的胸膜、膈或纵隔疾患 | 91 | 0.302% | 14 | 0.316% | 0 | 0.000% |
| 急性支气管炎 | 54 | 0.179% | 7 | 0.158% | 0 | 0.000% |
| 未特指的肺部感染 | 40 | 0.133% | 6 | 0.136% | 0 | 0.000% |
| 其他特指的主要影响肺间质的呼吸系统疾病 | 30 | 0.100% | 5 | 0.113% | 0 | 0.000% |
| 其他特指的呼吸系统疾病 | 9 | 0.030% | 3 | 0.068% | 0 | 0.000% |
| 多发性和未特指部位的急性上呼吸道感染 | 3 | 0.010% | 0 | 0.000% | 0 | 0.000% |
| 肺炎 | 3 | 0.010% | 0 | 0.000% | 0 | 0.000% |
| 气胸 | 2 | 0.007% | 1 | 0.023% | 0 | 0.000% |
| 脓胸 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 上呼吸道脓肿 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 哮喘 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 消化系统疾病:例数203(0.67%) | 某些特指的肝脏疾病 | 49 | 0.163% | 7 | 0.158% | 1 | 0.518% |
| 肠梗阻 | 33 | 0.110% | 5 | 0.113% | 0 | 0.000% |
| 胆囊炎 | 33 | 0.110% | 5 | 0.113% | 0 | 0.000% |
| 胃疾病 | 31 | 0.103% | 2 | 0.045% | 0 | 0.000% |
| 其他特指的消化系统疾病 | 29 | 0.096% | 5 | 0.113% | 0 | 0.000% |
| 腹股沟疝 | 5 | 0.017% | 0 | 0.000% | 0 | 0.000% |
| 非感染性胆管炎 | 4 | 0.013% | 1 | 0.023% | 0 | 0.000% |
| 阑尾炎 | 4 | 0.013% | 0 | 0.000% | 0 | 0.000% |
| 胃-食管反流病 | 3 | 0.010% | 0 | 0.000% | 0 | 0.000% |
| 肝血管性疾病 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 某些非感染性结肠炎或直肠炎 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 大肠息肉 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 胆管结石伴胆管炎 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 胆石症 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 腹膜炎 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 溃疡性结肠炎 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 未特指的肝脏疾病 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 未特指的炎性肠病 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 胃或十二指肠溃疡 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 循环系统疾病:例数190(0.63%) | 慢性缺血性心脏病 | 58 | 0.192% | 11 | 0.249% | 0 | 0.000% |
| 慢性下肢外周静脉功能不全 | 55 | 0.183% | 2 | 0.045% | 0 | 0.000% |
| 深静脉血栓形成 | 27 | 0.090% | 2 | 0.045% | 0 | 0.000% |
| 淋巴结炎 | 26 | 0.086% | 5 | 0.113% | 0 | 0.000% |
| 未特指的循环系统疾病 | 8 | 0.027% | 4 | 0.090% | 0 | 0.000% |
| 获得性全身性静脉异常 | 5 | 0.017% | 0 | 0.000% | 0 | 0.000% |
| 心包积液 | 3 | 0.010% | 0 | 0.000% | 0 | 0.000% |
| 主动脉瘤或主动脉夹层 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 二尖瓣疾病 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 急性动脉闭塞 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 浅表血栓性静脉炎 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 室上性心律失常 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 未特指的心力衰竭 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 原发性高血压 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 某些感染性疾病或寄生虫病:例数189(0.63%) | 流感，病毒未标明 | 170 | 0.564% | 35 | 0.791% | 1 | 0.518% |
| 其他特指的细菌性疾病 | 3 | 0.010% | 1 | 0.023% | 1 | 0.518% |
| 皮肤深层细菌性毛囊炎或脓性脓肿 | 5 | 0.017% | 0 | 0.000% | 0 | 0.000% |
| 慢性病毒性肝炎 | 4 | 0.013% | 0 | 0.000% | 0 | 0.000% |
| 结核病 | 2 | 0.007% | 1 | 0.023% | 0 | 0.000% |
| 水痘带状疱疹病毒感染 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 未特指感染性病原体的胃肠炎或结肠炎 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 急性风湿热 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 内分泌、营养或代谢疾病:例数153(0.51%) | 甲状腺或甲状腺激素系统疾患 | 146 | 0.485% | 20 | 0.452% | 5 | 2.591% |
| 糖尿病 | 5 | 0.017% | 1 | 0.023% | 0 | 0.000% |
| 体液、电解质或酸碱平衡紊乱 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 营养不良 | 1 | 0.003% | 1 | 0.023% | 0 | 0.000% |
| 血液或造血器官疾病:例数80(0.27%) | 再生障碍性贫血 | 40 | 0.133% | 3 | 0.068% | 0 | 0.000% |
| 血小板减少症 | 28 | 0.093% | 3 | 0.068% | 0 | 0.000% |
| 血小板增多症 | 5 | 0.017% | 0 | 0.000% | 0 | 0.000% |
| 血小板质量缺陷 | 4 | 0.013% | 1 | 0.023% | 0 | 0.000% |
| 红细胞增多症 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 未特指的脾脏疾病 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 神经系统疾病:例数77(0.26%) | 脑缺血 | 69 | 0.229% | 6 | 0.136% | 0 | 0.000% |
| 颅内出血 | 4 | 0.013% | 0 | 0.000% | 0 | 0.000% |
| 某些特指的脑血管病 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 帕金森综合征 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 未特指的癫痫或癫痫发作 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 未特指的头痛疾患 | 1 | 0.003% | 1 | 0.023% | 0 | 0.000% |
| 泌尿生殖系统疾病:例数52(0.17%) | 良性乳房疾病 | 47 | 0.156% | 6 | 0.136% | 2 | 1.036% |
| 某些特指的泌尿系统疾病 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 囊性或发育不良性肾病 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 尿石病 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 女性生殖道非炎性疾患 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 肾小球疾病 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| X 扩展码:例数31(0.10%) | 腺瘤和腺癌 | 28 | 0.093% | 10 | 0.226% | 1 | 0.518% |
| 纤维瘤性肿瘤 | 2 | 0.007% | 2 | 0.045% | 0 | 0.000% |
| 鳞状细胞肿瘤 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 耳或乳突疾病:例数26(0.09%) | 中耳炎 | 26 | 0.086% | 4 | 0.090% | 0 | 0.000% |
| 肌肉骨骼系统或结缔组织疾病:例数5(0.02%) | 某些特指的软组织疾患 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 其他特指的关节病 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 未特指的骨病或软骨病 | 1 | 0.003% | 1 | 0.023% | 0 | 0.000% |
| 损伤、中毒或外因的某些其他后果:例数5(0.02%) | 未特指的损伤、中毒和外因的某些其他后果 | 3 | 0.010% | 0 | 0.000% | 0 | 0.000% |
| 腹部、下背或骨盆的肌肉、筋膜或肌腱的损伤 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 腹内器官损伤 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 皮肤疾病:例数4(0.01%) | 累及生殖器和肛周的皮肤疾病 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 皮炎和湿疹 | 2 | 0.007% | 1 | 0.023% | 0 | 0.000% |
| 免疫系统疾病:例数3(0.01%) | 结节病 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 中性粒细胞减少症 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 精神、行为或神经发育障碍:例数1(0.00%) | 痴呆 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 视觉系统疾病:例数1(0.00%) | 眼眶疾患 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |

#### 5.1.3 组间比较

##### 所属类别

  全人群共涉及18种西医主要诊断的肿瘤4级/其他3级分类名称。发生ADR的患者，肿瘤:是152(78.76%)、否41(21.24%)，未发生ADR的患者，肿瘤:是23663(79.04%)、否6274(20.96%)，两组的分布不具有显著性差异(p=0.922)，其它主要诊断的比较检验过程保持一致。具有显著性差异的主要诊断有：内分泌、营养或代谢疾病、泌尿生殖系统疾病。比较检验结果详见表 13,且表中只保留发生ADR的西医主要诊断。

**表 13: 西医主要诊断所属分类详表**

| **变量** | **发生ADR (N=193)** | **未发生ADR (N=29937)** | **总计 (N=30130)** | **检验方法** | **P值** |
| --- | --- | --- | --- | --- | --- |
| 肿瘤 |  |  |  | Pearson's Chi-squared test | 0.922 |
| 是 | 152 (78.76%) | 23663 (79.04%) | 23815 (79.04%) |  |  |
| 否 | 41 (21.24%) | 6274 (20.96%) | 6315 (20.96%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 影响健康状态或与保健机构接触的因素 |  |  |  | Pearson's Chi-squared test | 0.280 |
| 是 | 21 (10.88%) | 4057 (13.55%) | 4078 (13.53%) |  |  |
| 否 | 172 (89.12%) | 25880 (86.45%) | 26052 (86.47%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 症状、体征或临床所见，不可归类在他处者 |  |  |  | Fisher's Exact Test for Count Data | 0.211 |
| 是 | 7 (3.63%) | 665 (2.22%) | 672 (2.23%) |  |  |
| 否 | 186 (96.37%) | 29272 (97.78%) | 29458 (97.77%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 内分泌、营养或代谢疾病 |  |  |  | Fisher's Exact Test for Count Data | 0.003 |
| 是 | 5 (2.59%) | 148 (0.49%) | 153 (0.51%) |  |  |
| 否 | 188 (97.41%) | 29789 (99.51%) | 29977 (99.49%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 呼吸系统疾病 |  |  |  | Fisher's Exact Test for Count Data | 0.591 |
| 是 | 2 (1.04%) | 543 (1.81%) | 545 (1.81%) |  |  |
| 否 | 191 (98.96%) | 29394 (98.19%) | 29585 (98.19%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 泌尿生殖系统疾病 |  |  |  | Fisher's Exact Test for Count Data | 0.044 |
| 是 | 2 (1.04%) | 50 (0.17%) | 52 (0.17%) |  |  |
| 否 | 191 (98.96%) | 29887 (99.83%) | 30078 (99.83%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 某些感染性疾病或寄生虫病 |  |  |  | Fisher's Exact Test for Count Data | 0.342 |
| 是 | 2 (1.04%) | 187 (0.62%) | 189 (0.63%) |  |  |
| 否 | 191 (98.96%) | 29750 (99.38%) | 29941 (99.37%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 消化系统疾病 |  |  |  | Fisher's Exact Test for Count Data | > 0.999 |
| 是 | 1 (0.52%) | 202 (0.67%) | 203 (0.67%) |  |  |
| 否 | 192 (99.48%) | 29735 (99.33%) | 29927 (99.33%) |  |  |
| Missing | 0 | 0 | 0 |  |  |

##### 诊断名称

  全人群共涉及199种西医主要诊断名称。发生ADR的患者，支气管和肺部恶性肿瘤:是41(21.24%)、否152(78.76%)，未发生ADR的患者，支气管和肺部恶性肿瘤:是6362(21.25%)、否23575(78.75%)，两组的分布不具有显著性差异(p=0.998)，其它主要诊断的比较检验过程保持一致。具有显著性差异的主要诊断有：甲状腺疾病、除肾盂之外的肾脏恶性肿瘤、乳房疾病、肝脏和肝内胆管恶性肿瘤、其他细菌性疾病。比较检验结果详见表 14,且表中只保留发生ADR的西医主要诊断。

**表 14: 西医主要诊断名称详表**

| **变量** | **发生ADR (N=193)** | **未发生ADR (N=29937)** | **总计 (N=30130)** | **检验方法** | **P值** |
| --- | --- | --- | --- | --- | --- |
| 支气管和肺部恶性肿瘤 |  |  |  | Pearson's Chi-squared test | 0.998 |
| 是 | 41 (21.24%) | 6362 (21.25%) | 6403 (21.25%) |  |  |
| 否 | 152 (78.76%) | 23575 (78.75%) | 23727 (78.75%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 乳腺恶性肿瘤 |  |  |  | Pearson's Chi-squared test | 0.202 |
| 是 | 28 (14.51%) | 3460 (11.56%) | 3488 (11.58%) |  |  |
| 否 | 165 (85.49%) | 26477 (88.44%) | 26642 (88.42%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 影响健康状态或与保健机构接触的因素 |  |  |  | Pearson's Chi-squared test | 0.280 |
| 是 | 21 (10.88%) | 4057 (13.55%) | 4078 (13.53%) |  |  |
| 否 | 172 (89.12%) | 25880 (86.45%) | 26052 (86.47%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 食管恶性肿瘤 |  |  |  | Pearson's Chi-squared test | 0.630 |
| 是 | 11 (5.70%) | 1964 (6.56%) | 1975 (6.55%) |  |  |
| 否 | 182 (94.30%) | 27973 (93.44%) | 28155 (93.45%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 胃部恶性肿瘤 |  |  |  | Pearson's Chi-squared test | 0.335 |
| 是 | 8 (4.15%) | 1726 (5.77%) | 1734 (5.76%) |  |  |
| 否 | 185 (95.85%) | 28211 (94.23%) | 28396 (94.24%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 乳房肿块 |  |  |  | Fisher's Exact Test for Count Data | 0.069 |
| 是 | 6 (3.11%) | 441 (1.47%) | 447 (1.48%) |  |  |
| 否 | 187 (96.89%) | 29496 (98.53%) | 29683 (98.52%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 鼻咽部恶性肿瘤 |  |  |  | Fisher's Exact Test for Count Data | 0.086 |
| 是 | 5 (2.59%) | 360 (1.20%) | 365 (1.21%) |  |  |
| 否 | 188 (97.41%) | 29577 (98.80%) | 29765 (98.79%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 甲状腺疾病 |  |  |  | Fisher's Exact Test for Count Data | 0.003 |
| 是 | 5 (2.59%) | 141 (0.47%) | 146 (0.48%) |  |  |
| 否 | 188 (97.41%) | 29796 (99.53%) | 29984 (99.52%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 卵巢恶性肿瘤 |  |  |  | Fisher's Exact Test for Count Data | 0.229 |
| 是 | 5 (2.59%) | 461 (1.54%) | 466 (1.55%) |  |  |
| 否 | 188 (97.41%) | 29476 (98.46%) | 29664 (98.45%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 除肾盂之外的肾脏恶性肿瘤 |  |  |  | Fisher's Exact Test for Count Data | 0.024 |
| 是 | 4 (2.07%) | 165 (0.55%) | 169 (0.56%) |  |  |
| 否 | 189 (97.93%) | 29772 (99.45%) | 29961 (99.44%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 脑部恶性肿瘤 |  |  |  | Fisher's Exact Test for Count Data | 0.117 |
| 是 | 4 (2.07%) | 286 (0.96%) | 290 (0.96%) |  |  |
| 否 | 189 (97.93%) | 29651 (99.04%) | 29840 (99.04%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 甲状腺恶性肿瘤 |  |  |  | Fisher's Exact Test for Count Data | > 0.999 |
| 是 | 3 (1.55%) | 578 (1.93%) | 581 (1.93%) |  |  |
| 否 | 190 (98.45%) | 29359 (98.07%) | 29549 (98.07%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 弥漫型非霍奇金淋巴瘤 |  |  |  | Fisher's Exact Test for Count Data | 0.132 |
| 是 | 3 (1.55%) | 193 (0.64%) | 196 (0.65%) |  |  |
| 否 | 190 (98.45%) | 29744 (99.36%) | 29934 (99.35%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 其它和未特指类型的非霍奇金氏淋巴瘤 |  |  |  | Fisher's Exact Test for Count Data | 0.443 |
| 是 | 3 (1.55%) | 293 (0.98%) | 296 (0.98%) |  |  |
| 否 | 190 (98.45%) | 29644 (99.02%) | 29834 (99.02%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 下咽部恶性肿瘤 |  |  |  | Fisher's Exact Test for Count Data | 0.760 |
| 是 | 3 (1.55%) | 434 (1.45%) | 437 (1.45%) |  |  |
| 否 | 190 (98.45%) | 29503 (98.55%) | 29693 (98.55%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 直肠恶性肿瘤 |  |  |  | Pearson's Chi-squared test | 0.213 |
| 是 | 3 (1.55%) | 932 (3.11%) | 935 (3.10%) |  |  |
| 否 | 190 (98.45%) | 29005 (96.89%) | 29195 (96.90%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 子宫颈恶性肿瘤 |  |  |  | Fisher's Exact Test for Count Data | 0.206 |
| 是 | 3 (1.55%) | 241 (0.81%) | 244 (0.81%) |  |  |
| 否 | 190 (98.45%) | 29696 (99.19%) | 29886 (99.19%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 子宫体恶性肿瘤 |  |  |  | Fisher's Exact Test for Count Data | 0.455 |
| 是 | 3 (1.55%) | 308 (1.03%) | 311 (1.03%) |  |  |
| 否 | 190 (98.45%) | 29629 (98.97%) | 29819 (98.97%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 多发性骨髓瘤和恶性浆细胞肿瘤 |  |  |  | Fisher's Exact Test for Count Data | 0.055 |
| 是 | 2 (1.04%) | 57 (0.19%) | 59 (0.20%) |  |  |
| 否 | 191 (98.96%) | 29880 (99.81%) | 30071 (99.80%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 其它和不清楚部位的唇、口腔和咽部的恶性肿瘤 |  |  |  | Fisher's Exact Test for Count Data | > 0.999 |
| 是 | 2 (1.04%) | 352 (1.18%) | 354 (1.17%) |  |  |
| 否 | 191 (98.96%) | 29585 (98.82%) | 29776 (98.83%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 乳房疾病 |  |  |  | Fisher's Exact Test for Count Data | 0.037 |
| 是 | 2 (1.04%) | 45 (0.15%) | 47 (0.16%) |  |  |
| 否 | 191 (98.96%) | 29892 (99.85%) | 30083 (99.84%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 髓系白血病 |  |  |  | Fisher's Exact Test for Count Data | 0.392 |
| 是 | 2 (1.04%) | 209 (0.70%) | 211 (0.70%) |  |  |
| 否 | 191 (98.96%) | 29728 (99.30%) | 29919 (99.30%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 胸腺恶性肿瘤 |  |  |  | Fisher's Exact Test for Count Data | 0.135 |
| 是 | 2 (1.04%) | 98 (0.33%) | 100 (0.33%) |  |  |
| 否 | 191 (98.96%) | 29839 (99.67%) | 30030 (99.67%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 胰腺恶性肿瘤 |  |  |  | Fisher's Exact Test for Count Data | 0.776 |
| 是 | 2 (1.04%) | 511 (1.71%) | 513 (1.70%) |  |  |
| 否 | 191 (98.96%) | 29426 (98.29%) | 29617 (98.30%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 膀胱恶性肿瘤 |  |  |  | Fisher's Exact Test for Count Data | 0.311 |
| 是 | 1 (0.52%) | 57 (0.19%) | 58 (0.19%) |  |  |
| 否 | 192 (99.48%) | 29880 (99.81%) | 30072 (99.81%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 扁桃腺恶性肿瘤 |  |  |  | Fisher's Exact Test for Count Data | 0.337 |
| 是 | 1 (0.52%) | 63 (0.21%) | 64 (0.21%) |  |  |
| 否 | 192 (99.48%) | 29874 (99.79%) | 30066 (99.79%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 胆囊恶性肿瘤 |  |  |  | Fisher's Exact Test for Count Data | 0.538 |
| 是 | 1 (0.52%) | 119 (0.40%) | 120 (0.40%) |  |  |
| 否 | 192 (99.48%) | 29818 (99.60%) | 30010 (99.60%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 肝脏和肝内胆管恶性肿瘤 |  |  |  | Pearson's Chi-squared test | 0.030 |
| 是 | 1 (0.52%) | 995 (3.32%) | 996 (3.31%) |  |  |
| 否 | 192 (99.48%) | 28942 (96.68%) | 29134 (96.69%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 肝脏疾病 |  |  |  | Fisher's Exact Test for Count Data | 0.275 |
| 是 | 1 (0.52%) | 49 (0.16%) | 50 (0.17%) |  |  |
| 否 | 192 (99.48%) | 29888 (99.84%) | 30080 (99.83%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 霍奇金淋巴瘤 |  |  |  | Fisher's Exact Test for Count Data | 0.617 |
| 是 | 1 (0.52%) | 148 (0.49%) | 149 (0.49%) |  |  |
| 否 | 192 (99.48%) | 29789 (99.51%) | 29981 (99.51%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 间皮瘤 |  |  |  | Fisher's Exact Test for Count Data | 0.154 |
| 是 | 1 (0.52%) | 25 (0.08%) | 26 (0.09%) |  |  |
| 否 | 192 (99.48%) | 29912 (99.92%) | 30104 (99.91%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 结肠直肠交接处恶性肿瘤 |  |  |  | Fisher's Exact Test for Count Data | 0.191 |
| 是 | 1 (0.52%) | 32 (0.11%) | 33 (0.11%) |  |  |
| 否 | 192 (99.48%) | 29905 (99.89%) | 30097 (99.89%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 口咽部恶性肿瘤 |  |  |  | Fisher's Exact Test for Count Data | 0.307 |
| 是 | 1 (0.52%) | 56 (0.19%) | 57 (0.19%) |  |  |
| 否 | 192 (99.48%) | 29881 (99.81%) | 30073 (99.81%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 流感和肺炎 |  |  |  | Fisher's Exact Test for Count Data | > 0.999 |
| 是 | 1 (0.52%) | 169 (0.56%) | 170 (0.56%) |  |  |
| 否 | 192 (99.48%) | 29768 (99.44%) | 29960 (99.44%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 慢性下呼吸道疾病 |  |  |  | Fisher's Exact Test for Count Data | > 0.999 |
| 是 | 1 (0.52%) | 175 (0.58%) | 176 (0.58%) |  |  |
| 否 | 192 (99.48%) | 29762 (99.42%) | 29954 (99.42%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 其他细菌性疾病 |  |  |  | Fisher's Exact Test for Count Data | 0.019 |
| 是 | 1 (0.52%) | 2 (0.01%) | 3 (0.01%) |  |  |
| 否 | 192 (99.48%) | 29935 (99.99%) | 30127 (99.99%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 其它和部位不确定的恶性肿瘤 |  |  |  | Fisher's Exact Test for Count Data | > 0.999 |
| 是 | 1 (0.52%) | 225 (0.75%) | 226 (0.75%) |  |  |
| 否 | 192 (99.48%) | 29712 (99.25%) | 29904 (99.25%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 其它和未特指的大唾液腺恶性肿瘤 |  |  |  | Fisher's Exact Test for Count Data | 0.175 |
| 是 | 1 (0.52%) | 29 (0.10%) | 30 (0.10%) |  |  |
| 否 | 192 (99.48%) | 29908 (99.90%) | 30100 (99.90%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 其它急性下呼吸道感染 |  |  |  | Fisher's Exact Test for Count Data | > 0.999 |
| 是 | 1 (0.52%) | 187 (0.62%) | 188 (0.62%) |  |  |
| 否 | 192 (99.48%) | 29750 (99.38%) | 29942 (99.38%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 涉及消化系统和腹部的症状和体征 |  |  |  | Fisher's Exact Test for Count Data | 0.371 |
| 是 | 1 (0.52%) | 71 (0.24%) | 72 (0.24%) |  |  |
| 否 | 192 (99.48%) | 29866 (99.76%) | 30058 (99.76%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 四肢骨和关节软骨恶性肿瘤 |  |  |  | Fisher's Exact Test for Count Data | 0.387 |
| 是 | 1 (0.52%) | 75 (0.25%) | 76 (0.25%) |  |  |
| 否 | 192 (99.48%) | 29862 (99.75%) | 30054 (99.75%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 透明细胞癌 |  |  |  | Fisher's Exact Test for Count Data | 0.159 |
| 是 | 1 (0.52%) | 26 (0.09%) | 27 (0.09%) |  |  |
| 否 | 192 (99.48%) | 29911 (99.91%) | 30103 (99.91%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 心脏、胸腔纵隔和胸膜的恶性肿瘤 |  |  |  | Fisher's Exact Test for Count Data | 0.597 |
| 是 | 1 (0.52%) | 140 (0.47%) | 141 (0.47%) |  |  |
| 否 | 192 (99.48%) | 29797 (99.53%) | 29989 (99.53%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 血液和造血器官的其他疾病 |  |  |  | Fisher's Exact Test for Count Data | 0.175 |
| 是 | 1 (0.52%) | 29 (0.10%) | 30 (0.10%) |  |  |
| 否 | 192 (99.48%) | 29908 (99.90%) | 30100 (99.90%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 眼、脑和其它中枢神经系统的恶性肿瘤 |  |  |  | Fisher's Exact Test for Count Data | 0.320 |
| 是 | 1 (0.52%) | 59 (0.20%) | 60 (0.20%) |  |  |
| 否 | 192 (99.48%) | 29878 (99.80%) | 30070 (99.80%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 周边和皮肤t细胞淋巴瘤 |  |  |  | Fisher's Exact Test for Count Data | > 0.999 |
| 是 | 1 (0.52%) | 176 (0.59%) | 177 (0.59%) |  |  |
| 否 | 192 (99.48%) | 29761 (99.41%) | 29953 (99.41%) |  |  |
| Missing | 0 | 0 | 0 |  |  |

### 5.2 次要诊断

#### 5.2.1 ADR人群诊断类别统计

  在193例ADR患者中，西医次要诊断系统分类中ADR发生例次降序排列，前5位的是，循环系统疾病55例(28.50%)69例次，消化系统疾病31例(16.06%)37例次，呼吸系统疾病22例(11.40%)24例次，内分泌、营养和代谢疾病22例(11.40%)23例次，肿瘤16例(8.29%)22例次。

**表 15: ADR人群西医次要诊断系统分类统计表**

| 系统分类名称 | 例数 | 例数占ADR人群比 | 例次 | 例次占总比 |
| --- | --- | --- | --- | --- |
| 循环系统疾病 | 55 | 28.50% | 69 | 27.94% |
| 消化系统疾病 | 31 | 16.06% | 37 | 14.98% |
| 呼吸系统疾病 | 22 | 11.40% | 24 | 9.72% |
| 内分泌、营养和代谢疾病 | 22 | 11.40% | 23 | 9.31% |
| 肿瘤 | 16 | 8.29% | 22 | 8.91% |
| 泌尿生殖系统疾病 | 18 | 9.33% | 21 | 8.50% |
| 某些感染性疾病或寄生虫病 | 14 | 7.25% | 14 | 5.67% |
| 影响健康状态或与保健机构接触的因素 | 9 | 4.66% | 9 | 3.64% |
| 症状、体征或临床所见，不可归类在他处者 | 8 | 4.15% | 8 | 3.24% |
| 肌肉骨骼系统或结缔组织疾病 | 6 | 3.11% | 6 | 2.43% |
| 血液或造血器官疾病 | 5 | 2.59% | 5 | 2.02% |
| 神经系统疾病 | 4 | 2.07% | 4 | 1.62% |
| 耳和乳突疾病 | 2 | 1.04% | 3 | 1.21% |
| 皮肤疾病 | 1 | 0.52% | 1 | 0.40% |
| 损伤、中毒和外因作用的某些其它结果 | 1 | 0.52% | 1 | 0.40% |

#### 5.2.2 诊断名例次统计

**表 16: 西医次要诊断例次统计表**

| **系统分类名称** | **诊断名称** | **全人群中发生例数** | **在全人群占比** | **AE人群中发生例数** | **在AE人群占比** | **ADR人群中发生例数** | **在ADR人群占比** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 循环系统疾病:例数6982(23.17%) | 高血压病 | 4337 | 14.394% | 807 | 18.233% | 35 | 18.135% |
| 高血压 | 4342 | 14.411% | 807 | 18.233% | 35 | 18.135% |
| 心脏病 | 1894 | 6.286% | 282 | 6.371% | 21 | 10.881% |
| 糖尿病 | 2024 | 6.718% | 368 | 8.315% | 19 | 9.845% |
| 恶性肿瘤 | 2712 | 9.001% | 416 | 9.399% | 16 | 8.290% |
| 食管、胃和十二指肠疾病 | 866 | 2.874% | 140 | 3.163% | 13 | 6.736% |
| 其它形式的心脏病 | 424 | 1.407% | 102 | 2.305% | 12 | 6.218% |
| 缺血性心脏病 | 1450 | 4.812% | 205 | 4.632% | 10 | 5.181% |
| 其它呼吸系统疾病 | 919 | 3.050% | 212 | 4.790% | 8 | 4.145% |
| 存在与家庭和个人经历以及某些影响健康状况条件有关的潜在健康危险的人群 | 833 | 2.765% | 105 | 2.372% | 8 | 4.145% |
| 肝脏疾病 | 892 | 2.961% | 152 | 3.434% | 8 | 4.145% |
| 病毒性肝炎 | 1061 | 3.521% | 153 | 3.457% | 7 | 3.627% |
| 其它胸膜疾病 | 546 | 1.812% | 116 | 2.621% | 7 | 3.627% |
| 脑血管疾病 | 903 | 2.997% | 198 | 4.474% | 6 | 3.109% |
| 慢性下呼吸道疾病 | 676 | 2.244% | 135 | 3.050% | 6 | 3.109% |
| 其它肠道疾病 | 363 | 1.205% | 58 | 1.310% | 6 | 3.109% |
| 乳房疾病 | 285 | 0.946% | 28 | 0.633% | 6 | 3.109% |
| 胆囊、胆道和胰腺疾病 | 626 | 2.078% | 134 | 3.028% | 5 | 2.591% |
| 再生障碍性贫血和其他的贫血 | 662 | 2.197% | 170 | 3.841% | 5 | 2.591% |
| 其它肾和输尿管疾病 | 311 | 1.032% | 51 | 1.152% | 5 | 2.591% |
| 支气管和肺部恶性肿瘤 | 315 | 1.045% | 61 | 1.378% | 4 | 2.073% |
| 男性生殖器官疾病 | 198 | 0.657% | 42 | 0.949% | 4 | 2.073% |
| 代谢性疾病 | 811 | 2.692% | 254 | 5.739% | 4 | 2.073% |
| 静脉、淋巴管、淋巴结疾病 | 422 | 1.401% | 80 | 1.808% | 3 | 1.554% |
| 呼吸器官继发性恶性肿瘤 | 398 | 1.321% | 77 | 1.740% | 3 | 1.554% |
| 继发和未特指的淋巴结恶性肿瘤 | 513 | 1.703% | 72 | 1.627% | 3 | 1.554% |
| 涉及消化系统和腹部的症状和体征 | 214 | 0.710% | 38 | 0.859% | 3 | 1.554% |
| 肺结核 | 146 | 0.485% | 21 | 0.474% | 3 | 1.554% |
| 脉、淋巴管、淋巴结疾病 | 423 | 1.404% | 80 | 1.808% | 3 | 1.554% |
| 肺心病和肺循环疾病 | 59 | 0.196% | 11 | 0.249% | 2 | 1.036% |
| 一般的症状和体征 | 523 | 1.736% | 111 | 2.508% | 2 | 1.036% |
| 流感和肺炎 | 422 | 1.401% | 102 | 2.305% | 2 | 1.036% |
| 其它泌尿系统疾病 | 117 | 0.388% | 25 | 0.565% | 2 | 1.036% |
| 骨病和软骨病 | 148 | 0.491% | 26 | 0.587% | 2 | 1.036% |
| 脊背病变 | 289 | 0.959% | 50 | 1.130% | 2 | 1.036% |
| 其它消化系统疾病 | 188 | 0.624% | 37 | 0.836% | 2 | 1.036% |
| 其它主要影响肺间质的呼吸道疾病 | 56 | 0.186% | 14 | 0.316% | 2 | 1.036% |
| 关节病 | 96 | 0.319% | 20 | 0.452% | 2 | 1.036% |
| 尿石症 | 97 | 0.322% | 15 | 0.339% | 2 | 1.036% |
| 中耳和乳突疾病 | 33 | 0.110% | 6 | 0.136% | 2 | 1.036% |
| 阑尾疾病 | 85 | 0.282% | 11 | 0.249% | 2 | 1.036% |
| 因特殊操作和护理接受健康服务的人群 | 491 | 1.630% | 96 | 2.169% | 1 | 0.518% |
| 肝脏和肝内胆管恶性肿瘤 | 196 | 0.651% | 28 | 0.633% | 1 | 0.518% |
| 疝 | 83 | 0.275% | 20 | 0.452% | 1 | 0.518% |
| 结肠恶性肿瘤 | 94 | 0.312% | 17 | 0.384% | 1 | 0.518% |
| 没有诊断的在诊断成像和功能研究中的异常发现 | 102 | 0.339% | 26 | 0.587% | 1 | 0.518% |
| 神经、神经根和神经丛疾病 | 48 | 0.159% | 7 | 0.158% | 1 | 0.518% |
| 肾小管-间质疾病 | 103 | 0.342% | 20 | 0.452% | 1 | 0.518% |
| 骨和关节软骨恶性肿瘤 | 187 | 0.621% | 33 | 0.746% | 1 | 0.518% |
| 卵巢恶性肿瘤 | 30 | 0.100% | 6 | 0.136% | 1 | 0.518% |
| 涉及循环和呼吸系统的症状和体征 | 70 | 0.232% | 10 | 0.226% | 1 | 0.518% |
| 食管恶性肿瘤 | 79 | 0.262% | 10 | 0.226% | 1 | 0.518% |
| 子宫颈恶性肿瘤 | 23 | 0.076% | 4 | 0.090% | 1 | 0.518% |
| 肺动脉栓塞 | 1 | 0.003% | 1 | 0.023% | 1 | 0.518% |
| 女性生殖道非炎性疾病 | 63 | 0.209% | 6 | 0.136% | 1 | 0.518% |
| 其他细菌性疾病 | 31 | 0.103% | 8 | 0.181% | 1 | 0.518% |
| 其它的神经系统变性疾病 | 16 | 0.053% | 3 | 0.068% | 1 | 0.518% |
| 其它和未特指部位的骨和关节软骨恶性肿瘤 | 128 | 0.425% | 25 | 0.565% | 1 | 0.518% |
| 其它内分泌腺和相关组织的恶性肿瘤 | 12 | 0.040% | 3 | 0.068% | 1 | 0.518% |
| 胰腺恶性肿瘤 | 21 | 0.070% | 5 | 0.113% | 1 | 0.518% |
| 动脉、小动脉和毛细血管疾病 | 81 | 0.269% | 12 | 0.271% | 0 | 0.000% |
| 其它部位的继发性恶性肿瘤 | 394 | 1.308% | 65 | 1.469% | 0 | 0.000% |
| 慢性风湿性心脏病 | 21 | 0.070% | 2 | 0.045% | 0 | 0.000% |
| 冠心病 | 21 | 0.070% | 5 | 0.113% | 0 | 0.000% |
| 甲状腺疾病 | 263 | 0.873% | 31 | 0.700% | 0 | 0.000% |
| 脑梗死 | 15 | 0.050% | 3 | 0.068% | 0 | 0.000% |
| 乳腺恶性肿瘤 | 120 | 0.398% | 18 | 0.407% | 0 | 0.000% |
| 胃部恶性肿瘤 | 91 | 0.302% | 9 | 0.203% | 0 | 0.000% |
| 短暂和突发性疾病 | 111 | 0.368% | 18 | 0.407% | 0 | 0.000% |
| 甲状腺恶性肿瘤 | 75 | 0.249% | 11 | 0.249% | 0 | 0.000% |
| 未特指部位的恶性肿瘤 | 56 | 0.186% | 6 | 0.136% | 0 | 0.000% |
| 消化器官恶性肿瘤 | 72 | 0.239% | 5 | 0.113% | 0 | 0.000% |
| 呼吸和胸内器官的恶性肿瘤 | 46 | 0.153% | 8 | 0.181% | 0 | 0.000% |
| 其它和部位不确定的恶性肿瘤 | 38 | 0.126% | 5 | 0.113% | 0 | 0.000% |
| 其它或未特指的循环系统疾病 | 7 | 0.023% | 3 | 0.068% | 0 | 0.000% |
| 膀胱恶性肿瘤 | 15 | 0.050% | 2 | 0.045% | 0 | 0.000% |
| 腹膜疾病 | 94 | 0.312% | 26 | 0.587% | 0 | 0.000% |
| 冠状动脉粥样硬化性心脏病 | 4 | 0.013% | 0 | 0.000% | 0 | 0.000% |
| 急性上呼吸道感染 | 120 | 0.398% | 32 | 0.723% | 0 | 0.000% |
| 其它上呼吸道疾病 | 148 | 0.491% | 15 | 0.339% | 0 | 0.000% |
| 前列腺恶性肿瘤 | 22 | 0.073% | 5 | 0.113% | 0 | 0.000% |
| 除肾盂之外的肾脏恶性肿瘤 | 17 | 0.056% | 1 | 0.023% | 0 | 0.000% |
| 多发性浆膜腔积液 | 20 | 0.066% | 12 | 0.271% | 0 | 0.000% |
| 喉部恶性肿瘤 | 11 | 0.037% | 2 | 0.045% | 0 | 0.000% |
| 口腔、唾液腺和上下颌疾病 | 62 | 0.206% | 4 | 0.090% | 0 | 0.000% |
| 脑瘫和其它的瘫痪综合症 | 15 | 0.050% | 4 | 0.090% | 0 | 0.000% |
| 肾衰竭 | 83 | 0.275% | 19 | 0.429% | 0 | 0.000% |
| 完全性右束支传导阻滞 | 3 | 0.010% | 1 | 0.023% | 0 | 0.000% |
| 以皮肤和黏膜损害为特征的病毒性感染 | 34 | 0.113% | 6 | 0.136% | 0 | 0.000% |
| 由于外部原因造成的肺疾病 | 42 | 0.139% | 10 | 0.226% | 0 | 0.000% |
| 肺部感染 | 37 | 0.123% | 10 | 0.226% | 0 | 0.000% |
| 腹部、腰脊柱、背下部、盆骨损伤 | 50 | 0.166% | 10 | 0.226% | 0 | 0.000% |
| 某些涉及免疫机能的异常 | 49 | 0.163% | 11 | 0.249% | 0 | 0.000% |
| 脑部恶性肿瘤 | 49 | 0.163% | 5 | 0.113% | 0 | 0.000% |
| 内耳疾病 | 11 | 0.037% | 2 | 0.045% | 0 | 0.000% |
| 肾功能不全 | 6 | 0.020% | 2 | 0.045% | 0 | 0.000% |
| 特性未定或未知的泌尿器官肿瘤 | 5 | 0.017% | 1 | 0.023% | 0 | 0.000% |
| 小肠恶性肿瘤 | 11 | 0.037% | 1 | 0.023% | 0 | 0.000% |
| 血液和造血器官的其他疾病 | 202 | 0.670% | 66 | 1.491% | 0 | 0.000% |
| 眼结膜疾病 | 4 | 0.013% | 0 | 0.000% | 0 | 0.000% |
| 直肠恶性肿瘤 | 50 | 0.166% | 3 | 0.068% | 0 | 0.000% |
| 中枢神经系统病毒感染 | 9 | 0.030% | 2 | 0.045% | 0 | 0.000% |
| 癌痛综合征 | 3 | 0.010% | 2 | 0.045% | 0 | 0.000% |
| 癌性溃疡 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 不完全性肠梗阻 | 4 | 0.013% | 3 | 0.068% | 0 | 0.000% |
| 齿龈恶性肿瘤 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 传染病和寄生虫病的后遗症 | 56 | 0.186% | 8 | 0.181% | 0 | 0.000% |
| 唇、口腔和咽部的恶性肿瘤 | 4 | 0.013% | 1 | 0.023% | 0 | 0.000% |
| 错构瘤 | 1 | 0.003% | 1 | 0.023% | 0 | 0.000% |
| 独立的（原发的）多部位恶性肿瘤 | 12 | 0.040% | 3 | 0.068% | 0 | 0.000% |
| 二尖瓣及主动脉瓣狭窄 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 非感染性肠炎和结肠炎 | 49 | 0.163% | 9 | 0.203% | 0 | 0.000% |
| 肺炎球菌感染 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 腹膜和腹膜后腔恶性肿瘤 | 13 | 0.043% | 0 | 0.000% | 0 | 0.000% |
| 肝动脉栓塞化疗后 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 睾丸恶性肿瘤 | 5 | 0.017% | 1 | 0.023% | 0 | 0.000% |
| 冠状动脉支架术后 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 霍奇金氏病 | 5 | 0.017% | 2 | 0.045% | 0 | 0.000% |
| 甲状腺良性肿瘤 | 3 | 0.010% | 1 | 0.023% | 0 | 0.000% |
| 晶状体疾病 | 41 | 0.136% | 9 | 0.203% | 0 | 0.000% |
| 精神分裂症、分裂型和妄想性精神障碍 | 17 | 0.056% | 2 | 0.045% | 0 | 0.000% |
| 口腔和消化器官特性未定或未知的肿瘤 | 2 | 0.007% | 1 | 0.023% | 0 | 0.000% |
| 淋巴、造血和相关组织的恶性肿瘤 | 12 | 0.040% | 1 | 0.023% | 0 | 0.000% |
| 脉管炎 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 泌尿系统先天性畸形 | 7 | 0.023% | 2 | 0.045% | 0 | 0.000% |
| 脑血管病 | 1 | 0.003% | 1 | 0.023% | 0 | 0.000% |
| 皮肤和皮下组织感染 | 36 | 0.119% | 5 | 0.113% | 0 | 0.000% |
| 其他肠胃疾病 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 其他的营养缺乏 | 3 | 0.010% | 0 | 0.000% | 0 | 0.000% |
| 其他泌尿系统疾病 | 18 | 0.060% | 5 | 0.113% | 0 | 0.000% |
| 其它传染病 | 4 | 0.013% | 1 | 0.023% | 0 | 0.000% |
| 其它和未特指部位的特性未定或未知的肿瘤 | 9 | 0.030% | 1 | 0.023% | 0 | 0.000% |
| 其它急性下呼吸道感染 | 15 | 0.050% | 4 | 0.090% | 0 | 0.000% |
| 其它结缔组织和软组织的恶性肿瘤 | 8 | 0.027% | 1 | 0.023% | 0 | 0.000% |
| 其它静脉疾病 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 其它消化器官恶性肿瘤 | 4 | 0.013% | 1 | 0.023% | 0 | 0.000% |
| 器质性（包括症状性）精神障碍 | 5 | 0.017% | 3 | 0.068% | 0 | 0.000% |
| 前臂骨折 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 青光眼 | 15 | 0.050% | 2 | 0.045% | 0 | 0.000% |
| 情感性精神障碍（心境障碍） | 33 | 0.110% | 6 | 0.136% | 0 | 0.000% |
| 乳腺癌 | 4 | 0.013% | 0 | 0.000% | 0 | 0.000% |
| 乳腺良性肿瘤 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 三尖瓣狭窄 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 涉及皮肤和皮下组织的症状和体征 | 13 | 0.043% | 5 | 0.113% | 0 | 0.000% |
| 肾和输尿管结石 | 1 | 0.003% | 1 | 0.023% | 0 | 0.000% |
| 输尿管占位性病变 | 1 | 0.003% | 1 | 0.023% | 0 | 0.000% |
| 特性未定或未知的内分泌腺肿瘤 | 13 | 0.043% | 1 | 0.023% | 0 | 0.000% |
| 完全性右束枝传导阻滞 | 1 | 0.003% | 1 | 0.023% | 0 | 0.000% |
| 胃炎 | 3 | 0.010% | 0 | 0.000% | 0 | 0.000% |
| 下呼吸道化脓性和坏死性疾病 | 31 | 0.103% | 4 | 0.090% | 0 | 0.000% |
| 下肢静脉炎 | 1 | 0.003% | 1 | 0.023% | 0 | 0.000% |
| 胸部损伤 | 29 | 0.096% | 2 | 0.045% | 0 | 0.000% |
| 因体检和检查接受健康服务的人群 | 33 | 0.110% | 5 | 0.113% | 0 | 0.000% |
| 营养不良 | 74 | 0.246% | 24 | 0.542% | 0 | 0.000% |
| 营养性贫血 | 28 | 0.093% | 7 | 0.158% | 0 | 0.000% |
| 主动脉钙化 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 主动脉瘤及主动脉夹层 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 子宫平滑肌瘤 | 66 | 0.219% | 8 | 0.181% | 0 | 0.000% |
| 子宫体恶性肿瘤 | 27 | 0.090% | 6 | 0.136% | 0 | 0.000% |
| 肿瘤:例数2711(9.00%) | 恶性肿瘤 | 2712 | 9.001% | 416 | 9.399% | 16 | 8.290% |
| 缺血性心脏病 | 1450 | 4.812% | 205 | 4.632% | 10 | 5.181% |
| 支气管和肺部恶性肿瘤 | 315 | 1.045% | 61 | 1.378% | 4 | 2.073% |
| 继发和未特指的淋巴结恶性肿瘤 | 513 | 1.703% | 72 | 1.627% | 3 | 1.554% |
| 呼吸器官继发性恶性肿瘤 | 398 | 1.321% | 77 | 1.740% | 3 | 1.554% |
| 消化器官继发性恶性肿瘤 | 398 | 1.321% | 77 | 1.740% | 3 | 1.554% |
| 肝脏和肝内胆管恶性肿瘤 | 196 | 0.651% | 28 | 0.633% | 1 | 0.518% |
| 其它和未特指部位的骨和关节软骨恶性肿瘤 | 128 | 0.425% | 25 | 0.565% | 1 | 0.518% |
| 结肠恶性肿瘤 | 94 | 0.312% | 17 | 0.384% | 1 | 0.518% |
| 食管恶性肿瘤 | 79 | 0.262% | 10 | 0.226% | 1 | 0.518% |
| 骨和关节软骨恶性肿瘤 | 187 | 0.621% | 33 | 0.746% | 1 | 0.518% |
| 卵巢恶性肿瘤 | 30 | 0.100% | 6 | 0.136% | 1 | 0.518% |
| 子宫颈恶性肿瘤 | 23 | 0.076% | 4 | 0.090% | 1 | 0.518% |
| 胰腺恶性肿瘤 | 21 | 0.070% | 5 | 0.113% | 1 | 0.518% |
| 其它内分泌腺和相关组织的恶性肿瘤 | 12 | 0.040% | 3 | 0.068% | 1 | 0.518% |
| 其它部位的继发性恶性肿瘤 | 394 | 1.308% | 65 | 1.469% | 0 | 0.000% |
| 乳腺恶性肿瘤 | 120 | 0.398% | 18 | 0.407% | 0 | 0.000% |
| 胃部恶性肿瘤 | 91 | 0.302% | 9 | 0.203% | 0 | 0.000% |
| 甲状腺恶性肿瘤 | 75 | 0.249% | 11 | 0.249% | 0 | 0.000% |
| 子宫平滑肌瘤 | 66 | 0.219% | 8 | 0.181% | 0 | 0.000% |
| 消化器官恶性肿瘤 | 72 | 0.239% | 5 | 0.113% | 0 | 0.000% |
| 未特指部位的恶性肿瘤 | 56 | 0.186% | 6 | 0.136% | 0 | 0.000% |
| 直肠恶性肿瘤 | 50 | 0.166% | 3 | 0.068% | 0 | 0.000% |
| 呼吸和胸内器官的恶性肿瘤 | 46 | 0.153% | 8 | 0.181% | 0 | 0.000% |
| 脑部恶性肿瘤 | 49 | 0.163% | 5 | 0.113% | 0 | 0.000% |
| 任何部位的血管瘤和淋巴管瘤 | 42 | 0.139% | 9 | 0.203% | 0 | 0.000% |
| 其它和部位不确定的恶性肿瘤 | 38 | 0.126% | 5 | 0.113% | 0 | 0.000% |
| 子宫体恶性肿瘤 | 27 | 0.090% | 6 | 0.136% | 0 | 0.000% |
| 良性脂肪瘤 | 25 | 0.083% | 6 | 0.136% | 0 | 0.000% |
| 心脏、胸腔纵隔和胸膜的恶性肿瘤 | 23 | 0.076% | 2 | 0.045% | 0 | 0.000% |
| 乳房良性肿瘤 | 22 | 0.073% | 1 | 0.023% | 0 | 0.000% |
| 肾上腺恶性肿瘤 | 23 | 0.076% | 7 | 0.158% | 0 | 0.000% |
| 前列腺恶性肿瘤 | 22 | 0.073% | 5 | 0.113% | 0 | 0.000% |
| 除肾盂之外的肾脏恶性肿瘤 | 17 | 0.056% | 1 | 0.023% | 0 | 0.000% |
| 腹膜和腹膜后腔恶性肿瘤 | 13 | 0.043% | 0 | 0.000% | 0 | 0.000% |
| 膀胱恶性肿瘤 | 15 | 0.050% | 2 | 0.045% | 0 | 0.000% |
| 独立的（原发的）多部位恶性肿瘤 | 12 | 0.040% | 3 | 0.068% | 0 | 0.000% |
| 其它皮肤恶性肿瘤 | 12 | 0.040% | 1 | 0.023% | 0 | 0.000% |
| 特性未定或未知的内分泌腺肿瘤 | 13 | 0.043% | 1 | 0.023% | 0 | 0.000% |
| 肺癌根治术 | 9 | 0.030% | 1 | 0.023% | 0 | 0.000% |
| 淋巴、造血和相关组织的恶性肿瘤 | 12 | 0.040% | 1 | 0.023% | 0 | 0.000% |
| 其它和未特指类型的非霍奇金氏淋巴瘤 | 10 | 0.033% | 1 | 0.023% | 0 | 0.000% |
| 小肠恶性肿瘤 | 11 | 0.037% | 1 | 0.023% | 0 | 0.000% |
| 癌症性恶病质 | 8 | 0.027% | 3 | 0.068% | 0 | 0.000% |
| 鼻咽部恶性肿瘤 | 8 | 0.027% | 0 | 0.000% | 0 | 0.000% |
| 喉部恶性肿瘤 | 11 | 0.037% | 2 | 0.045% | 0 | 0.000% |
| 淋巴性白血病 | 8 | 0.027% | 1 | 0.023% | 0 | 0.000% |
| 男性生殖器官的恶性肿瘤 | 12 | 0.040% | 1 | 0.023% | 0 | 0.000% |
| 其它和未特指部位的特性未定或未知的肿瘤 | 9 | 0.030% | 1 | 0.023% | 0 | 0.000% |
| 髓系白血病 | 8 | 0.027% | 3 | 0.068% | 0 | 0.000% |
| 其它结缔组织和软组织的恶性肿瘤 | 8 | 0.027% | 1 | 0.023% | 0 | 0.000% |
| 脑膜恶性肿瘤 | 7 | 0.023% | 1 | 0.023% | 0 | 0.000% |
| 其它和未特指的大唾液腺恶性肿瘤 | 6 | 0.020% | 1 | 0.023% | 0 | 0.000% |
| 女性生殖器官的恶性肿瘤 | 5 | 0.017% | 0 | 0.000% | 0 | 0.000% |
| 气管恶性肿瘤 | 5 | 0.017% | 0 | 0.000% | 0 | 0.000% |
| 乳房的恶性肿瘤 | 5 | 0.017% | 0 | 0.000% | 0 | 0.000% |
| 乳房原位癌 | 5 | 0.017% | 0 | 0.000% | 0 | 0.000% |
| 特性未定或未知的淋巴、造血和相关组织的其它肿瘤 | 5 | 0.017% | 0 | 0.000% | 0 | 0.000% |
| 胸腺恶性肿瘤 | 5 | 0.017% | 1 | 0.023% | 0 | 0.000% |
| 肛门和肛道恶性肿瘤 | 5 | 0.017% | 0 | 0.000% | 0 | 0.000% |
| 睾丸恶性肿瘤 | 5 | 0.017% | 1 | 0.023% | 0 | 0.000% |
| 霍奇金氏病 | 5 | 0.017% | 2 | 0.045% | 0 | 0.000% |
| 结肠、直肠、肛门和肛道的良性肿瘤 | 4 | 0.013% | 0 | 0.000% | 0 | 0.000% |
| 脑脊膜良性肿瘤 | 4 | 0.013% | 0 | 0.000% | 0 | 0.000% |
| 其它和不确定的消化器官恶性肿瘤 | 4 | 0.013% | 1 | 0.023% | 0 | 0.000% |
| 其它和未特指的内分泌腺良性肿瘤 | 4 | 0.013% | 1 | 0.023% | 0 | 0.000% |
| 其它和未特指的女性生殖器官恶性肿瘤 | 4 | 0.013% | 3 | 0.068% | 0 | 0.000% |
| 不明确、继发和未特指部位的恶性肿瘤 | 4 | 0.013% | 1 | 0.023% | 0 | 0.000% |
| 唇、口腔和咽部的恶性肿瘤 | 4 | 0.013% | 1 | 0.023% | 0 | 0.000% |
| 骨和关节软骨的良性肿瘤 | 3 | 0.010% | 2 | 0.045% | 0 | 0.000% |
| 弥漫型非霍奇金淋巴瘤 | 3 | 0.010% | 0 | 0.000% | 0 | 0.000% |
| 其它消化器官恶性肿瘤 | 4 | 0.013% | 1 | 0.023% | 0 | 0.000% |
| 腮腺恶性肿瘤 | 3 | 0.010% | 0 | 0.000% | 0 | 0.000% |
| 输尿管恶性肿瘤 | 3 | 0.010% | 0 | 0.000% | 0 | 0.000% |
| 四肢骨和关节软骨恶性肿瘤 | 3 | 0.010% | 1 | 0.023% | 0 | 0.000% |
| 髓样和淋巴肿瘤伴PDGFRA重排 | 3 | 0.010% | 1 | 0.023% | 0 | 0.000% |
| 特性未定或未知的泌尿器官肿瘤 | 5 | 0.017% | 1 | 0.023% | 0 | 0.000% |
| 眼、脑和其它中枢神经系统的恶性肿瘤 | 4 | 0.013% | 2 | 0.045% | 0 | 0.000% |
| 子宫颈原位癌 | 3 | 0.010% | 0 | 0.000% | 0 | 0.000% |
| 贲门癌根治术 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 胆囊恶性肿瘤 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 多发性骨髓瘤和恶性浆细胞肿瘤 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 骨髓增生异常综合症 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 间皮瘤 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 间叶瘤 | 2 | 0.007% | 2 | 0.045% | 0 | 0.000% |
| 卵巢肿瘤 | 2 | 0.007% | 1 | 0.023% | 0 | 0.000% |
| 滤泡状（结节性）非霍奇金氏淋巴瘤 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 泌尿道恶性肿瘤 | 3 | 0.010% | 0 | 0.000% | 0 | 0.000% |
| 皮肤恶性黑素瘤 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 其他特指的肝癌 | 2 | 0.007% | 1 | 0.023% | 0 | 0.000% |
| 其它的和未特指的泌尿器官恶性肿瘤 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 其它和不确定部位的消化系统良性肿瘤 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 其它和未特指部位的原位癌 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 其它和未特指的胆管恶性肿瘤 | 2 | 0.007% | 1 | 0.023% | 0 | 0.000% |
| 其它和未特指的口部恶性肿瘤 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 其它和未特指的淋巴、造血和相关组织的恶性肿瘤 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 乳腺癌 | 4 | 0.013% | 0 | 0.000% | 0 | 0.000% |
| 肾盂恶性肿瘤 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 特性未定或未知的脑和中枢神经系统肿瘤 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 腺癌 | 6 | 0.020% | 1 | 0.023% | 0 | 0.000% |
| 中耳和呼吸系统原位癌 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| r-刀治疗脑肿瘤 | 1 | 0.003% | 1 | 0.023% | 0 | 0.000% |
| 部位未特指的子宫恶性肿瘤 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 胆囊癌切除个人史 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 恶性肿瘤的家族史 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 黑素细胞痣 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 喉恶性肿瘤 | 1 | 0.003% | 1 | 0.023% | 0 | 0.000% |
| 呼吸和胸内器官交搭跨越的恶性肿瘤 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 呼吸和胸内器官特性未定或未知的肿瘤 | 1 | 0.003% | 1 | 0.023% | 0 | 0.000% |
| 甲状腺良性肿瘤 | 3 | 0.010% | 1 | 0.023% | 0 | 0.000% |
| 间皮和软组织的恶性肿瘤 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 结缔组织和其它软组织的其它良性肿瘤 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 口腔和消化器官特性未定或未知的肿瘤 | 2 | 0.007% | 1 | 0.023% | 0 | 0.000% |
| 口咽部恶性肿瘤 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 良性肿瘤 | 48 | 0.159% | 6 | 0.136% | 0 | 0.000% |
| 卵巢癌 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 面部恶性肿瘤 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 女性生殖器官特性未定或未知的肿瘤 | 1 | 0.003% | 1 | 0.023% | 0 | 0.000% |
| 其它的良性皮肤肿瘤 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 其它和未特指部位的良性肿瘤 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 其它和未特指的舌部恶性肿瘤 | 1 | 0.003% | 1 | 0.023% | 0 | 0.000% |
| 其它和未特指的生殖器官原位癌 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 其它和未特指的消化器官原位癌 | 1 | 0.003% | 1 | 0.023% | 0 | 0.000% |
| 乳腺良性肿瘤 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 乳腺纤维瘤 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 舌底恶性肿瘤 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 未特指细胞类型的白血病 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 下咽部恶性肿瘤 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 阴茎恶性肿瘤 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 左肾上腺良性肿瘤 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 消化系统疾病:例数2621(8.70%) | 食管、胃和十二指肠疾病 | 866 | 2.874% | 140 | 3.163% | 13 | 6.736% |
| 食管、胃和十二指肠疾 | 867 | 2.878% | 141 | 3.186% | 13 | 6.736% |
| 缺血性心脏病 | 1450 | 4.812% | 205 | 4.632% | 10 | 5.181% |
| 肝脏疾病 | 892 | 2.961% | 152 | 3.434% | 8 | 4.145% |
| 其它肠道疾病 | 363 | 1.205% | 58 | 1.310% | 6 | 3.109% |
| 胆囊、胆道和胰腺疾病 | 626 | 2.078% | 134 | 3.028% | 5 | 2.591% |
| 其它消化系统疾病 | 188 | 0.624% | 37 | 0.836% | 2 | 1.036% |
| 阑尾疾病 | 85 | 0.282% | 11 | 0.249% | 2 | 1.036% |
| 疝 | 83 | 0.275% | 20 | 0.452% | 1 | 0.518% |
| 腹膜疾病 | 94 | 0.312% | 26 | 0.587% | 0 | 0.000% |
| 口腔、唾液腺和上下颌疾病 | 62 | 0.206% | 4 | 0.090% | 0 | 0.000% |
| 非感染性肠炎和结肠炎 | 49 | 0.163% | 9 | 0.203% | 0 | 0.000% |
| 多发性浆膜腔积液 | 20 | 0.066% | 12 | 0.271% | 0 | 0.000% |
| 肠梗阻 | 10 | 0.033% | 4 | 0.090% | 0 | 0.000% |
| 食管隆起性病变 | 5 | 0.017% | 1 | 0.023% | 0 | 0.000% |
| 不完全性肠梗阻 | 4 | 0.013% | 3 | 0.068% | 0 | 0.000% |
| Budd-Chiari综合征 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 肠道菌群失调 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 肠造瘘术后功能障碍 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 胆道感染 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 胆管梗阻 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 胆囊占位性病变 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 腹壁溃疡 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 腹腔包裹积液 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 腹腔囊肿 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 黄疸病 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 急性肠梗阻 | 1 | 0.003% | 1 | 0.023% | 0 | 0.000% |
| 急性胃炎 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 其它食管疾病 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 浅表性胃炎 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 未特指部位的胃溃疡 | 1 | 0.003% | 1 | 0.023% | 0 | 0.000% |
| 胃溃疡 | 2 | 0.007% | 1 | 0.023% | 0 | 0.000% |
| 胃下垂 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 消化道出血 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 右上腹囊性占位 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 呼吸系统疾病:例数2067(6.86%) | 缺血性心脏病 | 1450 | 4.812% | 205 | 4.632% | 10 | 5.181% |
| 呼吸系统疾病 | 924 | 3.067% | 215 | 4.858% | 9 | 4.663% |
| 其它呼吸系统疾病 | 919 | 3.050% | 212 | 4.790% | 8 | 4.145% |
| 其它胸膜疾病 | 546 | 1.812% | 116 | 2.621% | 7 | 3.627% |
| 胸膜疾病 | 548 | 1.819% | 117 | 2.643% | 7 | 3.627% |
| 慢性下呼吸道疾病 | 676 | 2.244% | 135 | 3.050% | 6 | 3.109% |
| 其它主要影响肺间质的呼吸道疾病 | 56 | 0.186% | 14 | 0.316% | 2 | 1.036% |
| 其它上呼吸道疾病 | 148 | 0.491% | 15 | 0.339% | 0 | 0.000% |
| 急性上呼吸道感染 | 120 | 0.398% | 32 | 0.723% | 0 | 0.000% |
| 由于外部原因造成的肺疾病 | 42 | 0.139% | 10 | 0.226% | 0 | 0.000% |
| 肺部感染 | 37 | 0.123% | 10 | 0.226% | 0 | 0.000% |
| 下呼吸道化脓性和坏死性疾病 | 31 | 0.103% | 4 | 0.090% | 0 | 0.000% |
| 其它急性下呼吸道感染 | 15 | 0.050% | 4 | 0.090% | 0 | 0.000% |
| 上呼吸道感染 | 131 | 0.435% | 32 | 0.723% | 0 | 0.000% |
| 慢性支气管炎 | 7 | 0.023% | 1 | 0.023% | 0 | 0.000% |
| 慢性下呼吸道感染 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 其他上呼吸道疾病 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 放射性其它呼吸系统疾病 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 非小细胞癌 | 1 | 0.003% | 1 | 0.023% | 0 | 0.000% |
| 肺气肿 | 1 | 0.003% | 1 | 0.023% | 0 | 0.000% |
| 慢性阻塞性肺疾病 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 其它呼吸系统疾病 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 其它呼吸系统疾病合并代谢性酸中毒 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 未特指生物体所致的肺炎 | 1 | 0.003% | 1 | 0.023% | 0 | 0.000% |
| 咽炎 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 支气管炎 | 8 | 0.027% | 1 | 0.023% | 0 | 0.000% |
| 左侧上颌窦囊肿 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 内分泌、营养和代谢疾病:例数2227(7.39%) | 糖尿病 | 2024 | 6.718% | 368 | 8.315% | 19 | 9.845% |
| 缺血性心脏病 | 1450 | 4.812% | 205 | 4.632% | 10 | 5.181% |
| 代谢性疾病 | 811 | 2.692% | 254 | 5.739% | 4 | 2.073% |
| 消化器官继发性恶性肿瘤 | 398 | 1.321% | 77 | 1.740% | 3 | 1.554% |
| 甲状腺疾病 | 263 | 0.873% | 31 | 0.700% | 0 | 0.000% |
| 营养不良 | 74 | 0.246% | 24 | 0.542% | 0 | 0.000% |
| 其他内分泌腺疾病 | 11 | 0.037% | 1 | 0.023% | 0 | 0.000% |
| 电解质紊乱 | 5 | 0.017% | 2 | 0.045% | 0 | 0.000% |
| 其他的营养缺乏 | 3 | 0.010% | 0 | 0.000% | 0 | 0.000% |
| 垂体功能减退症 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 肥胖和其他的营养过剩 | 2 | 0.007% | 1 | 0.023% | 0 | 0.000% |
| 甲状腺结节 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 糖调节和胰腺内分泌的其他疾病 | 2 | 0.007% | 1 | 0.023% | 0 | 0.000% |
| 某些感染性疾病或寄生虫病:例数1586(5.26%) | 缺血性心脏病 | 1450 | 4.812% | 205 | 4.632% | 10 | 5.181% |
| 病毒性肝炎 | 1061 | 3.521% | 153 | 3.457% | 7 | 3.627% |
| 肺结核 | 146 | 0.485% | 21 | 0.474% | 3 | 1.554% |
| 流感和肺炎 | 422 | 1.401% | 102 | 2.305% | 2 | 1.036% |
| 其他细菌性疾病 | 31 | 0.103% | 8 | 0.181% | 1 | 0.518% |
| 真菌病 | 23 | 0.076% | 5 | 0.113% | 1 | 0.518% |
| 传染病和寄生虫病的后遗症 | 56 | 0.186% | 8 | 0.181% | 0 | 0.000% |
| 以皮肤和黏膜损害为特征的病毒性感染 | 34 | 0.113% | 6 | 0.136% | 0 | 0.000% |
| 肠道传染病 | 18 | 0.060% | 4 | 0.090% | 0 | 0.000% |
| 急性风湿热 | 13 | 0.043% | 2 | 0.045% | 0 | 0.000% |
| 主要为性传播模式的感染 | 12 | 0.040% | 2 | 0.045% | 0 | 0.000% |
| 中枢神经系统病毒感染 | 9 | 0.030% | 2 | 0.045% | 0 | 0.000% |
| 某些传染病和寄生虫病 | 3 | 0.010% | 0 | 0.000% | 0 | 0.000% |
| 其它传染病 | 4 | 0.013% | 1 | 0.023% | 0 | 0.000% |
| 其他病毒性疾病 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 肺慢性炎症 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 结核性胸膜炎 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 慢性乙肝 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 其他螺旋体疾病 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 蠕虫病 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 痰气交阻证 | 1 | 0.003% | 1 | 0.023% | 0 | 0.000% |
| 影响健康状态或与保健机构接触的因素:例数1180(3.92%) | 缺血性心脏病 | 1450 | 4.812% | 205 | 4.632% | 10 | 5.181% |
| 存在与家庭和个人经历以及某些影响健康状况条件有关的潜在健康危险的人群 | 833 | 2.765% | 105 | 2.372% | 8 | 4.145% |
| 存在与家庭和个人经历以及某些影响健康状况条件有关的潜在健康危险的 | 834 | 2.768% | 106 | 2.395% | 8 | 4.145% |
| 在与家庭和个人经历以及某些影响健康状况条件有关的潜在健康危险的人群 | 834 | 2.768% | 106 | 2.395% | 8 | 4.145% |
| 因特殊操作和护理接受健康服务的人群 | 491 | 1.630% | 96 | 2.169% | 1 | 0.518% |
| 特殊操作和护理接受健康服务的人群 | 492 | 1.633% | 97 | 2.192% | 1 | 0.518% |
| 因体检和检查接受健康服务的人群 | 33 | 0.110% | 5 | 0.113% | 0 | 0.000% |
| 存在与传染病相关的潜在健康危险的人群 | 10 | 0.033% | 0 | 0.000% | 0 | 0.000% |
| 后天性器官缺失 | 4 | 0.013% | 0 | 0.000% | 0 | 0.000% |
| 影响健康状况和接触健康服务的因素 | 3 | 0.010% | 0 | 0.000% | 0 | 0.000% |
| 双侧输卵管结扎术 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 因生育接受健康服务的人群 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 单侧卵巢切除术 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 胆囊切除术后 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 腹腔感染置管引流中 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 冠状动脉搭桥术后 | 1 | 0.003% | 1 | 0.023% | 0 | 0.000% |
| 脾切除术 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 上颈囊炎 | 1 | 0.003% | 1 | 0.023% | 0 | 0.000% |
| 泌尿生殖系统疾病:例数1098(3.64%) | 缺血性心脏病 | 1450 | 4.812% | 205 | 4.632% | 10 | 5.181% |
| 乳房疾病 | 285 | 0.946% | 28 | 0.633% | 6 | 3.109% |
| 其它肾和输尿管疾病 | 311 | 1.032% | 51 | 1.152% | 5 | 2.591% |
| 男性生殖器官疾病 | 198 | 0.657% | 42 | 0.949% | 4 | 2.073% |
| 其它泌尿系统疾病 | 117 | 0.388% | 25 | 0.565% | 2 | 1.036% |
| 尿石症 | 97 | 0.322% | 15 | 0.339% | 2 | 1.036% |
| 肾小管-间质疾病 | 103 | 0.342% | 20 | 0.452% | 1 | 0.518% |
| 女性生殖道非炎性疾病 | 63 | 0.209% | 6 | 0.136% | 1 | 0.518% |
| 肾衰竭 | 83 | 0.275% | 19 | 0.429% | 0 | 0.000% |
| 女性盆腔器官炎性疾病 | 30 | 0.100% | 4 | 0.090% | 0 | 0.000% |
| 肾小球疾病 | 26 | 0.086% | 8 | 0.181% | 0 | 0.000% |
| 其他泌尿系统疾病 | 18 | 0.060% | 5 | 0.113% | 0 | 0.000% |
| 继发性尿崩症 | 6 | 0.020% | 1 | 0.023% | 0 | 0.000% |
| 肾功能不全 | 6 | 0.020% | 2 | 0.045% | 0 | 0.000% |
| 输尿管引流术 | 3 | 0.010% | 0 | 0.000% | 0 | 0.000% |
| 泌尿生殖道的其它疾病 | 2 | 0.007% | 1 | 0.023% | 0 | 0.000% |
| 泌尿生殖系统疾病 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 连续性尿崩症 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 男性生殖系统疾病 | 3 | 0.010% | 1 | 0.023% | 0 | 0.000% |
| 盆腔积液 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 肾衰病 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 肾盂积水 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 阴道残端复术 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 子宫颈炎性疾病 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 症状、体征或临床所见，不可归类在他处者:例数846(2.81%) | 缺血性心脏病 | 1450 | 4.812% | 205 | 4.632% | 10 | 5.181% |
| 涉及消化系统和腹部的症状和体征 | 214 | 0.710% | 38 | 0.859% | 3 | 1.554% |
| 一般的症状和体征 | 523 | 1.736% | 111 | 2.508% | 2 | 1.036% |
| 没有诊断的在诊断成像和功能研究中的异常发现 | 102 | 0.339% | 26 | 0.587% | 1 | 0.518% |
| 涉及循环和呼吸系统的症状和体征 | 70 | 0.232% | 10 | 0.226% | 1 | 0.518% |
| 腋下淋巴结肿大 | 1 | 0.003% | 1 | 0.023% | 1 | 0.518% |
| 没有诊断的在验血中的异常发现 | 25 | 0.083% | 6 | 0.136% | 0 | 0.000% |
| 涉及泌尿系统的症状和体征 | 15 | 0.050% | 2 | 0.045% | 0 | 0.000% |
| 涉及皮肤和皮下组织的症状和体征 | 13 | 0.043% | 5 | 0.113% | 0 | 0.000% |
| 涉及认识、知觉、情感状态和行为的症状和体征 | 7 | 0.023% | 1 | 0.023% | 0 | 0.000% |
| 涉及神经和骨胳肌肉系统的症状和体征 | 3 | 0.010% | 1 | 0.023% | 0 | 0.000% |
| 癌痛综合征 | 3 | 0.010% | 2 | 0.045% | 0 | 0.000% |
| 癌痛综合症 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 骶尾部疼痛 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 窦性心动过速 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 窦性心律过速 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 二尖瓣修补术后 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 发热期 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 肺占没有诊断的在诊断成像和功能研究中的异常发现位 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 腹壁及大网膜种植转移 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 涉及消化系统或腹部的症状和体征 | 1 | 0.003% | 1 | 0.023% | 0 | 0.000% |
| 噎嗝 | 1 | 0.003% | 1 | 0.023% | 0 | 0.000% |
| 症状、体征或临床所见，不可归类在他处者 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 肌肉骨骼系统和结缔组织疾病:例数4(0.01%) | 脊椎病 | 4 | 0.013% | 1 | 0.023% | 0 | 0.000% |
| 血液或造血器官疾病:例数428(1.42%) | 缺血性心脏病 | 1450 | 4.812% | 205 | 4.632% | 10 | 5.181% |
| 再生障碍性贫血和其他的贫血 | 662 | 2.197% | 170 | 3.841% | 5 | 2.591% |
| 贫血 | 692 | 2.297% | 177 | 3.999% | 5 | 2.591% |
| 血液和造血器官的其他疾病 | 202 | 0.670% | 66 | 1.491% | 0 | 0.000% |
| 营养性贫血 | 28 | 0.093% | 7 | 0.158% | 0 | 0.000% |
| 缺铁性贫血 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 溶血性贫血 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 血小板减少症 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 血液和造血器官疾病:例数361(1.20%) | 缺血性心脏病 | 1450 | 4.812% | 205 | 4.632% | 10 | 5.181% |
| 再生障碍性贫血和其他的贫血 | 662 | 2.197% | 170 | 3.841% | 5 | 2.591% |
| 贫血 | 692 | 2.297% | 177 | 3.999% | 5 | 2.591% |
| 血液和造血器官的其他疾病 | 202 | 0.670% | 66 | 1.491% | 0 | 0.000% |
| 神经系统疾病:例数206(0.68%) | 缺血性心脏病 | 1450 | 4.812% | 205 | 4.632% | 10 | 5.181% |
| 慢性下呼吸道疾病 | 676 | 2.244% | 135 | 3.050% | 6 | 3.109% |
| 神经、神经根和神经丛疾病 | 48 | 0.159% | 7 | 0.158% | 1 | 0.518% |
| 其它神经系统疾病 | 24 | 0.080% | 4 | 0.090% | 1 | 0.518% |
| 中枢神经系统炎症性疾病 | 18 | 0.060% | 6 | 0.136% | 1 | 0.518% |
| 其它的神经系统变性疾病 | 16 | 0.053% | 3 | 0.068% | 1 | 0.518% |
| 短暂和突发性疾病 | 111 | 0.368% | 18 | 0.407% | 0 | 0.000% |
| 锥体外运动障碍 | 14 | 0.046% | 2 | 0.045% | 0 | 0.000% |
| 脑瘫和其它的瘫痪综合症 | 15 | 0.050% | 4 | 0.090% | 0 | 0.000% |
| 多发性神经病变和其他周围神经系统疾病 | 12 | 0.040% | 4 | 0.090% | 0 | 0.000% |
| 肌神经接点和肌肉疾病 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 脑萎缩 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 中枢神经系统脱髓鞘疾病 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 损伤、中毒和外因的某些其它结果:例数1(0.00%) | 胸部损伤 | 29 | 0.096% | 2 | 0.045% | 0 | 0.000% |
| 皮肤疾病:例数108(0.36%) | 其它皮肤和皮下组织疾病 | 25 | 0.083% | 4 | 0.090% | 1 | 0.518% |
| 皮肤和皮下组织感染 | 36 | 0.119% | 5 | 0.113% | 0 | 0.000% |
| 银屑病 | 28 | 0.093% | 8 | 0.181% | 0 | 0.000% |
| 皮炎和湿疹 | 18 | 0.060% | 2 | 0.045% | 0 | 0.000% |
| 与辐射有关的皮肤和皮下组织疾病 | 6 | 0.020% | 3 | 0.068% | 0 | 0.000% |
| 风疹和红斑 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 皮肤附器疾病 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 荨麻疹 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 压疮 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 视觉系统疾病:例数86(0.29%) | 晶状体疾病 | 41 | 0.136% | 9 | 0.203% | 0 | 0.000% |
| 视觉障碍和失明 | 20 | 0.066% | 7 | 0.158% | 0 | 0.000% |
| 青光眼 | 15 | 0.050% | 2 | 0.045% | 0 | 0.000% |
| 脉胳膜、视网膜疾病 | 9 | 0.030% | 3 | 0.068% | 0 | 0.000% |
| 其它视网膜疾病 | 4 | 0.013% | 0 | 0.000% | 0 | 0.000% |
| 眼及附器的其它疾病 | 5 | 0.017% | 0 | 0.000% | 0 | 0.000% |
| 巩膜、角膜、虹膜和睫状体疾病 | 3 | 0.010% | 0 | 0.000% | 0 | 0.000% |
| 眼睑、泪腺系统和眼眶疾病 | 4 | 0.013% | 1 | 0.023% | 0 | 0.000% |
| 结膜炎 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 眼结膜疾病 | 4 | 0.013% | 0 | 0.000% | 0 | 0.000% |
| 黄斑变性 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 免疫系统疾病:例数78(0.26%) | 某些涉及免疫机能的异常 | 49 | 0.163% | 11 | 0.249% | 0 | 0.000% |
| 凝血缺陷、紫癫和其他出血性疾病 | 42 | 0.139% | 15 | 0.339% | 0 | 0.000% |
| 中性粒细胞减少症 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 发育异常:例数55(0.18%) | 缺血性心脏病 | 1450 | 4.812% | 205 | 4.632% | 10 | 5.181% |
| 其它先天性畸形 | 28 | 0.093% | 5 | 0.113% | 0 | 0.000% |
| 循环系统先天性畸形 | 11 | 0.037% | 2 | 0.045% | 0 | 0.000% |
| 其它的消化系统先天性畸形 | 6 | 0.020% | 2 | 0.045% | 0 | 0.000% |
| 泌尿系统先天性畸形 | 7 | 0.023% | 2 | 0.045% | 0 | 0.000% |
| 神经系统先天性畸形 | 3 | 0.010% | 1 | 0.023% | 0 | 0.000% |
| 呼吸系统先天性畸形 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 肌肉骨胳系统先天性畸形和变形 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 生殖器官先天性畸形 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 精神、行为或神经发育障碍:例数54(0.18%) | 情感性精神障碍（心境障碍） | 33 | 0.110% | 6 | 0.136% | 0 | 0.000% |
| 精神分裂症、分裂型和妄想性精神障碍 | 17 | 0.056% | 2 | 0.045% | 0 | 0.000% |
| 神经症性、应激性和躯体形式障碍 | 10 | 0.033% | 2 | 0.045% | 0 | 0.000% |
| 器质性（包括症状性）精神障碍 | 5 | 0.017% | 3 | 0.068% | 0 | 0.000% |
| 精神发育迟缓 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 精神和行为障碍 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 强迫综合征 | 1 | 0.003% | 1 | 0.023% | 0 | 0.000% |
| 耳和乳突疾病:例数46(0.15%) | 中耳和乳突疾病 | 33 | 0.110% | 6 | 0.136% | 2 | 1.036% |
| 其它耳病 | 11 | 0.037% | 1 | 0.023% | 1 | 0.518% |
| 内耳疾病 | 11 | 0.037% | 2 | 0.045% | 0 | 0.000% |
| 妊娠、分娩和产褥期:例数8(0.03%) | 分娩 | 5 | 0.017% | 0 | 0.000% | 0 | 0.000% |
| 伴有流产后果的妊娠 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 主要与产褥期相关的并发症 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 主要与胎儿、羊膜腔和可能的分娩问题相关的母体护理 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 动脉、小动脉和毛细血管疾病:例数2(0.01%) | 腹主动脉瘤 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 淋巴、造血和相关组织的恶性肿瘤:例数1(0.00%) | 周边和皮肤T细胞淋巴瘤 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 女性生殖道非炎性疾病:例数1(0.00%) | 子宫内膜异位 | 1 | 0.003% | 1 | 0.023% | 0 | 0.000% |
| 皮肤和皮下组织感染:例数1(0.00%) | 皮肤和皮下组织感染 | 36 | 0.119% | 5 | 0.113% | 0 | 0.000% |
| 其它肠道疾病:例数1(0.00%) | 乙状结肠造瘘口闭合术 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 其它皮肤疾病:例数1(0.00%) | 其它皮肤和皮下组织疾病 | 25 | 0.083% | 4 | 0.090% | 1 | 0.518% |
| 乳房的恶性肿瘤:例数1(0.00%) | 乳腺癌 | 4 | 0.013% | 0 | 0.000% | 0 | 0.000% |
| 涉及皮肤和皮下组织的症状和体征:例数1(0.00%) | 涉及皮肤和皮下组织的症状和体征 | 13 | 0.043% | 5 | 0.113% | 0 | 0.000% |
| 手术和医疗护理并发症:例数1(0.00%) | 手术处置并发症 | 3 | 0.010% | 1 | 0.023% | 0 | 0.000% |
| 症状、体征和异常的临床和化验结:例数1(0.00%) | 涉及循环和呼吸系统的症状和体征 | 70 | 0.232% | 10 | 0.226% | 1 | 0.518% |

#### 5.2.3 组间比较

具有显著性差异的次要诊断有：其它形式的心脏病、其它肠道疾病、乳房疾病、男性生殖器官疾病、其它主要影响肺间质的呼吸道疾病、中耳和乳突疾病、肺动脉栓塞、呼吸系统疾病、腋下淋巴结肿大。比较检验结果详见表 17,且表中只保留发生ADR的西医次要诊断。

**表 17: 西医次要诊断详表**

| **变量** | **发生ADR (N=193)** | **未发生ADR (N=29937)** | **总计 (N=30130)** | **检验方法** | **P值** |
| --- | --- | --- | --- | --- | --- |
| 高血压病 |  |  |  | Pearson's Chi-squared test | 0.508 |
| 是 | 31 (16.06%) | 4306 (14.38%) | 4337 (14.39%) |  |  |
| 否 | 162 (83.94%) | 25631 (85.62%) | 25793 (85.61%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 糖尿病 |  |  |  | Pearson's Chi-squared test | 0.380 |
| 是 | 16 (8.29%) | 2007 (6.70%) | 2023 (6.71%) |  |  |
| 否 | 177 (91.71%) | 27930 (93.30%) | 28107 (93.29%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 其它形式的心脏病 |  |  |  | Fisher's Exact Test for Count Data | < 0.001 |
| 是 | 11 (5.70%) | 413 (1.38%) | 424 (1.41%) |  |  |
| 否 | 182 (94.30%) | 29524 (98.62%) | 29706 (98.59%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 缺血性心脏病 |  |  |  | Pearson's Chi-squared test | 0.810 |
| 是 | 10 (5.18%) | 1440 (4.81%) | 1450 (4.81%) |  |  |
| 否 | 183 (94.82%) | 28497 (95.19%) | 28680 (95.19%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 食管、胃和十二指肠疾病 |  |  |  | Pearson's Chi-squared test | 0.054 |
| 是 | 10 (5.18%) | 856 (2.86%) | 866 (2.87%) |  |  |
| 否 | 183 (94.82%) | 29081 (97.14%) | 29264 (97.13%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 肝脏疾病 |  |  |  | Pearson's Chi-squared test | 0.330 |
| 是 | 8 (4.15%) | 884 (2.95%) | 892 (2.96%) |  |  |
| 否 | 185 (95.85%) | 29053 (97.05%) | 29238 (97.04%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 存在与家庭和个人经历以及某些影响健康状况条件有关的潜在健康危险的人群 |  |  |  | Pearson's Chi-squared test | 0.464 |
| 是 | 7 (3.63%) | 826 (2.76%) | 833 (2.76%) |  |  |
| 否 | 186 (96.37%) | 29111 (97.24%) | 29297 (97.24%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 其它呼吸系统疾病 |  |  |  | Pearson's Chi-squared test | 0.636 |
| 是 | 7 (3.63%) | 910 (3.04%) | 917 (3.04%) |  |  |
| 否 | 186 (96.37%) | 29027 (96.96%) | 29213 (96.96%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 其它胸膜疾病 |  |  |  | Fisher's Exact Test for Count Data | 0.092 |
| 是 | 7 (3.63%) | 539 (1.80%) | 546 (1.81%) |  |  |
| 否 | 186 (96.37%) | 29398 (98.20%) | 29584 (98.19%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 病毒性肝炎 |  |  |  | Pearson's Chi-squared test | 0.755 |
| 是 | 6 (3.11%) | 1055 (3.52%) | 1061 (3.52%) |  |  |
| 否 | 187 (96.89%) | 28882 (96.48%) | 29069 (96.48%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 慢性下呼吸道疾病 |  |  |  | Fisher's Exact Test for Count Data | 0.334 |
| 是 | 6 (3.11%) | 670 (2.24%) | 676 (2.24%) |  |  |
| 否 | 187 (96.89%) | 29267 (97.76%) | 29454 (97.76%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 其它肠道疾病 |  |  |  | Fisher's Exact Test for Count Data | 0.030 |
| 是 | 6 (3.11%) | 357 (1.19%) | 363 (1.20%) |  |  |
| 否 | 187 (96.89%) | 29580 (98.81%) | 29767 (98.80%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 乳房疾病 |  |  |  | Fisher's Exact Test for Count Data | 0.010 |
| 是 | 6 (3.11%) | 279 (0.93%) | 285 (0.95%) |  |  |
| 否 | 187 (96.89%) | 29658 (99.07%) | 29845 (99.05%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 再生障碍性贫血和其他的贫血 |  |  |  | Fisher's Exact Test for Count Data | 0.619 |
| 是 | 5 (2.59%) | 657 (2.19%) | 662 (2.20%) |  |  |
| 否 | 188 (97.41%) | 29280 (97.81%) | 29468 (97.80%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 胆囊、胆道和胰腺疾病 |  |  |  | Fisher's Exact Test for Count Data | > 0.999 |
| 是 | 4 (2.07%) | 622 (2.08%) | 626 (2.08%) |  |  |
| 否 | 189 (97.93%) | 29315 (97.92%) | 29504 (97.92%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 男性生殖器官疾病 |  |  |  | Fisher's Exact Test for Count Data | 0.039 |
| 是 | 4 (2.07%) | 194 (0.65%) | 198 (0.66%) |  |  |
| 否 | 189 (97.93%) | 29743 (99.35%) | 29932 (99.34%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 脑血管疾病 |  |  |  | Pearson's Chi-squared test | 0.450 |
| 是 | 4 (2.07%) | 899 (3.00%) | 903 (3.00%) |  |  |
| 否 | 189 (97.93%) | 29038 (97.00%) | 29227 (97.00%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 其它肾和输尿管疾病 |  |  |  | Fisher's Exact Test for Count Data | 0.140 |
| 是 | 4 (2.07%) | 307 (1.03%) | 311 (1.03%) |  |  |
| 否 | 189 (97.93%) | 29630 (98.97%) | 29819 (98.97%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 支气管和肺部恶性肿瘤 |  |  |  | Fisher's Exact Test for Count Data | 0.145 |
| 是 | 4 (2.07%) | 311 (1.04%) | 315 (1.05%) |  |  |
| 否 | 189 (97.93%) | 29626 (98.96%) | 29815 (98.95%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 代谢性疾病 |  |  |  | Pearson's Chi-squared test | 0.327 |
| 是 | 3 (1.55%) | 808 (2.70%) | 811 (2.69%) |  |  |
| 否 | 190 (98.45%) | 29129 (97.30%) | 29319 (97.31%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 呼吸器官继发性恶性肿瘤 |  |  |  | Fisher's Exact Test for Count Data | 0.744 |
| 是 | 3 (1.55%) | 395 (1.32%) | 398 (1.32%) |  |  |
| 否 | 190 (98.45%) | 29542 (98.68%) | 29732 (98.68%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 继发和未特指的淋巴结恶性肿瘤 |  |  |  | Fisher's Exact Test for Count Data | > 0.999 |
| 是 | 3 (1.55%) | 510 (1.70%) | 513 (1.70%) |  |  |
| 否 | 190 (98.45%) | 29427 (98.30%) | 29617 (98.30%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 静脉、淋巴管、淋巴结疾病 |  |  |  | Fisher's Exact Test for Count Data | 0.754 |
| 是 | 3 (1.55%) | 419 (1.40%) | 422 (1.40%) |  |  |
| 否 | 190 (98.45%) | 29518 (98.60%) | 29708 (98.60%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 涉及消化系统和腹部的症状和体征 |  |  |  | Fisher's Exact Test for Count Data | 0.158 |
| 是 | 3 (1.55%) | 211 (0.70%) | 214 (0.71%) |  |  |
| 否 | 190 (98.45%) | 29726 (99.30%) | 29916 (99.29%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 消化器官继发性恶性肿瘤 |  |  |  | Fisher's Exact Test for Count Data | 0.744 |
| 是 | 3 (1.55%) | 395 (1.32%) | 398 (1.32%) |  |  |
| 否 | 190 (98.45%) | 29542 (98.68%) | 29732 (98.68%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 肺结核 |  |  |  | Fisher's Exact Test for Count Data | 0.240 |
| 是 | 2 (1.04%) | 144 (0.48%) | 146 (0.48%) |  |  |
| 否 | 191 (98.96%) | 29793 (99.52%) | 29984 (99.52%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 骨病和软骨病 |  |  |  | Fisher's Exact Test for Count Data | 0.245 |
| 是 | 2 (1.04%) | 146 (0.49%) | 148 (0.49%) |  |  |
| 否 | 191 (98.96%) | 29791 (99.51%) | 29982 (99.51%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 脊背病变 |  |  |  | Fisher's Exact Test for Count Data | 0.709 |
| 是 | 2 (1.04%) | 287 (0.96%) | 289 (0.96%) |  |  |
| 否 | 191 (98.96%) | 29650 (99.04%) | 29841 (99.04%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 阑尾疾病 |  |  |  | Fisher's Exact Test for Count Data | 0.103 |
| 是 | 2 (1.04%) | 83 (0.28%) | 85 (0.28%) |  |  |
| 否 | 191 (98.96%) | 29854 (99.72%) | 30045 (99.72%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 其它泌尿系统疾病 |  |  |  | Fisher's Exact Test for Count Data | 0.173 |
| 是 | 2 (1.04%) | 115 (0.38%) | 117 (0.39%) |  |  |
| 否 | 191 (98.96%) | 29822 (99.62%) | 30013 (99.61%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 其它消化系统疾病 |  |  |  | Fisher's Exact Test for Count Data | 0.339 |
| 是 | 2 (1.04%) | 186 (0.62%) | 188 (0.62%) |  |  |
| 否 | 191 (98.96%) | 29751 (99.38%) | 29942 (99.38%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 其它主要影响肺间质的呼吸道疾病 |  |  |  | Fisher's Exact Test for Count Data | 0.050 |
| 是 | 2 (1.04%) | 54 (0.18%) | 56 (0.19%) |  |  |
| 否 | 191 (98.96%) | 29883 (99.82%) | 30074 (99.81%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 一般的症状和体征 |  |  |  | Fisher's Exact Test for Count Data | 0.778 |
| 是 | 2 (1.04%) | 521 (1.74%) | 523 (1.74%) |  |  |
| 否 | 191 (98.96%) | 29416 (98.26%) | 29607 (98.26%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 中耳和乳突疾病 |  |  |  | Fisher's Exact Test for Count Data | 0.019 |
| 是 | 2 (1.04%) | 31 (0.10%) | 33 (0.11%) |  |  |
| 否 | 191 (98.96%) | 29906 (99.90%) | 30097 (99.89%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 恶性肿瘤 |  |  |  | Fisher's Exact Test for Count Data | > 0.999 |
| 是 | 1 (0.52%) | 164 (0.55%) | 165 (0.55%) |  |  |
| 否 | 192 (99.48%) | 29773 (99.45%) | 29965 (99.45%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 肺动脉栓塞 |  |  |  | Fisher's Exact Test for Count Data | 0.006 |
| 是 | 1 (0.52%) | 0 (0.00%) | 1 (0.00%) |  |  |
| 否 | 192 (99.48%) | 29937 (100.00%) | 30129 (100.00%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 肺心病和肺循环疾病 |  |  |  | Fisher's Exact Test for Count Data | 0.316 |
| 是 | 1 (0.52%) | 58 (0.19%) | 59 (0.20%) |  |  |
| 否 | 192 (99.48%) | 29879 (99.81%) | 30071 (99.80%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 肝脏和肝内胆管恶性肿瘤 |  |  |  | Fisher's Exact Test for Count Data | > 0.999 |
| 是 | 1 (0.52%) | 195 (0.65%) | 196 (0.65%) |  |  |
| 否 | 192 (99.48%) | 29742 (99.35%) | 29934 (99.35%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 关节病 |  |  |  | Fisher's Exact Test for Count Data | 0.367 |
| 是 | 1 (0.52%) | 70 (0.23%) | 71 (0.24%) |  |  |
| 否 | 192 (99.48%) | 29867 (99.77%) | 30059 (99.76%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 呼吸系统疾病 |  |  |  | Fisher's Exact Test for Count Data | 0.032 |
| 是 | 1 (0.52%) | 4 (0.01%) | 5 (0.02%) |  |  |
| 否 | 192 (99.48%) | 29933 (99.99%) | 30125 (99.98%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 结肠恶性肿瘤 |  |  |  | Fisher's Exact Test for Count Data | 0.454 |
| 是 | 1 (0.52%) | 93 (0.31%) | 94 (0.31%) |  |  |
| 否 | 192 (99.48%) | 29844 (99.69%) | 30036 (99.69%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 流感和肺炎 |  |  |  | Fisher's Exact Test for Count Data | 0.531 |
| 是 | 1 (0.52%) | 421 (1.41%) | 422 (1.40%) |  |  |
| 否 | 192 (99.48%) | 29516 (98.59%) | 29708 (98.60%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 卵巢恶性肿瘤 |  |  |  | Fisher's Exact Test for Count Data | 0.175 |
| 是 | 1 (0.52%) | 29 (0.10%) | 30 (0.10%) |  |  |
| 否 | 192 (99.48%) | 29908 (99.90%) | 30100 (99.90%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 没有诊断的在诊断成像和功能研究中的异常发现 |  |  |  | Fisher's Exact Test for Count Data | 0.478 |
| 是 | 1 (0.52%) | 100 (0.33%) | 101 (0.34%) |  |  |
| 否 | 192 (99.48%) | 29837 (99.67%) | 30029 (99.66%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 尿石症 |  |  |  | Fisher's Exact Test for Count Data | 0.464 |
| 是 | 1 (0.52%) | 96 (0.32%) | 97 (0.32%) |  |  |
| 否 | 192 (99.48%) | 29841 (99.68%) | 30033 (99.68%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 女性生殖道非炎性疾病 |  |  |  | Fisher's Exact Test for Count Data | 0.333 |
| 是 | 1 (0.52%) | 62 (0.21%) | 63 (0.21%) |  |  |
| 否 | 192 (99.48%) | 29875 (99.79%) | 30067 (99.79%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 其他细菌性疾病 |  |  |  | Fisher's Exact Test for Count Data | 0.181 |
| 是 | 1 (0.52%) | 30 (0.10%) | 31 (0.10%) |  |  |
| 否 | 192 (99.48%) | 29907 (99.90%) | 30099 (99.90%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 其它的神经系统变性疾病 |  |  |  | Fisher's Exact Test for Count Data | 0.098 |
| 是 | 1 (0.52%) | 15 (0.05%) | 16 (0.05%) |  |  |
| 否 | 192 (99.48%) | 29922 (99.95%) | 30114 (99.95%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 其它耳病 |  |  |  | Fisher's Exact Test for Count Data | 0.068 |
| 是 | 1 (0.52%) | 10 (0.03%) | 11 (0.04%) |  |  |
| 否 | 192 (99.48%) | 29927 (99.97%) | 30119 (99.96%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 其它和未特指部位的骨和关节软骨恶性肿瘤 |  |  |  | Fisher's Exact Test for Count Data | 0.561 |
| 是 | 1 (0.52%) | 127 (0.42%) | 128 (0.42%) |  |  |
| 否 | 192 (99.48%) | 29810 (99.58%) | 30002 (99.58%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 其它内分泌腺和相关组织的恶性肿瘤 |  |  |  | Fisher's Exact Test for Count Data | 0.074 |
| 是 | 1 (0.52%) | 11 (0.04%) | 12 (0.04%) |  |  |
| 否 | 192 (99.48%) | 29926 (99.96%) | 30118 (99.96%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 其它皮肤和皮下组织疾病 |  |  |  | Fisher's Exact Test for Count Data | 0.148 |
| 是 | 1 (0.52%) | 24 (0.08%) | 25 (0.08%) |  |  |
| 否 | 192 (99.48%) | 29913 (99.92%) | 30105 (99.92%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 其它神经系统疾病 |  |  |  | Fisher's Exact Test for Count Data | 0.143 |
| 是 | 1 (0.52%) | 23 (0.08%) | 24 (0.08%) |  |  |
| 否 | 192 (99.48%) | 29914 (99.92%) | 30106 (99.92%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 疝 |  |  |  | Fisher's Exact Test for Count Data | 0.410 |
| 是 | 1 (0.52%) | 81 (0.27%) | 82 (0.27%) |  |  |
| 否 | 192 (99.48%) | 29856 (99.73%) | 30048 (99.73%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 涉及循环和呼吸系统的症状和体征 |  |  |  | Fisher's Exact Test for Count Data | 0.363 |
| 是 | 1 (0.52%) | 69 (0.23%) | 70 (0.23%) |  |  |
| 否 | 192 (99.48%) | 29868 (99.77%) | 30060 (99.77%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 神经、神经根和神经丛疾病 |  |  |  | Fisher's Exact Test for Count Data | 0.266 |
| 是 | 1 (0.52%) | 47 (0.16%) | 48 (0.16%) |  |  |
| 否 | 192 (99.48%) | 29890 (99.84%) | 30082 (99.84%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 肾小管-间质疾病 |  |  |  | Fisher's Exact Test for Count Data | 0.485 |
| 是 | 1 (0.52%) | 102 (0.34%) | 103 (0.34%) |  |  |
| 否 | 192 (99.48%) | 29835 (99.66%) | 30027 (99.66%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 食管恶性肿瘤 |  |  |  | Fisher's Exact Test for Count Data | 0.398 |
| 是 | 1 (0.52%) | 78 (0.26%) | 79 (0.26%) |  |  |
| 否 | 192 (99.48%) | 29859 (99.74%) | 30051 (99.74%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 手术和医疗护理并发症 |  |  |  | Fisher's Exact Test for Count Data | 0.251 |
| 是 | 1 (0.52%) | 44 (0.15%) | 45 (0.15%) |  |  |
| 否 | 192 (99.48%) | 29893 (99.85%) | 30085 (99.85%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 炎性多发性关节病变 |  |  |  | Fisher's Exact Test for Count Data | 0.148 |
| 是 | 1 (0.52%) | 24 (0.08%) | 25 (0.08%) |  |  |
| 否 | 192 (99.48%) | 29913 (99.92%) | 30105 (99.92%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 腋下淋巴结肿大 |  |  |  | Fisher's Exact Test for Count Data | 0.006 |
| 是 | 1 (0.52%) | 0 (0.00%) | 1 (0.00%) |  |  |
| 否 | 192 (99.48%) | 29937 (100.00%) | 30129 (100.00%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 胰腺恶性肿瘤 |  |  |  | Fisher's Exact Test for Count Data | 0.126 |
| 是 | 1 (0.52%) | 20 (0.07%) | 21 (0.07%) |  |  |
| 否 | 192 (99.48%) | 29917 (99.93%) | 30109 (99.93%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 因特殊操作和护理接受健康服务的人群 |  |  |  | Fisher's Exact Test for Count Data | 0.383 |
| 是 | 1 (0.52%) | 490 (1.64%) | 491 (1.63%) |  |  |
| 否 | 192 (99.48%) | 29447 (98.36%) | 29639 (98.37%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 真菌病 |  |  |  | Fisher's Exact Test for Count Data | 0.137 |
| 是 | 1 (0.52%) | 22 (0.07%) | 23 (0.08%) |  |  |
| 否 | 192 (99.48%) | 29915 (99.93%) | 30107 (99.92%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 中枢神经系统炎症性疾病 |  |  |  | Fisher's Exact Test for Count Data | 0.109 |
| 是 | 1 (0.52%) | 17 (0.06%) | 18 (0.06%) |  |  |
| 否 | 192 (99.48%) | 29920 (99.94%) | 30112 (99.94%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 子宫颈恶性肿瘤 |  |  |  | Fisher's Exact Test for Count Data | 0.137 |
| 是 | 1 (0.52%) | 22 (0.07%) | 23 (0.08%) |  |  |
| 否 | 192 (99.48%) | 29915 (99.93%) | 30107 (99.92%) |  |  |
| Missing | 0 | 0 | 0 |  |  |

## 6.中医诊断

### 6.1 主要诊断

#### 6.1.1 ADR人群诊断类别统计

**表 18: ADR人群中医主要诊断系统分类统计表**

| 系统分类名称 | 例数 | 例数占ADR人群比 | 例次 | 例次占总比 |
| --- | --- | --- | --- | --- |
| 癌类病 | 12 | 6.22% | 12 | 60.00% |
| 乳房类病 | 7 | 3.63% | 7 | 35.00% |
| 积聚类病 | 1 | 0.52% | 1 | 5.00% |

#### 6.1.2 诊断名例次统计

**表 19: 中医主要诊断例次统计表**

| **系统分类名称** | **诊断名称** | **全人群中发生例数** | **在全人群占比** | **AE人群中发生例数** | **在AE人群占比** | **ADR人群中发生例数** | **在ADR人群占比** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 癌类病:例数1420(4.71%) | 肺癌 | 378 | 1.255% | 61 | 1.378% | 5 | 2.591% |
| 乳癌 | 158 | 0.524% | 28 | 0.633% | 2 | 1.036% |
| 肠癌 | 205 | 0.680% | 31 | 0.700% | 1 | 0.518% |
| 胃癌 | 130 | 0.431% | 23 | 0.520% | 1 | 0.518% |
| 肝癌 | 85 | 0.282% | 19 | 0.429% | 1 | 0.518% |
| 卵巢恶性肿瘤 | 55 | 0.183% | 12 | 0.271% | 1 | 0.518% |
| 肾癌 | 11 | 0.037% | 4 | 0.090% | 1 | 0.518% |
| 直肠癌 | 1 | 0.003% | 1 | 0.023% | 1 | 0.518% |
| 食管癌 | 117 | 0.388% | 20 | 0.452% | 0 | 0.000% |
| 失荣 | 56 | 0.186% | 7 | 0.158% | 0 | 0.000% |
| 宫颈癌 | 33 | 0.110% | 5 | 0.113% | 0 | 0.000% |
| 颃颡岩 | 28 | 0.093% | 2 | 0.045% | 0 | 0.000% |
| 胰癌 | 26 | 0.086% | 4 | 0.090% | 0 | 0.000% |
| 膀胱癌 | 21 | 0.070% | 2 | 0.045% | 0 | 0.000% |
| 胆癌 | 23 | 0.076% | 3 | 0.068% | 0 | 0.000% |
| 子宫内膜癌 | 14 | 0.046% | 1 | 0.023% | 0 | 0.000% |
| 骨髓癌 | 10 | 0.033% | 0 | 0.000% | 0 | 0.000% |
| 咽喉菌 | 8 | 0.027% | 1 | 0.023% | 0 | 0.000% |
| 尿道癌 | 7 | 0.023% | 2 | 0.045% | 0 | 0.000% |
| 腮岩 | 6 | 0.020% | 0 | 0.000% | 0 | 0.000% |
| 癃闭 | 5 | 0.017% | 1 | 0.023% | 0 | 0.000% |
| 上石疽 | 5 | 0.017% | 0 | 0.000% | 0 | 0.000% |
| 舌岩 | 5 | 0.017% | 3 | 0.068% | 0 | 0.000% |
| 石瘿 | 5 | 0.017% | 1 | 0.023% | 0 | 0.000% |
| 牙岩 | 5 | 0.017% | 1 | 0.023% | 0 | 0.000% |
| 胆癌 | 3 | 0.010% | 0 | 0.000% | 0 | 0.000% |
| 喉岩 | 3 | 0.010% | 2 | 0.045% | 0 | 0.000% |
| 鼻岩 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 唇癌 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 臌胀病 | 3 | 0.010% | 0 | 0.000% | 0 | 0.000% |
| 输卵管癌 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 子岩 | 2 | 0.007% | 1 | 0.023% | 0 | 0.000% |
| 胆宫 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 肾岩翻花 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 阴道癌 | 1 | 0.003% | 1 | 0.023% | 0 | 0.000% |
| 乳房类病:例数265(0.88%) | 乳癖 | 257 | 0.853% | 23 | 0.520% | 7 | 3.627% |
| 乳核 | 8 | 0.027% | 0 | 0.000% | 0 | 0.000% |
| 积聚类病:例数73(0.24%) | 肺积 | 27 | 0.090% | 9 | 0.203% | 1 | 0.518% |
| 积病 | 46 | 0.153% | 7 | 0.158% | 0 | 0.000% |
| 临时诊断用术语:例数63(0.21%) | 腹痛 | 17 | 0.056% | 2 | 0.045% | 0 | 0.000% |
| 咳嗽 | 15 | 0.050% | 4 | 0.090% | 0 | 0.000% |
| 胃痛 | 12 | 0.040% | 1 | 0.023% | 0 | 0.000% |
| 腰痛 | 8 | 0.027% | 1 | 0.023% | 0 | 0.000% |
| 尿血 | 5 | 0.017% | 2 | 0.045% | 0 | 0.000% |
| 腹水 | 2 | 0.007% | 1 | 0.023% | 0 | 0.000% |
| 眩晕 | 2 | 0.007% | 0 | 0.000% | 0 | 0.000% |
| 鼻衄 | 1 | 0.003% | 1 | 0.023% | 0 | 0.000% |
| 咯血 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 瘤类病:例数36(0.12%) | 肉瘤 | 16 | 0.053% | 4 | 0.090% | 0 | 0.000% |
| 脑瘤 | 9 | 0.030% | 2 | 0.045% | 0 | 0.000% |
| 骨瘤 | 5 | 0.017% | 3 | 0.068% | 0 | 0.000% |
| 纵膈肿瘤 | 4 | 0.013% | 1 | 0.023% | 0 | 0.000% |
| 肠瘤 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 肺系病:例数5(0.02%) | 肺痿 | 5 | 0.017% | 1 | 0.023% | 0 | 0.000% |
| 心系病:例数2(0.01%) | 痴呆病 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 癫狂病 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 颅脑类病:例数1(0.00%) | 中风病 | 1 | 0.003% | 1 | 0.023% | 0 | 0.000% |
| 皮肤类病:例数1(0.00%) | 瘾疹 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 虚劳类病:例数1(0.00%) | 内伤发热病 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |
| 瘿类病:例数1(0.00%) | 瘿肿 | 1 | 0.003% | 0 | 0.000% | 0 | 0.000% |

#### 6.1.3 组间比较

  全人群共涉及60种中医主要诊断名称。发生ADR的患者，乳癖:是7(3.63%)、否186(96.37%)，未发生ADR的患者，乳癖:是250(0.84%)、否29687(99.16%)，两组的发生比例具有显著性差异(p=0.001)，。其它主要诊断的比较检验过程保持一致。具有显著性差异的主要诊断有：乳癖、直肠癌。比较检验结果详见表 20,且表中只保留发生ADR的中医主要诊断。

**表 20: 中医主要诊断详表**

| **变量** | **发生ADR (N=193)** | **未发生ADR (N=29937)** | **总计 (N=30130)** | **检验方法** | **P值** |
| --- | --- | --- | --- | --- | --- |
| 乳癖 |  |  |  | Fisher's Exact Test for Count Data | 0.001 |
| 是 | 7 (3.63%) | 250 (0.84%) | 257 (0.85%) |  |  |
| 否 | 186 (96.37%) | 29687 (99.16%) | 29873 (99.15%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 肺癌 |  |  |  | Fisher's Exact Test for Count Data | 0.097 |
| 是 | 5 (2.59%) | 373 (1.25%) | 378 (1.25%) |  |  |
| 否 | 188 (97.41%) | 29564 (98.75%) | 29752 (98.75%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 乳癌 |  |  |  | Fisher's Exact Test for Count Data | 0.269 |
| 是 | 2 (1.04%) | 156 (0.52%) | 158 (0.52%) |  |  |
| 否 | 191 (98.96%) | 29781 (99.48%) | 29972 (99.48%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 肺积 |  |  |  | Fisher's Exact Test for Count Data | 0.159 |
| 是 | 1 (0.52%) | 26 (0.09%) | 27 (0.09%) |  |  |
| 否 | 192 (99.48%) | 29911 (99.91%) | 30103 (99.91%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 肝癌 |  |  |  | Fisher's Exact Test for Count Data | 0.421 |
| 是 | 1 (0.52%) | 84 (0.28%) | 85 (0.28%) |  |  |
| 否 | 192 (99.48%) | 29853 (99.72%) | 30045 (99.72%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 卵巢恶性肿瘤 |  |  |  | Fisher's Exact Test for Count Data | 0.298 |
| 是 | 1 (0.52%) | 54 (0.18%) | 55 (0.18%) |  |  |
| 否 | 192 (99.48%) | 29883 (99.82%) | 30075 (99.82%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 肾癌 |  |  |  | Fisher's Exact Test for Count Data | 0.068 |
| 是 | 1 (0.52%) | 10 (0.03%) | 11 (0.04%) |  |  |
| 否 | 192 (99.48%) | 29927 (99.97%) | 30119 (99.96%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 胃癌 |  |  |  | Fisher's Exact Test for Count Data | 0.567 |
| 是 | 1 (0.52%) | 129 (0.43%) | 130 (0.43%) |  |  |
| 否 | 192 (99.48%) | 29808 (99.57%) | 30000 (99.57%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 直肠癌 |  |  |  | Fisher's Exact Test for Count Data | 0.006 |
| 是 | 1 (0.52%) | 0 (0.00%) | 1 (0.00%) |  |  |
| 否 | 192 (99.48%) | 29937 (100.00%) | 30129 (100.00%) |  |  |
| Missing | 0 | 0 | 0 |  |  |

#### 6.1.4 中医主要诊断中医证候

  全人群共涉及85种中医主要诊断中医证候，发生ADR与未发生ADR两组的诊断比例具有显著性差异的中医证候有：肺脾气虚证。比较检验结果详见表 21,且表中只保留发生ADR的中医主要诊断中医证候。

**表 21: 中医主要诊断中医证候详表**

| **变量** | **发生ADR (N=193)** | **未发生ADR (N=29937)** | **总计 (N=30130)** | **检验方法** | **P值** |
| --- | --- | --- | --- | --- | --- |
| 肺脾气虚证 |  |  |  | Fisher's Exact Test for Count Data | 0.006 |
| 是 | 1 (0.52%) | 0 (0.00%) | 1 (0.00%) |  |  |
| 否 | 192 (99.48%) | 29937 (100.00%) | 30129 (100.00%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 肺郁痰瘀证 |  |  |  | Fisher's Exact Test for Count Data | 0.080 |
| 是 | 1 (0.52%) | 12 (0.04%) | 13 (0.04%) |  |  |
| 否 | 192 (99.48%) | 29925 (99.96%) | 30117 (99.96%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 气阴两虚证 |  |  |  | Fisher's Exact Test for Count Data | 0.261 |
| 是 | 1 (0.52%) | 46 (0.15%) | 47 (0.16%) |  |  |
| 否 | 192 (99.48%) | 29891 (99.85%) | 30083 (99.84%) |  |  |
| Missing | 0 | 0 | 0 |  |  |

## 7.既往史

### 7.1 家族史、预防接种史、传染病史、过敏史、手术外伤史、输血史概述

| **变量** | **发生ADR (N=193)** | **未发生ADR (N=29937)** | **总计 (N=30130)** | **检验方法** | **P值** |
| --- | --- | --- | --- | --- | --- |
| 家族史 |  |  |  | Pearson's Chi-squared test | 0.832 |
| 有 | 39 (20.21%) | 5867 (19.60%) | 5906 (19.60%) |  |  |
| 无 | 154 (79.79%) | 24070 (80.40%) | 24224 (80.40%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 预防接种史 |  |  |  | Pearson's Chi-squared test | 0.539 |
| 有 | 9 (69.23%) | 1729 (60.90%) | 1738 (60.94%) |  |  |
| 无 | 4 (30.77%) | 1110 (39.10%) | 1114 (39.06%) |  |  |
| Missing | 180 | 27098 | 27278 |  |  |
| 传染病史 |  |  |  | Pearson's Chi-squared test | 0.344 |
| 有 | 15 (7.85%) | 1837 (6.20%) | 1852 (6.21%) |  |  |
| 无 | 176 (92.15%) | 27813 (93.80%) | 27989 (93.79%) |  |  |
| Missing | 2 | 287 | 289 |  |  |
| 过敏史 |  |  |  | Pearson's Chi-squared test | 0.346 |
| 有 | 24 (12.50%) | 3103 (10.42%) | 3127 (10.43%) |  |  |
| 无 | 168 (87.50%) | 26686 (89.58%) | 26854 (89.57%) |  |  |
| Missing | 1 | 148 | 149 |  |  |
| 手术/外伤史 |  |  |  | Pearson's Chi-squared test | 0.777 |
| 有 | 113 (58.85%) | 17867 (59.86%) | 17980 (59.85%) |  |  |
| 无 | 79 (41.15%) | 11982 (40.14%) | 12061 (40.15%) |  |  |
| Missing | 1 | 88 | 89 |  |  |
| 输血史 |  |  |  | Pearson's Chi-squared test | 0.355 |
| 有 | 7 (3.66%) | 1511 (5.15%) | 1518 (5.14%) |  |  |
| 无 | 184 (96.34%) | 27849 (94.85%) | 28033 (94.86%) |  |  |
| Missing | 2 | 577 | 579 |  |  |

### 7.2 既往不良反应史

  在使用复方苦参注射液的30130例患者中，具有显著性差异的既往不良反应史为：未指定的草药和传统药物、氨苄西林、单硝酸异山梨酯、吉美嘧啶、葡萄糖酸钙、替加氟、氧嗪酸钾。组间比较详见表 22,该表只保留发生ADR的既往不良反应史信息统计。

**表 22: 既往不良反应史信息详表**

| **变量** | **发生ADR (N=193)** | **未发生ADR (N=29937)** | **总计 (N=30130)** | **检验方法** | **P值** |
| --- | --- | --- | --- | --- | --- |
| 青霉素（未特指） |  |  |  | Pearson's Chi-squared test | 0.369 |
| 是 | 9 (4.66%) | 1040 (3.47%) | 1049 (3.48%) |  |  |
| 否 | 184 (95.34%) | 28897 (96.53%) | 29081 (96.52%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 未指定的草药和传统药物 |  |  |  | Fisher's Exact Test for Count Data | 0.013 |
| 是 | 3 (1.55%) | 74 (0.25%) | 77 (0.26%) |  |  |
| 否 | 190 (98.45%) | 29863 (99.75%) | 30053 (99.74%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 磺胺 |  |  |  | Fisher's Exact Test for Count Data | > 0.999 |
| 是 | 3 (1.55%) | 566 (1.89%) | 569 (1.89%) |  |  |
| 否 | 190 (98.45%) | 29371 (98.11%) | 29561 (98.11%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 头孢丙烯 |  |  |  | Fisher's Exact Test for Count Data | 0.678 |
| 是 | 2 (1.04%) | 250 (0.84%) | 252 (0.84%) |  |  |
| 否 | 191 (98.96%) | 29687 (99.16%) | 29878 (99.16%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 阿莫西林 |  |  |  | Fisher's Exact Test for Count Data | 0.464 |
| 是 | 1 (0.52%) | 96 (0.32%) | 97 (0.32%) |  |  |
| 否 | 192 (99.48%) | 29841 (99.68%) | 30033 (99.68%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 安乃近 |  |  |  | Fisher's Exact Test for Count Data | 0.242 |
| 是 | 1 (0.52%) | 42 (0.14%) | 43 (0.14%) |  |  |
| 否 | 192 (99.48%) | 29895 (99.86%) | 30087 (99.86%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 氨苄西林 |  |  |  | Fisher's Exact Test for Count Data | 0.038 |
| 是 | 1 (0.52%) | 5 (0.02%) | 6 (0.02%) |  |  |
| 否 | 192 (99.48%) | 29932 (99.98%) | 30124 (99.98%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 氨基比林 |  |  |  | Fisher's Exact Test for Count Data | 0.246 |
| 是 | 1 (0.52%) | 43 (0.14%) | 44 (0.15%) |  |  |
| 否 | 192 (99.48%) | 29894 (99.86%) | 30086 (99.85%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 苯巴比妥 |  |  |  | Fisher's Exact Test for Count Data | 0.207 |
| 是 | 1 (0.52%) | 35 (0.12%) | 36 (0.12%) |  |  |
| 否 | 192 (99.48%) | 29902 (99.88%) | 30094 (99.88%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 大青薯根茎 |  |  |  | Fisher's Exact Test for Count Data | 0.056 |
| 是 | 1 (0.52%) | 8 (0.03%) | 9 (0.03%) |  |  |
| 否 | 192 (99.48%) | 29929 (99.97%) | 30121 (99.97%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 单硝酸异山梨酯 |  |  |  | Fisher's Exact Test for Count Data | 0.013 |
| 是 | 1 (0.52%) | 1 (0.00%) | 2 (0.01%) |  |  |
| 否 | 192 (99.48%) | 29936 (100.00%) | 30128 (99.99%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 非那西丁 |  |  |  | Fisher's Exact Test for Count Data | 0.202 |
| 是 | 1 (0.52%) | 34 (0.11%) | 35 (0.12%) |  |  |
| 否 | 192 (99.48%) | 29903 (99.89%) | 30095 (99.88%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 红霉素 |  |  |  | Fisher's Exact Test for Count Data | 0.270 |
| 是 | 1 (0.52%) | 48 (0.16%) | 49 (0.16%) |  |  |
| 否 | 192 (99.48%) | 29889 (99.84%) | 30081 (99.84%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 黄精属根茎 |  |  |  | Fisher's Exact Test for Count Data | 0.056 |
| 是 | 1 (0.52%) | 8 (0.03%) | 9 (0.03%) |  |  |
| 否 | 192 (99.48%) | 29929 (99.97%) | 30121 (99.97%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 黄芩根 |  |  |  | Fisher's Exact Test for Count Data | 0.217 |
| 是 | 1 (0.52%) | 37 (0.12%) | 38 (0.13%) |  |  |
| 否 | 192 (99.48%) | 29900 (99.88%) | 30092 (99.87%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 吉美嘧啶 |  |  |  | Fisher's Exact Test for Count Data | 0.019 |
| 是 | 1 (0.52%) | 2 (0.01%) | 3 (0.01%) |  |  |
| 否 | 192 (99.48%) | 29935 (99.99%) | 30127 (99.99%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 甲氧氯普胺 |  |  |  | Fisher's Exact Test for Count Data | 0.121 |
| 是 | 1 (0.52%) | 19 (0.06%) | 20 (0.07%) |  |  |
| 否 | 192 (99.48%) | 29918 (99.94%) | 30110 (99.93%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 金银花蕾 |  |  |  | Fisher's Exact Test for Count Data | 0.232 |
| 是 | 1 (0.52%) | 40 (0.13%) | 41 (0.14%) |  |  |
| 否 | 192 (99.48%) | 29897 (99.87%) | 30089 (99.86%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 咖啡因 |  |  |  | Fisher's Exact Test for Count Data | 0.143 |
| 是 | 1 (0.52%) | 23 (0.08%) | 24 (0.08%) |  |  |
| 否 | 192 (99.48%) | 29914 (99.92%) | 30106 (99.92%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 连翘果实 |  |  |  | Fisher's Exact Test for Count Data | 0.227 |
| 是 | 1 (0.52%) | 39 (0.13%) | 40 (0.13%) |  |  |
| 否 | 192 (99.48%) | 29898 (99.87%) | 30090 (99.87%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 链霉素 |  |  |  | Fisher's Exact Test for Count Data | 0.432 |
| 是 | 1 (0.52%) | 87 (0.29%) | 88 (0.29%) |  |  |
| 否 | 192 (99.48%) | 29850 (99.71%) | 30042 (99.71%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 麦冬块根 |  |  |  | Fisher's Exact Test for Count Data | 0.092 |
| 是 | 1 (0.52%) | 14 (0.05%) | 15 (0.05%) |  |  |
| 否 | 192 (99.48%) | 29923 (99.95%) | 30115 (99.95%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 宁夏枸杞果实 |  |  |  | Fisher's Exact Test for Count Data | 0.056 |
| 是 | 1 (0.52%) | 8 (0.03%) | 9 (0.03%) |  |  |
| 否 | 192 (99.48%) | 29929 (99.97%) | 30121 (99.97%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 破伤风抗毒素 |  |  |  | Fisher's Exact Test for Count Data | 0.068 |
| 是 | 1 (0.52%) | 10 (0.03%) | 11 (0.04%) |  |  |
| 否 | 192 (99.48%) | 29927 (99.97%) | 30119 (99.96%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 葡萄糖酸钙 |  |  |  | Fisher's Exact Test for Count Data | 0.013 |
| 是 | 1 (0.52%) | 1 (0.00%) | 2 (0.01%) |  |  |
| 否 | 192 (99.48%) | 29936 (100.00%) | 30128 (99.99%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 庆大霉素 |  |  |  | Fisher's Exact Test for Count Data | 0.154 |
| 是 | 1 (0.52%) | 25 (0.08%) | 26 (0.09%) |  |  |
| 否 | 192 (99.48%) | 29912 (99.92%) | 30104 (99.91%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 人参根 |  |  |  | Fisher's Exact Test for Count Data | 0.191 |
| 是 | 1 (0.52%) | 32 (0.11%) | 33 (0.11%) |  |  |
| 否 | 192 (99.48%) | 29905 (99.89%) | 30097 (99.89%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 沙参属根 |  |  |  | Fisher's Exact Test for Count Data | 0.056 |
| 是 | 1 (0.52%) | 8 (0.03%) | 9 (0.03%) |  |  |
| 否 | 192 (99.48%) | 29929 (99.97%) | 30121 (99.97%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 替加氟 |  |  |  | Fisher's Exact Test for Count Data | 0.019 |
| 是 | 1 (0.52%) | 2 (0.01%) | 3 (0.01%) |  |  |
| 否 | 192 (99.48%) | 29935 (99.99%) | 30127 (99.99%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 头孢菌素c |  |  |  | Fisher's Exact Test for Count Data | 0.175 |
| 是 | 1 (0.52%) | 29 (0.10%) | 30 (0.10%) |  |  |
| 否 | 192 (99.48%) | 29908 (99.90%) | 30100 (99.90%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 氧嗪酸钾 |  |  |  | Fisher's Exact Test for Count Data | 0.019 |
| 是 | 1 (0.52%) | 2 (0.01%) | 3 (0.01%) |  |  |
| 否 | 192 (99.48%) | 29935 (99.99%) | 30127 (99.99%) |  |  |
| Missing | 0 | 0 | 0 |  |  |

## 8.间隔用药

  全人群中发生ADR的患者，间隔用药:间隔用药134(69.43%)、连续用药59(30.57%)，未发生ADR的患者，间隔用药:间隔用药20997(70.14%)、连续用药8940(29.86%)，两组的发生比例不具有显著性差异(p=0.831)。本节之后的同类型分类变量描述统计保持格式一致。

**表 23: 间隔用药信息详表**

| **变量** | **发生ADR (N=193)** | **未发生ADR (N=29937)** | **总计 (N=30130)** | **检验方法** | **P值** |
| --- | --- | --- | --- | --- | --- |
| 间隔用药 |  |  |  | Pearson's Chi-squared test | 0.831 |
| 间隔用药 | 134 (69.43%) | 20997 (70.14%) | 21131 (70.13%) |  |  |
| 连续用药 | 59 (30.57%) | 8940 (29.86%) | 8999 (29.87%) |  |  |
| Missing | 0 | 0 | 0 |  |  |

### 8.1 是否间隔液期间进行冲管

  全人群中发生与未发生ADR两组患者的间隔液期间进行冲管比例具有显著性差异，详见见表 24。其中连续用药的8999例患者在表格中表现为数据缺失，具体表现为发生ADR患者人群中缺失59例，未发生ADR患者人群中缺失8940例，本节中后续表格中的缺失值代表相同意义。

**表 24: 是否间隔液期间进行冲管信息详表**

| **变量** | **发生ADR (N=193)** | **未发生ADR (N=29937)** | **总计 (N=30130)** | **检验方法** | **P值** |
| --- | --- | --- | --- | --- | --- |
| 是间隔液期间进行冲管 |  |  |  | Pearson's Chi-squared test | 0.029 |
| 是 | 38 (28.36%) | 7882 (37.54%) | 7920 (37.48%) |  |  |
| 否 | 96 (71.64%) | 13115 (62.46%) | 13211 (62.52%) |  |  |
| Missing | 59 | 8940 | 8999 |  |  |

### 8.2 间隔时间

  全人群中发生与未发生ADR两组患者的间隔时间比例不具有显著性差异，详见见表 25。

**表 25: 间隔时间信息详表**

| **变量** | **发生ADR (N=193)** | **未发生ADR (N=29937)** | **总计 (N=30130)** | **检验方法** | **P值** |
| --- | --- | --- | --- | --- | --- |
| 间隔时间 |  |  |  | Pearson's Chi-squared test | 0.139 |
| <5 | 107 (79.85%) | 15110 (71.96%) | 15217 (72.01%) |  |  |
| 5 | 3 (2.24%) | 540 (2.57%) | 543 (2.57%) |  |  |
| 10 | 21 (15.67%) | 3420 (16.29%) | 3441 (16.28%) |  |  |
| 15 | 3 (2.24%) | 1737 (8.27%) | 1740 (8.23%) |  |  |
| 20 | 0 (0.00%) | 189 (0.90%) | 189 (0.89%) |  |  |
| 70 | 0 (0.00%) | 1 (0.00%) | 1 (0.00%) |  |  |
| Missing | 59 | 8940 | 8999 |  |  |

### 8.3 间隔液

  全人群共涉及333种间隔液,ADR人群共涉及55种间隔液。其中所使用的间隔液对应的发生ADR比例从大到小前5位为奥美拉唑钠注射液(7.77%)、泮托拉唑钠注射液(5.70%)、0.9%生理盐水(4.15%)、核糖核酸注射液(3.11%)、还原型谷胱甘肽注射液(2.59%)，发生ADR与未发生ADR患者具有显著性差异的间隔液为丹红注射液、灯盏花素注射液、地塞米松注射液、鸦胆子油乳注射液、酚磺乙胺注射液、阿魏酸钠注射液、氨茶碱注射液、木糖醇注射液、哌拉西林钠舒巴坦钠注射液、溴己新注射液、中长链脂肪乳注射液、注射液兰索拉唑，详见表 26所示。

**表 26: 间隔液信息详表**

| **变量** | **发生ADR (N=193)** | **未发生ADR (N=29937)** | **总计 (N=30130)** | **检验方法** | **P值** |
| --- | --- | --- | --- | --- | --- |
| 奥美拉唑钠注射液 |  |  |  | Pearson's Chi-squared test | 0.404 |
| 是 | 15 (7.77%) | 1888 (6.31%) | 1903 (6.32%) |  |  |
| 否 | 178 (92.23%) | 28049 (93.69%) | 28227 (93.68%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 泮托拉唑钠注射液 |  |  |  | Pearson's Chi-squared test | 0.843 |
| 是 | 11 (5.70%) | 1808 (6.04%) | 1819 (6.04%) |  |  |
| 否 | 182 (94.30%) | 28129 (93.96%) | 28311 (93.96%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 0.9%生理盐水 |  |  |  | Pearson's Chi-squared test | 0.068 |
| 是 | 8 (4.15%) | 2287 (7.64%) | 2295 (7.62%) |  |  |
| 否 | 185 (95.85%) | 27650 (92.36%) | 27835 (92.38%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 核糖核酸注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.056 |
| 是 | 6 (3.11%) | 418 (1.40%) | 424 (1.41%) |  |  |
| 否 | 187 (96.89%) | 29519 (98.60%) | 29706 (98.59%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 还原型谷胱甘肽注射液 |  |  |  | Pearson's Chi-squared test | 0.962 |
| 是 | 5 (2.59%) | 792 (2.65%) | 797 (2.65%) |  |  |
| 否 | 188 (97.41%) | 29145 (97.35%) | 29333 (97.35%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 氨溴索注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.296 |
| 是 | 4 (2.07%) | 353 (1.18%) | 357 (1.18%) |  |  |
| 否 | 189 (97.93%) | 29584 (98.82%) | 29773 (98.82%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 丹红注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.045 |
| 是 | 4 (2.07%) | 203 (0.68%) | 207 (0.69%) |  |  |
| 否 | 189 (97.93%) | 29734 (99.32%) | 29923 (99.31%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 灯盏花素注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.012 |
| 是 | 4 (2.07%) | 132 (0.44%) | 136 (0.45%) |  |  |
| 否 | 189 (97.93%) | 29805 (99.56%) | 29994 (99.55%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 痰热清注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.068 |
| 是 | 4 (2.07%) | 235 (0.78%) | 239 (0.79%) |  |  |
| 否 | 189 (97.93%) | 29702 (99.22%) | 29891 (99.21%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 异甘草酸镁注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.581 |
| 是 | 4 (2.07%) | 519 (1.73%) | 523 (1.74%) |  |  |
| 否 | 189 (97.93%) | 29418 (98.27%) | 29607 (98.26%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 奥美拉唑注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.762 |
| 是 | 3 (1.55%) | 437 (1.46%) | 440 (1.46%) |  |  |
| 否 | 190 (98.45%) | 29500 (98.54%) | 29690 (98.54%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 薄芝糖肽注射液 |  |  |  | Fisher's Exact Test for Count Data | > 0.999 |
| 是 | 3 (1.55%) | 584 (1.95%) | 587 (1.95%) |  |  |
| 否 | 190 (98.45%) | 29353 (98.05%) | 29543 (98.05%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 地塞米松注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.009 |
| 是 | 3 (1.55%) | 64 (0.21%) | 67 (0.22%) |  |  |
| 否 | 190 (98.45%) | 29873 (99.79%) | 30063 (99.78%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 康艾注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.101 |
| 是 | 3 (1.55%) | 171 (0.57%) | 174 (0.58%) |  |  |
| 否 | 190 (98.45%) | 29766 (99.43%) | 29956 (99.42%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 鸦胆子油乳注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.015 |
| 是 | 3 (1.55%) | 78 (0.26%) | 81 (0.27%) |  |  |
| 否 | 190 (98.45%) | 29859 (99.74%) | 30049 (99.73%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 盐酸托烷司琼注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.759 |
| 是 | 3 (1.55%) | 432 (1.44%) | 435 (1.44%) |  |  |
| 否 | 190 (98.45%) | 29505 (98.56%) | 29695 (98.56%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 10%氯化钾注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.093 |
| 是 | 2 (1.04%) | 78 (0.26%) | 80 (0.27%) |  |  |
| 否 | 191 (98.96%) | 29859 (99.74%) | 30050 (99.73%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 艾迪注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.254 |
| 是 | 2 (1.04%) | 150 (0.50%) | 152 (0.50%) |  |  |
| 否 | 191 (98.96%) | 29787 (99.50%) | 29978 (99.50%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 多索茶碱注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.365 |
| 是 | 2 (1.04%) | 197 (0.66%) | 199 (0.66%) |  |  |
| 否 | 191 (98.96%) | 29740 (99.34%) | 29931 (99.34%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 酚磺乙胺注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.005 |
| 是 | 2 (1.04%) | 15 (0.05%) | 17 (0.06%) |  |  |
| 否 | 191 (98.96%) | 29922 (99.95%) | 30113 (99.94%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 复方二氯醋酸二异丙胺注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.339 |
| 是 | 2 (1.04%) | 186 (0.62%) | 188 (0.62%) |  |  |
| 否 | 191 (98.96%) | 29751 (99.38%) | 29942 (99.38%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 复方甘草酸苷注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.658 |
| 是 | 2 (1.04%) | 223 (0.74%) | 225 (0.75%) |  |  |
| 否 | 191 (98.96%) | 29714 (99.26%) | 29905 (99.25%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 肝水解肽注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.240 |
| 是 | 2 (1.04%) | 144 (0.48%) | 146 (0.48%) |  |  |
| 否 | 191 (98.96%) | 29793 (99.52%) | 29984 (99.52%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 兰索拉唑注射液 |  |  |  | Pearson's Chi-squared test | 0.062 |
| 是 | 2 (1.04%) | 1052 (3.51%) | 1054 (3.50%) |  |  |
| 否 | 191 (98.96%) | 28885 (96.49%) | 29076 (96.50%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 胎盘多肽注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.717 |
| 是 | 2 (1.04%) | 296 (0.99%) | 298 (0.99%) |  |  |
| 否 | 191 (98.96%) | 29641 (99.01%) | 29832 (99.01%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 维生素b6注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.191 |
| 是 | 2 (1.04%) | 123 (0.41%) | 125 (0.41%) |  |  |
| 否 | 191 (98.96%) | 29814 (99.59%) | 30005 (99.59%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 维生素c注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.706 |
| 是 | 2 (1.04%) | 284 (0.95%) | 286 (0.95%) |  |  |
| 否 | 191 (98.96%) | 29653 (99.05%) | 29844 (99.05%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 小牛脾提取物注射液 |  |  |  | Fisher's Exact Test for Count Data | > 0.999 |
| 是 | 2 (1.04%) | 452 (1.51%) | 454 (1.51%) |  |  |
| 否 | 191 (98.96%) | 29485 (98.49%) | 29676 (98.49%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 血栓通注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.196 |
| 是 | 2 (1.04%) | 125 (0.42%) | 127 (0.42%) |  |  |
| 否 | 191 (98.96%) | 29812 (99.58%) | 30003 (99.58%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 阿魏酸钠注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.006 |
| 是 | 1 (0.52%) | 0 (0.00%) | 1 (0.00%) |  |  |
| 否 | 192 (99.48%) | 29937 (100.00%) | 30129 (100.00%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 氨茶碱注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.019 |
| 是 | 1 (0.52%) | 2 (0.01%) | 3 (0.01%) |  |  |
| 否 | 192 (99.48%) | 29935 (99.99%) | 30127 (99.99%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 斑蝥酸钠维生素b6注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.367 |
| 是 | 1 (0.52%) | 70 (0.23%) | 71 (0.24%) |  |  |
| 否 | 192 (99.48%) | 29867 (99.77%) | 30059 (99.76%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 丙氨酰谷氨酰胺注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.346 |
| 是 | 1 (0.52%) | 65 (0.22%) | 66 (0.22%) |  |  |
| 否 | 192 (99.48%) | 29872 (99.78%) | 30064 (99.78%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 参麦注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.535 |
| 是 | 1 (0.52%) | 435 (1.45%) | 436 (1.45%) |  |  |
| 否 | 192 (99.48%) | 29502 (98.55%) | 29694 (98.55%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 参芪扶正注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.733 |
| 是 | 1 (0.52%) | 361 (1.21%) | 362 (1.20%) |  |  |
| 否 | 192 (99.48%) | 29576 (98.79%) | 29768 (98.80%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 大株红景天注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.154 |
| 是 | 1 (0.52%) | 25 (0.08%) | 26 (0.09%) |  |  |
| 否 | 192 (99.48%) | 29912 (99.92%) | 30104 (99.91%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 丹参川芎嗪注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.307 |
| 是 | 1 (0.52%) | 56 (0.19%) | 57 (0.19%) |  |  |
| 否 | 192 (99.48%) | 29881 (99.81%) | 30073 (99.81%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 丹参酮ⅱa磺酸钠注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.196 |
| 是 | 1 (0.52%) | 33 (0.11%) | 34 (0.11%) |  |  |
| 否 | 192 (99.48%) | 29904 (99.89%) | 30096 (99.89%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 地塞米松磷酸钠注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.485 |
| 是 | 1 (0.52%) | 102 (0.34%) | 103 (0.34%) |  |  |
| 否 | 192 (99.48%) | 29835 (99.66%) | 30027 (99.66%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 二羟丙茶碱注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.062 |
| 是 | 1 (0.52%) | 9 (0.03%) | 10 (0.03%) |  |  |
| 否 | 192 (99.48%) | 29928 (99.97%) | 30120 (99.97%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 复方氨基酸注射液 |  |  |  | Fisher's Exact Test for Count Data | > 0.999 |
| 是 | 1 (0.52%) | 186 (0.62%) | 187 (0.62%) |  |  |
| 否 | 192 (99.48%) | 29751 (99.38%) | 29943 (99.38%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 甘露醇注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.391 |
| 是 | 1 (0.52%) | 76 (0.25%) | 77 (0.26%) |  |  |
| 否 | 192 (99.48%) | 29861 (99.75%) | 30053 (99.74%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 肝素钠注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.556 |
| 是 | 1 (0.52%) | 125 (0.42%) | 126 (0.42%) |  |  |
| 否 | 192 (99.48%) | 29812 (99.58%) | 30004 (99.58%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 红花注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.627 |
| 是 | 1 (0.52%) | 152 (0.51%) | 153 (0.51%) |  |  |
| 否 | 192 (99.48%) | 29785 (99.49%) | 29977 (99.49%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 甲硫氨酸维b1注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.121 |
| 是 | 1 (0.52%) | 19 (0.06%) | 20 (0.07%) |  |  |
| 否 | 192 (99.48%) | 29918 (99.94%) | 30110 (99.93%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 甲泼尼龙琥珀酸钠注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.062 |
| 是 | 1 (0.52%) | 9 (0.03%) | 10 (0.03%) |  |  |
| 否 | 192 (99.48%) | 29928 (99.97%) | 30120 (99.97%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 木糖醇注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.025 |
| 是 | 1 (0.52%) | 3 (0.01%) | 4 (0.01%) |  |  |
| 否 | 192 (99.48%) | 29934 (99.99%) | 30126 (99.99%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 哌拉西林钠舒巴坦钠注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.050 |
| 是 | 1 (0.52%) | 7 (0.02%) | 8 (0.03%) |  |  |
| 否 | 192 (99.48%) | 29930 (99.98%) | 30122 (99.97%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 消癌平注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.098 |
| 是 | 1 (0.52%) | 15 (0.05%) | 16 (0.05%) |  |  |
| 否 | 192 (99.48%) | 29922 (99.95%) | 30114 (99.95%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 溴己新注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.038 |
| 是 | 1 (0.52%) | 5 (0.02%) | 6 (0.02%) |  |  |
| 否 | 192 (99.48%) | 29932 (99.98%) | 30124 (99.98%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 盐酸甲氧氯普胺注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.104 |
| 是 | 1 (0.52%) | 16 (0.05%) | 17 (0.06%) |  |  |
| 否 | 192 (99.48%) | 29921 (99.95%) | 30113 (99.94%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 伊班膦酸钠注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.109 |
| 是 | 1 (0.52%) | 17 (0.06%) | 18 (0.06%) |  |  |
| 否 | 192 (99.48%) | 29920 (99.94%) | 30112 (99.94%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 中长链脂肪乳注射液 |  |  |  | Fisher's Exact Test for Count Data | 0.050 |
| 是 | 1 (0.52%) | 7 (0.02%) | 8 (0.03%) |  |  |
| 否 | 192 (99.48%) | 29930 (99.98%) | 30122 (99.97%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 注射液兰索拉唑 |  |  |  | Fisher's Exact Test for Count Data | 0.025 |
| 是 | 1 (0.52%) | 3 (0.01%) | 4 (0.01%) |  |  |
| 否 | 192 (99.48%) | 29934 (99.99%) | 30126 (99.99%) |  |  |
| Missing | 0 | 0 | 0 |  |  |

**横向占比统计**

| **变量** | **发生ADR (N=193)** | **未发生ADR (N=29937)** | **总计 (N=30130)** | **检验方法** | **统计量** | **P值** |
| --- | --- | --- | --- | --- | --- | --- |
| 奥美拉唑钠注射液 |  |  |  | Pearson's Chi-squared test | X-squared = 0.7 | 0.404 |
| 是 | 15(0.79%) | 1888 ( 99.21% ) | 1903 (6.32%) |  |  |  |
| 否 | 178(0.63%) | 28049 ( 99.37% ) | 28227 (93.68%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 泮托拉唑钠注射液 |  |  |  | Pearson's Chi-squared test | X-squared = 0.04 | 0.843 |
| 是 | 11(0.60%) | 1808 ( 99.40% ) | 1819 (6.04%) |  |  |  |
| 否 | 182(0.64%) | 28129 ( 99.36% ) | 28311 (93.96%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 0.9%生理盐水 |  |  |  | Pearson's Chi-squared test | X-squared = 3.33 | 0.068 |
| 是 | 8(0.35%) | 2287 ( 99.65% ) | 2295 (7.62%) |  |  |  |
| 否 | 185(0.66%) | 27650 ( 99.34% ) | 27835 (92.38%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 核糖核酸注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.056 |
| 是 | 6(1.42%) | 418 ( 98.58% ) | 424 (1.41%) |  |  |  |
| 否 | 187(0.63%) | 29519 ( 99.37% ) | 29706 (98.59%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 还原型谷胱甘肽注射液 |  |  |  | Pearson's Chi-squared test | X-squared = 0 | 0.962 |
| 是 | 5(0.63%) | 792 ( 99.37% ) | 797 (2.65%) |  |  |  |
| 否 | 188(0.64%) | 29145 ( 99.36% ) | 29333 (97.35%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 氨溴索注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.296 |
| 是 | 4(1.12%) | 353 ( 98.88% ) | 357 (1.18%) |  |  |  |
| 否 | 189(0.63%) | 29584 ( 99.37% ) | 29773 (98.82%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 丹红注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.045 |
| 是 | 4(1.93%) | 203 ( 98.07% ) | 207 (0.69%) |  |  |  |
| 否 | 189(0.63%) | 29734 ( 99.37% ) | 29923 (99.31%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 灯盏花素注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.012 |
| 是 | 4(2.94%) | 132 ( 97.06% ) | 136 (0.45%) |  |  |  |
| 否 | 189(0.63%) | 29805 ( 99.37% ) | 29994 (99.55%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 痰热清注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.068 |
| 是 | 4(1.67%) | 235 ( 98.33% ) | 239 (0.79%) |  |  |  |
| 否 | 189(0.63%) | 29702 ( 99.37% ) | 29891 (99.21%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 异甘草酸镁注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.581 |
| 是 | 4(0.76%) | 519 ( 99.24% ) | 523 (1.74%) |  |  |  |
| 否 | 189(0.64%) | 29418 ( 99.36% ) | 29607 (98.26%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 奥美拉唑注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.762 |
| 是 | 3(0.68%) | 437 ( 99.32% ) | 440 (1.46%) |  |  |  |
| 否 | 190(0.64%) | 29500 ( 99.36% ) | 29690 (98.54%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 薄芝糖肽注射液 |  |  |  | Fisher's Exact Test for Count Data |  | > 0.999 |
| 是 | 3(0.51%) | 584 ( 99.49% ) | 587 (1.95%) |  |  |  |
| 否 | 190(0.64%) | 29353 ( 99.36% ) | 29543 (98.05%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 地塞米松注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.009 |
| 是 | 3(4.48%) | 64 ( 95.52% ) | 67 (0.22%) |  |  |  |
| 否 | 190(0.63%) | 29873 ( 99.37% ) | 30063 (99.78%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 康艾注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.101 |
| 是 | 3(1.72%) | 171 ( 98.28% ) | 174 (0.58%) |  |  |  |
| 否 | 190(0.63%) | 29766 ( 99.37% ) | 29956 (99.42%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 鸦胆子油乳注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.015 |
| 是 | 3(3.70%) | 78 ( 96.30% ) | 81 (0.27%) |  |  |  |
| 否 | 190(0.63%) | 29859 ( 99.37% ) | 30049 (99.73%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 盐酸托烷司琼注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.759 |
| 是 | 3(0.69%) | 432 ( 99.31% ) | 435 (1.44%) |  |  |  |
| 否 | 190(0.64%) | 29505 ( 99.36% ) | 29695 (98.56%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 10%氯化钾注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.093 |
| 是 | 2(2.50%) | 78 ( 97.50% ) | 80 (0.27%) |  |  |  |
| 否 | 191(0.64%) | 29859 ( 99.36% ) | 30050 (99.73%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 艾迪注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.254 |
| 是 | 2(1.32%) | 150 ( 98.68% ) | 152 (0.50%) |  |  |  |
| 否 | 191(0.64%) | 29787 ( 99.36% ) | 29978 (99.50%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 多索茶碱注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.365 |
| 是 | 2(1.01%) | 197 ( 98.99% ) | 199 (0.66%) |  |  |  |
| 否 | 191(0.64%) | 29740 ( 99.36% ) | 29931 (99.34%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 酚磺乙胺注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.005 |
| 是 | 2(11.76%) | 15 ( 88.24% ) | 17 (0.06%) |  |  |  |
| 否 | 191(0.63%) | 29922 ( 99.37% ) | 30113 (99.94%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 复方二氯醋酸二异丙胺注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.339 |
| 是 | 2(1.06%) | 186 ( 98.94% ) | 188 (0.62%) |  |  |  |
| 否 | 191(0.64%) | 29751 ( 99.36% ) | 29942 (99.38%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 复方甘草酸苷注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.658 |
| 是 | 2(0.89%) | 223 ( 99.11% ) | 225 (0.75%) |  |  |  |
| 否 | 191(0.64%) | 29714 ( 99.36% ) | 29905 (99.25%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 肝水解肽注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.240 |
| 是 | 2(1.37%) | 144 ( 98.63% ) | 146 (0.48%) |  |  |  |
| 否 | 191(0.64%) | 29793 ( 99.36% ) | 29984 (99.52%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 兰索拉唑注射液 |  |  |  | Pearson's Chi-squared test | X-squared = 3.49 | 0.062 |
| 是 | 2(0.19%) | 1052 ( 99.81% ) | 1054 (3.50%) |  |  |  |
| 否 | 191(0.66%) | 28885 ( 99.34% ) | 29076 (96.50%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 胎盘多肽注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.717 |
| 是 | 2(0.67%) | 296 ( 99.33% ) | 298 (0.99%) |  |  |  |
| 否 | 191(0.64%) | 29641 ( 99.36% ) | 29832 (99.01%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 维生素b6注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.191 |
| 是 | 2(1.60%) | 123 ( 98.40% ) | 125 (0.41%) |  |  |  |
| 否 | 191(0.64%) | 29814 ( 99.36% ) | 30005 (99.59%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 维生素c注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.706 |
| 是 | 2(0.70%) | 284 ( 99.30% ) | 286 (0.95%) |  |  |  |
| 否 | 191(0.64%) | 29653 ( 99.36% ) | 29844 (99.05%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 小牛脾提取物注射液 |  |  |  | Fisher's Exact Test for Count Data |  | > 0.999 |
| 是 | 2(0.44%) | 452 ( 99.56% ) | 454 (1.51%) |  |  |  |
| 否 | 191(0.64%) | 29485 ( 99.36% ) | 29676 (98.49%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 血栓通注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.196 |
| 是 | 2(1.57%) | 125 ( 98.43% ) | 127 (0.42%) |  |  |  |
| 否 | 191(0.64%) | 29812 ( 99.36% ) | 30003 (99.58%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 阿魏酸钠注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.006 |
| 是 | 1(100.00%) | 0 ( 0.00% ) | 1 (0.00%) |  |  |  |
| 否 | 192(0.64%) | 29937 ( 99.36% ) | 30129 (100.00%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 氨茶碱注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.019 |
| 是 | 1(33.33%) | 2 ( 66.67% ) | 3 (0.01%) |  |  |  |
| 否 | 192(0.64%) | 29935 ( 99.36% ) | 30127 (99.99%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 斑蝥酸钠维生素b6注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.367 |
| 是 | 1(1.41%) | 70 ( 98.59% ) | 71 (0.24%) |  |  |  |
| 否 | 192(0.64%) | 29867 ( 99.36% ) | 30059 (99.76%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 丙氨酰谷氨酰胺注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.346 |
| 是 | 1(1.52%) | 65 ( 98.48% ) | 66 (0.22%) |  |  |  |
| 否 | 192(0.64%) | 29872 ( 99.36% ) | 30064 (99.78%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 参麦注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.535 |
| 是 | 1(0.23%) | 435 ( 99.77% ) | 436 (1.45%) |  |  |  |
| 否 | 192(0.65%) | 29502 ( 99.35% ) | 29694 (98.55%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 参芪扶正注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.733 |
| 是 | 1(0.28%) | 361 ( 99.72% ) | 362 (1.20%) |  |  |  |
| 否 | 192(0.64%) | 29576 ( 99.36% ) | 29768 (98.80%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 大株红景天注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.154 |
| 是 | 1(3.85%) | 25 ( 96.15% ) | 26 (0.09%) |  |  |  |
| 否 | 192(0.64%) | 29912 ( 99.36% ) | 30104 (99.91%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 丹参川芎嗪注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.307 |
| 是 | 1(1.75%) | 56 ( 98.25% ) | 57 (0.19%) |  |  |  |
| 否 | 192(0.64%) | 29881 ( 99.36% ) | 30073 (99.81%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 丹参酮ⅱa磺酸钠注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.196 |
| 是 | 1(2.94%) | 33 ( 97.06% ) | 34 (0.11%) |  |  |  |
| 否 | 192(0.64%) | 29904 ( 99.36% ) | 30096 (99.89%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 地塞米松磷酸钠注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.485 |
| 是 | 1(0.97%) | 102 ( 99.03% ) | 103 (0.34%) |  |  |  |
| 否 | 192(0.64%) | 29835 ( 99.36% ) | 30027 (99.66%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 二羟丙茶碱注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.062 |
| 是 | 1(10.00%) | 9 ( 90.00% ) | 10 (0.03%) |  |  |  |
| 否 | 192(0.64%) | 29928 ( 99.36% ) | 30120 (99.97%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 复方氨基酸注射液 |  |  |  | Fisher's Exact Test for Count Data |  | > 0.999 |
| 是 | 1(0.53%) | 186 ( 99.47% ) | 187 (0.62%) |  |  |  |
| 否 | 192(0.64%) | 29751 ( 99.36% ) | 29943 (99.38%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 甘露醇注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.391 |
| 是 | 1(1.30%) | 76 ( 98.70% ) | 77 (0.26%) |  |  |  |
| 否 | 192(0.64%) | 29861 ( 99.36% ) | 30053 (99.74%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 肝素钠注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.556 |
| 是 | 1(0.79%) | 125 ( 99.21% ) | 126 (0.42%) |  |  |  |
| 否 | 192(0.64%) | 29812 ( 99.36% ) | 30004 (99.58%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 红花注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.627 |
| 是 | 1(0.65%) | 152 ( 99.35% ) | 153 (0.51%) |  |  |  |
| 否 | 192(0.64%) | 29785 ( 99.36% ) | 29977 (99.49%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 甲硫氨酸维b1注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.121 |
| 是 | 1(5.00%) | 19 ( 95.00% ) | 20 (0.07%) |  |  |  |
| 否 | 192(0.64%) | 29918 ( 99.36% ) | 30110 (99.93%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 甲泼尼龙琥珀酸钠注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.062 |
| 是 | 1(10.00%) | 9 ( 90.00% ) | 10 (0.03%) |  |  |  |
| 否 | 192(0.64%) | 29928 ( 99.36% ) | 30120 (99.97%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 木糖醇注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.025 |
| 是 | 1(25.00%) | 3 ( 75.00% ) | 4 (0.01%) |  |  |  |
| 否 | 192(0.64%) | 29934 ( 99.36% ) | 30126 (99.99%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 哌拉西林钠舒巴坦钠注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.050 |
| 是 | 1(12.50%) | 7 ( 87.50% ) | 8 (0.03%) |  |  |  |
| 否 | 192(0.64%) | 29930 ( 99.36% ) | 30122 (99.97%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 消癌平注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.098 |
| 是 | 1(6.25%) | 15 ( 93.75% ) | 16 (0.05%) |  |  |  |
| 否 | 192(0.64%) | 29922 ( 99.36% ) | 30114 (99.95%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 溴己新注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.038 |
| 是 | 1(16.67%) | 5 ( 83.33% ) | 6 (0.02%) |  |  |  |
| 否 | 192(0.64%) | 29932 ( 99.36% ) | 30124 (99.98%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 盐酸甲氧氯普胺注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.104 |
| 是 | 1(5.88%) | 16 ( 94.12% ) | 17 (0.06%) |  |  |  |
| 否 | 192(0.64%) | 29921 ( 99.36% ) | 30113 (99.94%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 伊班膦酸钠注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.109 |
| 是 | 1(5.56%) | 17 ( 94.44% ) | 18 (0.06%) |  |  |  |
| 否 | 192(0.64%) | 29920 ( 99.36% ) | 30112 (99.94%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 中长链脂肪乳注射液 |  |  |  | Fisher's Exact Test for Count Data |  | 0.050 |
| 是 | 1(12.50%) | 7 ( 87.50% ) | 8 (0.03%) |  |  |  |
| 否 | 192(0.64%) | 29930 ( 99.36% ) | 30122 (99.97%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |
| 注射液兰索拉唑 |  |  |  | Fisher's Exact Test for Count Data |  | 0.025 |
| 是 | 1(25.00%) | 3 ( 75.00% ) | 4 (0.01%) |  |  |  |
| 否 | 192(0.64%) | 29934 ( 99.36% ) | 30126 (99.99%) |  |  |  |
| Missing | 0 | 0 | 0 |  |  |  |

### 8.4 间隔液使用剂量例次

  表 27展示非单组ADR的间隔液的剂量使用例次信息，其中不涉及ADR的间隔液未纳入统计。

**表 27: 间隔液信息详表**

| **间隔液剂量** | **发生ADR** | **未发生ADR** | **总计** |
| --- | --- | --- | --- |
| 泮托拉唑钠注射液(mg) | 发生ADR (N=15) | 未发生ADR (N=1888) | 总计 (N=1903) |
| Mean (SD) | 49.33 (10.33) | 47.19 (11.71) | 47.20 (11.70) |
| Median (Q1, Q3) | 40.00 (40.00, 60.00) | 40.00 (40.00, 60.00) | 40.00 (40.00, 60.00) |
| Min - Max | 40.00 - 60.00 | 4.00 - 80.00 | 4.00 - 80.00 |
| 泮托拉唑钠注射液(mg) | 发生ADR (N=11) | 未发生ADR (N=1808) | 总计 (N=1819) |
| Mean (SD) | 47.69 (16.00) | 51.54 (17.11) | 51.51 (17.10) |
| Median (Q1, Q3) | 40.00 (40.00, 42.30) | 40.00 (40.00, 60.00) | 40.00 (40.00, 60.00) |
| Min - Max | 40.00 - 80.00 | 10.00 - 160.00 | 10.00 - 160.00 |
| 泮托拉唑钠注射液(ml) | 发生ADR (N=8) | 未发生ADR (N=2287) | 总计 (N=2295) |
| Mean (SD) | 51.25 (86.26) | 40.99 (91.68) | 41.02 (91.64) |
| Median (Q1, Q3) | 10.00 (10.00, 32.50) | 10.00 (10.00, 20.00) | 10.00 (10.00, 20.00) |
| Min - Max | 10.00 - 250.00 | 1.00 - 1000.00 | 1.00 - 1000.00 |
| 泮托拉唑钠注射液(mg) | 发生ADR (N=6) | 未发生ADR (N=418) | 总计 (N=424) |
| Mean (SD) | 116.67 (60.55) | 105.43 (48.35) | 105.59 (48.48) |
| Median (Q1, Q3) | 125.00 (62.50, 150.00) | 100.00 (50.00, 150.00) | 100.00 (50.00, 150.00) |
| Min - Max | 50.00 - 200.00 | 20.00 - 300.00 | 20.00 - 300.00 |
| 泮托拉唑钠注射液(mg) | 发生ADR (N=5) | 未发生ADR (N=792) | 总计 (N=797) |
| Mean (SD) | 1560.00 (536.66) | 1908.23 (478.28) | 1906.05 (479.08) |
| Median (Q1, Q3) | 1200.00 (1200.00, 1800.00) | 1800.00 (1800.00, 2400.00) | 1800.00 (1800.00, 2400.00) |
| Min - Max | 1200.00 - 2400.00 | 20.00 - 3000.00 | 20.00 - 3000.00 |
| 泮托拉唑钠注射液(mg) | 发生ADR (N=4) | 未发生ADR (N=353) | 总计 (N=357) |
| Mean (SD) | 45.00 (30.00) | 41.30 (23.55) | 41.34 (23.58) |
| Median (Q1, Q3) | 30.00 (30.00, 45.00) | 30.00 (30.00, 30.00) | 30.00 (30.00, 30.00) |
| Min - Max | 30.00 - 90.00 | 15.00 - 120.00 | 15.00 - 120.00 |
| 泮托拉唑钠注射液(ml) | 发生ADR (N=4) | 未发生ADR (N=203) | 总计 (N=207) |
| Mean (SD) | 22.50 (12.58) | 33.79 (8.08) | 33.57 (8.29) |
| Median (Q1, Q3) | 20.00 (17.50, 25.00) | 30.00 (30.00, 40.00) | 30.00 (30.00, 40.00) |
| Min - Max | 10.00 - 40.00 | 10.00 - 100.00 | 10.00 - 100.00 |
| 泮托拉唑钠注射液(mg) | 发生ADR (N=4) | 未发生ADR (N=132) | 总计 (N=136) |
| Mean (SD) | 100.00 (0.00) | 90.15 (25.05) | 90.44 (24.73) |
| Median (Q1, Q3) | 100.00 (100.00, 100.00) | 100.00 (100.00, 100.00) | 100.00 (100.00, 100.00) |
| Min - Max | 100.00 - 100.00 | 50.00 - 200.00 | 50.00 - 200.00 |
| 泮托拉唑钠注射液(ml) | 发生ADR (N=4) | 未发生ADR (N=235) | 总计 (N=239) |
| Mean (SD) | 22.50 (5.00) | 24.60 (15.80) | 24.56 (15.68) |
| Median (Q1, Q3) | 20.00 (20.00, 22.50) | 20.00 (20.00, 30.00) | 20.00 (20.00, 30.00) |
| Min - Max | 20.00 - 30.00 | 10.00 - 250.00 | 10.00 - 250.00 |
| 泮托拉唑钠注射液(mg) | 发生ADR (N=4) | 未发生ADR (N=519) | 总计 (N=523) |
| Mean (SD) | 150.00 (0.00) | 233.01 (2191.27) | 232.38 (2182.85) |
| Median (Q1, Q3) | 150.00 (150.00, 150.00) | 150.00 (100.00, 150.00) | 150.00 (100.00, 150.00) |
| Min - Max | 150.00 - 150.00 | 10.00 - 50000.00 | 10.00 - 50000.00 |
| 泮托拉唑钠注射液(mg) | 发生ADR (N=3) | 未发生ADR (N=437) | 总计 (N=440) |
| Mean (SD) | 53.33 (11.55) | 52.40 (11.53) | 52.41 (11.52) |
| Median (Q1, Q3) | 60.00 (50.00, 60.00) | 60.00 (40.00, 60.00) | 60.00 (40.00, 60.00) |
| Min - Max | 40.00 - 60.00 | 40.00 - 80.00 | 40.00 - 80.00 |
| 泮托拉唑钠注射液(ml) | 发生ADR (N=3) | 未发生ADR (N=584) | 总计 (N=587) |
| Mean (SD) | 4.00 (0.00) | 5.96 (2.77) | 5.95 (2.77) |
| Median (Q1, Q3) | 4.00 (4.00, 4.00) | 4.00 (4.00, 8.00) | 4.00 (4.00, 8.00) |
| Min - Max | 4.00 - 4.00 | 2.00 - 15.00 | 2.00 - 15.00 |
| 泮托拉唑钠注射液(mg) | 发生ADR (N=3) | 未发生ADR (N=64) | 总计 (N=67) |
| Mean (SD) | 8.33 (2.89) | 8.63 (18.12) | 8.62 (17.71) |
| Median (Q1, Q3) | 10.00 (7.50, 10.00) | 5.00 (5.00, 10.00) | 5.00 (5.00, 10.00) |
| Min - Max | 5.00 - 10.00 | 2.00 - 150.00 | 2.00 - 150.00 |
| 泮托拉唑钠注射液(ml) | 发生ADR (N=3) | 未发生ADR (N=171) | 总计 (N=174) |
| Mean (SD) | 46.67 (5.77) | 41.55 (8.95) | 41.64 (8.92) |
| Median (Q1, Q3) | 50.00 (45.00, 50.00) | 40.00 (40.00, 50.00) | 40.00 (40.00, 50.00) |
| Min - Max | 40.00 - 50.00 | 20.00 - 60.00 | 20.00 - 60.00 |
| 泮托拉唑钠注射液(ml) | 发生ADR (N=3) | 未发生ADR (N=78) | 总计 (N=81) |
| Mean (SD) | 30.00 (0.00) | 26.54 (5.77) | 26.67 (5.70) |
| Median (Q1, Q3) | 30.00 (30.00, 30.00) | 30.00 (20.00, 30.00) | 30.00 (20.00, 30.00) |
| Min - Max | 30.00 - 30.00 | 10.00 - 40.00 | 10.00 - 40.00 |
| 泮托拉唑钠注射液(ml) | 发生ADR (N=3) | 未发生ADR (N=432) | 总计 (N=435) |
| Mean (SD) | 2.33 (2.32) | 1.93 (2.06) | 1.93 (2.06) |
| Median (Q1, Q3) | 1.20 (1.00, 3.10) | 1.00 (1.00, 1.20) | 1.00 (1.00, 1.20) |
| Min - Max | 0.80 - 5.00 | 0.40 - 20.00 | 0.40 - 20.00 |
| 泮托拉唑钠注射液(ml) | 发生ADR (N=2) | 未发生ADR (N=78) | 总计 (N=80) |
| Mean (SD) | 10.00 (0.00) | 11.36 (4.12) | 11.32 (4.07) |
| Median (Q1, Q3) | 10.00 (10.00, 10.00) | 10.00 (10.00, 10.00) | 10.00 (10.00, 10.00) |
| Min - Max | 10.00 - 10.00 | 5.00 - 30.00 | 5.00 - 30.00 |
| 泮托拉唑钠注射液(ml) | 发生ADR (N=2) | 未发生ADR (N=150) | 总计 (N=152) |
| Mean (SD) | 50.00 (0.00) | 67.20 (23.92) | 66.97 (23.84) |
| Median (Q1, Q3) | 50.00 (50.00, 50.00) | 50.00 (50.00, 100.00) | 50.00 (50.00, 100.00) |
| Min - Max | 50.00 - 50.00 | 10.00 - 100.00 | 10.00 - 100.00 |
| 泮托拉唑钠注射液(mg) | 发生ADR (N=2) | 未发生ADR (N=197) | 总计 (N=199) |
| Mean (SD) | 250.00 (70.71) | 252.79 (76.30) | 252.76 (76.08) |
| Median (Q1, Q3) | 250.00 (225.00, 275.00) | 200.00 (200.00, 300.00) | 200.00 (200.00, 300.00) |
| Min - Max | 200.00 - 300.00 | 100.00 - 800.00 | 100.00 - 800.00 |
| 泮托拉唑钠注射液(mg) | 发生ADR (N=2) | 未发生ADR (N=15) | 总计 (N=17) |
| Mean (SD) | 1750.00 (1767.77) | 1900.00 (1055.60) | 1882.35 (1082.96) |
| Median (Q1, Q3) | 1750.00 (1125.00, 2375.00) | 2000.00 (1000.00, 3000.00) | 2000.00 (1000.00, 3000.00) |
| Min - Max | 500.00 - 3000.00 | 500.00 - 3000.00 | 500.00 - 3000.00 |
| 泮托拉唑钠注射液(mg) | 发生ADR (N=2) | 未发生ADR (N=186) | 总计 (N=188) |
| Mean (SD) | 80.00 (0.00) | 83.17 (31.36) | 83.14 (31.20) |
| Median (Q1, Q3) | 80.00 (80.00, 80.00) | 80.00 (80.00, 80.00) | 80.00 (80.00, 80.00) |
| Min - Max | 80.00 - 80.00 | 5.00 - 160.00 | 5.00 - 160.00 |
| 泮托拉唑钠注射液(mg) | 发生ADR (N=2) | 未发生ADR (N=223) | 总计 (N=225) |
| Mean (SD) | 160.00 (0.00) | 155.07 (54.87) | 155.11 (54.63) |
| Median (Q1, Q3) | 160.00 (160.00, 160.00) | 160.00 (160.00, 160.00) | 160.00 (160.00, 160.00) |
| Min - Max | 160.00 - 160.00 | 20.00 - 320.00 | 20.00 - 320.00 |
| 泮托拉唑钠注射液(mg) | 发生ADR (N=2) | 未发生ADR (N=144) | 总计 (N=146) |
| Mean (SD) | 100.00 (0.00) | 111.53 (37.89) | 111.37 (37.65) |
| Median (Q1, Q3) | 100.00 (100.00, 100.00) | 100.00 (100.00, 150.00) | 100.00 (100.00, 150.00) |
| Min - Max | 100.00 - 100.00 | 10.00 - 150.00 | 10.00 - 150.00 |
| 泮托拉唑钠注射液(mg) | 发生ADR (N=2) | 未发生ADR (N=1052) | 总计 (N=1054) |
| Mean (SD) | 30.00 (0.00) | 30.94 (5.23) | 30.94 (5.23) |
| Median (Q1, Q3) | 30.00 (30.00, 30.00) | 30.00 (30.00, 30.00) | 30.00 (30.00, 30.00) |
| Min - Max | 30.00 - 30.00 | 30.00 - 60.00 | 30.00 - 60.00 |
| 泮托拉唑钠注射液(ml) | 发生ADR (N=2) | 未发生ADR (N=296) | 总计 (N=298) |
| Mean (SD) | 6.00 (2.83) | 6.89 (1.79) | 6.88 (1.80) |
| Median (Q1, Q3) | 6.00 (5.00, 7.00) | 8.00 (4.00, 8.00) | 8.00 (4.00, 8.00) |
| Min - Max | 4.00 - 8.00 | 4.00 - 8.00 | 4.00 - 8.00 |
| 泮托拉唑钠注射液(ml) | 发生ADR (N=2) | 未发生ADR (N=123) | 总计 (N=125) |
| Mean (SD) | 2.00 (0.00) | 2.37 (0.76) | 2.37 (0.76) |
| Median (Q1, Q3) | 2.00 (2.00, 2.00) | 2.00 (2.00, 2.00) | 2.00 (2.00, 2.00) |
| Min - Max | 2.00 - 2.00 | 2.00 - 6.00 | 2.00 - 6.00 |
| 泮托拉唑钠注射液(mg) | 发生ADR (N=2) | 未发生ADR (N=284) | 总计 (N=286) |
| Mean (SD) | 2000.00 (0.00) | 2085.21 (942.10) | 2084.62 (938.82) |
| Median (Q1, Q3) | 2000.00 (2000.00, 2000.00) | 2000.00 (1000.00, 3000.00) | 2000.00 (1000.00, 3000.00) |
| Min - Max | 2000.00 - 2000.00 | 200.00 - 6000.00 | 200.00 - 6000.00 |
| 泮托拉唑钠注射液(mg) | 发生ADR (N=2) | 未发生ADR (N=452) | 总计 (N=454) |
| Mean (SD) | 12.50 (3.54) | 16.36 (6.37) | 16.34 (6.36) |
| Median (Q1, Q3) | 12.50 (11.25, 13.75) | 15.00 (10.00, 25.00) | 15.00 (10.00, 25.00) |
| Min - Max | 10.00 - 15.00 | 5.00 - 37.50 | 5.00 - 37.50 |
| 泮托拉唑钠注射液(mg) | 发生ADR (N=2) | 未发生ADR (N=125) | 总计 (N=127) |
| Mean (SD) | 450.00 (70.71) | 471.00 (79.84) | 470.67 (79.50) |
| Median (Q1, Q3) | 450.00 (425.00, 475.00) | 500.00 (500.00, 500.00) | 500.00 (500.00, 500.00) |
| Min - Max | 400.00 - 500.00 | 50.00 - 500.00 | 50.00 - 500.00 |
| 泮托拉唑钠注射液(mg) | 发生ADR (N=1) | 未发生ADR (N=2) | 总计 (N=3) |
| Mean (SD) | 250.00 (NA) | 250.00 (0.00) | 250.00 (0.00) |
| Median (Q1, Q3) | 250.00 (250.00, 250.00) | 250.00 (250.00, 250.00) | 250.00 (250.00, 250.00) |
| Min - Max | 250.00 - 250.00 | 250.00 - 250.00 | 250.00 - 250.00 |
| 泮托拉唑钠注射液(ml) | 发生ADR (N=1) | 未发生ADR (N=70) | 总计 (N=71) |
| Mean (SD) | 20.00 (NA) | 38.29 (8.34) | 38.03 (8.56) |
| Median (Q1, Q3) | 20.00 (20.00, 20.00) | 40.00 (40.00, 40.00) | 40.00 (35.00, 40.00) |
| Min - Max | 20.00 - 20.00 | 20.00 - 80.00 | 20.00 - 80.00 |
| 泮托拉唑钠注射液(ml) | 发生ADR (N=1) | 未发生ADR (N=65) | 总计 (N=66) |
| Mean (SD) | 50.00 (NA) | 61.69 (31.95) | 61.52 (31.73) |
| Median (Q1, Q3) | 50.00 (50.00, 50.00) | 50.00 (50.00, 50.00) | 50.00 (50.00, 50.00) |
| Min - Max | 50.00 - 50.00 | 35.00 - 210.00 | 35.00 - 210.00 |
| 泮托拉唑钠注射液(ml) | 发生ADR (N=1) | 未发生ADR (N=435) | 总计 (N=436) |
| Mean (SD) | 45.00 (NA) | 71.94 (32.74) | 71.88 (32.73) |
| Median (Q1, Q3) | 45.00 (45.00, 45.00) | 60.00 (60.00, 100.00) | 60.00 (60.00, 100.00) |
| Min - Max | 45.00 - 45.00 | 10.00 - 500.00 | 10.00 - 500.00 |
| 泮托拉唑钠注射液(ml) | 发生ADR (N=1) | 未发生ADR (N=361) | 总计 (N=362) |
| Mean (SD) | 250.00 (NA) | 246.72 (25.69) | 246.73 (25.65) |
| Median (Q1, Q3) | 250.00 (250.00, 250.00) | 250.00 (250.00, 250.00) | 250.00 (250.00, 250.00) |
| Min - Max | 250.00 - 250.00 | 20.00 - 250.00 | 20.00 - 250.00 |
| 泮托拉唑钠注射液(ml) | 发生ADR (N=1) | 未发生ADR (N=25) | 总计 (N=26) |
| Mean (SD) | 10.00 (NA) | 14.40 (18.05) | 14.23 (17.70) |
| Median (Q1, Q3) | 10.00 (10.00, 10.00) | 10.00 (10.00, 10.00) | 10.00 (10.00, 10.00) |
| Min - Max | 10.00 - 10.00 | 10.00 - 100.00 | 10.00 - 100.00 |
| 泮托拉唑钠注射液(ml) | 发生ADR (N=1) | 未发生ADR (N=56) | 总计 (N=57) |
| Mean (SD) | 10.00 (NA) | 12.32 (3.43) | 12.28 (3.42) |
| Median (Q1, Q3) | 10.00 (10.00, 10.00) | 10.00 (10.00, 15.00) | 10.00 (10.00, 15.00) |
| Min - Max | 10.00 - 10.00 | 10.00 - 20.00 | 10.00 - 20.00 |
| 泮托拉唑钠注射液(mg) | 发生ADR (N=1) | 未发生ADR (N=33) | 总计 (N=34) |
| Mean (SD) | 50.00 (NA) | 47.88 (12.93) | 47.94 (12.74) |
| Median (Q1, Q3) | 50.00 (50.00, 50.00) | 50.00 (40.00, 50.00) | 50.00 (40.00, 50.00) |
| Min - Max | 50.00 - 50.00 | 30.00 - 100.00 | 30.00 - 100.00 |
| 泮托拉唑钠注射液(mg) | 发生ADR (N=1) | 未发生ADR (N=102) | 总计 (N=103) |
| Mean (SD) | 10.00 (NA) | 7.47 (12.82) | 7.49 (12.76) |
| Median (Q1, Q3) | 10.00 (10.00, 10.00) | 5.00 (5.00, 5.00) | 5.00 (5.00, 5.00) |
| Min - Max | 10.00 - 10.00 | 2.50 - 125.00 | 2.50 - 125.00 |
| 泮托拉唑钠注射液(mg) | 发生ADR (N=1) | 未发生ADR (N=9) | 总计 (N=10) |
| Mean (SD) | 250.00 (NA) | 427.78 (137.18) | 410.00 (141.03) |
| Median (Q1, Q3) | 250.00 (250.00, 250.00) | 500.00 (250.00, 500.00) | 500.00 (250.00, 500.00) |
| Min - Max | 250.00 - 250.00 | 250.00 - 600.00 | 250.00 - 600.00 |
| 泮托拉唑钠注射液(ml) | 发生ADR (N=1) | 未发生ADR (N=186) | 总计 (N=187) |
| Mean (SD) | 175.00 (NA) | 234.53 (88.65) | 234.21 (88.52) |
| Median (Q1, Q3) | 175.00 (175.00, 175.00) | 200.00 (200.00, 250.00) | 200.00 (200.00, 250.00) |
| Min - Max | 175.00 - 175.00 | 20.00 - 600.00 | 20.00 - 600.00 |
| 泮托拉唑钠注射液(ml) | 发生ADR (N=1) | 未发生ADR (N=76) | 总计 (N=77) |
| Mean (SD) | 125.00 (NA) | 166.32 (74.33) | 165.78 (73.99) |
| Median (Q1, Q3) | 125.00 (125.00, 125.00) | 125.00 (125.00, 250.00) | 125.00 (125.00, 250.00) |
| Min - Max | 125.00 - 125.00 | 40.00 - 500.00 | 40.00 - 500.00 |
| 泮托拉唑钠注射液(iu) | 发生ADR (N=1) | 未发生ADR (N=125) | 总计 (N=126) |
| Mean (SD) | NA | 1233.33 (568.04) | 1233.33 (568.04) |
| Median (Q1, Q3) | NA | 1600.00 (775.00, 1600.00) | 1600.00 (775.00, 1600.00) |
| Min - Max | NA | 500.00 - 1600.00 | 500.00 - 1600.00 |
| 泮托拉唑钠注射液(ml) | 发生ADR (N=1) | 未发生ADR (N=152) | 总计 (N=153) |
| Mean (SD) | 20.00 (NA) | 19.93 (0.81) | 19.93 (0.81) |
| Median (Q1, Q3) | 20.00 (20.00, 20.00) | 20.00 (20.00, 20.00) | 20.00 (20.00, 20.00) |
| Min - Max | 20.00 - 20.00 | 10.00 - 20.00 | 10.00 - 20.00 |
| 泮托拉唑钠注射液(mg) | 发生ADR (N=1) | 未发生ADR (N=19) | 总计 (N=20) |
| Mean (SD) | 200.00 (NA) | 172.63 (92.91) | 174.00 (90.64) |
| Median (Q1, Q3) | 200.00 (200.00, 200.00) | 200.00 (200.00, 200.00) | 200.00 (200.00, 200.00) |
| Min - Max | 200.00 - 200.00 | 20.00 - 400.00 | 20.00 - 400.00 |
| 泮托拉唑钠注射液(mg) | 发生ADR (N=1) | 未发生ADR (N=9) | 总计 (N=10) |
| Mean (SD) | 40.00 (NA) | 40.00 (0.00) | 40.00 (0.00) |
| Median (Q1, Q3) | 40.00 (40.00, 40.00) | 40.00 (40.00, 40.00) | 40.00 (40.00, 40.00) |
| Min - Max | 40.00 - 40.00 | 40.00 - 40.00 | 40.00 - 40.00 |
| 泮托拉唑钠注射液(ml) | 发生ADR (N=1) | 未发生ADR (N=3) | 总计 (N=4) |
| Mean (SD) | 250.00 (NA) | 250.00 (0.00) | 250.00 (0.00) |
| Median (Q1, Q3) | 250.00 (250.00, 250.00) | 250.00 (250.00, 250.00) | 250.00 (250.00, 250.00) |
| Min - Max | 250.00 - 250.00 | 250.00 - 250.00 | 250.00 - 250.00 |
| 泮托拉唑钠注射液(mg) | 发生ADR (N=1) | 未发生ADR (N=7) | 总计 (N=8) |
| Mean (SD) | 4500.00 (NA) | 3500.00 (866.03) | 3625.00 (876.27) |
| Median (Q1, Q3) | 4500.00 (4500.00, 4500.00) | 3000.00 (3000.00, 3750.00) | 3000.00 (3000.00, 4500.00) |
| Min - Max | 4500.00 - 4500.00 | 3000.00 - 5000.00 | 3000.00 - 5000.00 |
| 泮托拉唑钠注射液(ml) | 发生ADR (N=1) | 未发生ADR (N=15) | 总计 (N=16) |
| Mean (SD) | 20.00 (NA) | 26.67 (9.76) | 26.25 (9.57) |
| Median (Q1, Q3) | 20.00 (20.00, 20.00) | 20.00 (20.00, 40.00) | 20.00 (20.00, 40.00) |
| Min - Max | 20.00 - 20.00 | 20.00 - 40.00 | 20.00 - 40.00 |
| 泮托拉唑钠注射液(mg) | 发生ADR (N=1) | 未发生ADR (N=5) | 总计 (N=6) |
| Mean (SD) | 8.00 (NA) | 8.00 (4.00) | 8.00 (3.58) |
| Median (Q1, Q3) | 8.00 (8.00, 8.00) | 8.00 (4.00, 12.00) | 8.00 (5.00, 11.00) |
| Min - Max | 8.00 - 8.00 | 4.00 - 12.00 | 4.00 - 12.00 |
| 泮托拉唑钠注射液(mg) | 发生ADR (N=1) | 未发生ADR (N=16) | 总计 (N=17) |
| Mean (SD) | 20.00 (NA) | 13.75 (5.00) | 14.12 (5.07) |
| Median (Q1, Q3) | 20.00 (20.00, 20.00) | 10.00 (10.00, 20.00) | 10.00 (10.00, 20.00) |
| Min - Max | 20.00 - 20.00 | 10.00 - 20.00 | 10.00 - 20.00 |
| 泮托拉唑钠注射液(mg) | 发生ADR (N=1) | 未发生ADR (N=17) | 总计 (N=18) |
| Mean (SD) | 6.00 (NA) | 2.41 (1.50) | 2.61 (1.69) |
| Median (Q1, Q3) | 6.00 (6.00, 6.00) | 2.00 (1.00, 4.00) | 2.00 (1.00, 4.00) |
| Min - Max | 6.00 - 6.00 | 1.00 - 6.00 | 1.00 - 6.00 |
| 泮托拉唑钠注射液(ml) | 发生ADR (N=1) | 未发生ADR (N=7) | 总计 (N=8) |
| Mean (SD) | 250.00 (NA) | 250.00 (0.00) | 250.00 (0.00) |
| Median (Q1, Q3) | 250.00 (250.00, 250.00) | 250.00 (250.00, 250.00) | 250.00 (250.00, 250.00) |
| Min - Max | 250.00 - 250.00 | 250.00 - 250.00 | 250.00 - 250.00 |
| 泮托拉唑钠注射液(mg) | 发生ADR (N=1) | 未发生ADR (N=3) | 总计 (N=4) |
| Mean (SD) | 30.00 (NA) | 33.33 (5.77) | 32.50 (5.00) |
| Median (Q1, Q3) | 30.00 (30.00, 30.00) | 30.00 (30.00, 35.00) | 30.00 (30.00, 32.50) |
| Min - Max | 30.00 - 30.00 | 30.00 - 40.00 | 30.00 - 40.00 |

### 8.5 间隔用药次数

  发生ADR与未发生ADR人群的间隔用药次数具有显著性差异，详见表 28。

**表 28: 间隔用药次数信息详表**

| **变量** | **发生ADR (N=193)** | **未发生ADR (N=29937)** | **总计 (N=30130)** | **检验方法** | **P值** |
| --- | --- | --- | --- | --- | --- |
| 间隔用药次数 |  |  |  | Wilcoxon rank sum tests | 0.002 |
| Mean (SD) | 9.19 (5.72) | 7.59 (4.69) | 7.60 (4.70) |  |  |
| Median (Q1, Q3) | 8.00 (5.00, 14.00) | 6.00 (4.00, 10.00) | 6.00 (4.00, 10.00) |  |  |
| Min - Max | 1.00 - 18.00 | 1.00 - 41.00 | 1.00 - 41.00 |  |  |
| Missing | 59 | 8940 | 8999 |  |  |
| 平均秩 | 12200.164 | 10555.571 | 10566 |  |  |
| 正态性检验P值 | < 0.001 | < 0.001 |  |  |  |

## 9.复方苦参注射液用药详情

### 9.1 是否首次用药

  发生ADR的患者，首次使用:是65(33.68%)、否128(66.32%)，未发生ADR的患者，首次使用:是10573(35.32%)、否19364(64.68%)，两组的发生比例不具有显著性差异(p=0.635)，详见表 29。

**表 29: 是否首次用药信息详表**

| **变量** | **发生ADR (N=193)** | **未发生ADR (N=29937)** | **总计 (N=30130)** | **检验方法** | **P值** |
| --- | --- | --- | --- | --- | --- |
| 首次使用 |  |  |  | Pearson's Chi-squared test | 0.635 |
| 是 | 65 (33.68%) | 10573 (35.32%) | 10638 (35.31%) |  |  |
| 否 | 128 (66.32%) | 19364 (64.68%) | 19492 (64.69%) |  |  |
| Missing | 0 | 0 | 0 |  |  |

### 9.2 每日给药剂量

  发生ADR的患者，每日给药剂量(ml):均数(标准差)为17.32(4.71),中位数(上下四分位数)为20.00(15.00,20.00)，未发生ADR的患者，每日给药剂量(ml):均数(标准差)为17.42(4.98),中位数(上下四分位数)为20.00(15.00,20.00)，两组的分布不具有显著性差异(p=0.806)，。详见表 30所示。

**表 30: 每日给药剂量信息详表**

| **变量** | **发生ADR (N=193)** | **未发生ADR (N=29937)** | **总计 (N=30130)** | **检验方法** | **P值** |
| --- | --- | --- | --- | --- | --- |
| 每日给药剂量(ml) |  |  |  | Wilcoxon rank sum tests | 0.806 |
| Mean (SD) | 17.32 (4.71) | 17.42 (4.98) | 17.42 (4.98) |  |  |
| Median (Q1, Q3) | 20.00 (15.00, 20.00) | 20.00 (15.00, 20.00) | 20.00 (15.00, 20.00) |  |  |
| Min - Max | 10.00 - 30.00 | 10.00 - 40.00 | 10.00 - 40.00 |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 平均秩 | 14922.114 | 15066.424 | 15065.5 |  |  |
| 正态性检验P值 | < 0.001 | < 0.001 |  |  |  |

  各用药剂量描述

| **变量** | **发生ADR (N=193)** | **未发生ADR (N=29937)** | **总计 (N=30130)** | **检验方法** | **P值** |
| --- | --- | --- | --- | --- | --- |
| 每日给药剂量(ml) |  |  |  | Pearson's Chi-squared test | 0.602 |
| 10 | 29 (15.03%) | 4724 (15.78%) | 4753 (15.77%) |  |  |
| 12 | 11 (5.70%) | 2398 (8.01%) | 2409 (8.00%) |  |  |
| 14 | 0 (0.00%) | 95 (0.32%) | 95 (0.32%) |  |  |
| 15 | 48 (24.87%) | 5692 (19.01%) | 5740 (19.05%) |  |  |
| 16 | 0 (0.00%) | 177 (0.59%) | 177 (0.59%) |  |  |
| 18 | 0 (0.00%) | 30 (0.10%) | 30 (0.10%) |  |  |
| 20 | 92 (47.67%) | 14460 (48.30%) | 14552 (48.30%) |  |  |
| 25 | 6 (3.11%) | 924 (3.09%) | 930 (3.09%) |  |  |
| 30 | 7 (3.63%) | 1432 (4.78%) | 1439 (4.78%) |  |  |
| 40 | 0 (0.00%) | 5 (0.02%) | 5 (0.02%) |  |  |
| Missing | 0 | 0 | 0 |  |  |

### 9.3 平均用药量

  发生ADR与未发生ADR的平均用药量无显著性差异。详见表 31所示。

**表 31: 用药详情：平均用药量信息详表**

| **变量** | **发生ADR (N=193)** | **未发生ADR (N=29937)** | **总计 (N=30130)** | **检验方法** | **P值** |
| --- | --- | --- | --- | --- | --- |
| 平均用药量 |  |  |  | Wilcoxon rank sum tests | 0.834 |
| Mean (SD) | 16.82 (3.81) | 16.86 (3.91) | 16.86 (3.91) |  |  |
| Median (Q1, Q3) | 20.00 (15.00, 20.00) | 20.00 (15.00, 20.00) | 20.00 (15.00, 20.00) |  |  |
| Min - Max | 10.00 - 20.00 | 10.00 - 25.00 | 10.00 - 25.00 |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 平均秩 | 14947.635 | 15066.26 | 15065.5 |  |  |
| 正态性检验P值 | < 0.001 | < 0.001 |  |  |  |

### 9.4 溶媒种类

  发生ADR与未发生ADR的各溶媒发生使用比例无显著性差异。详见表 32所示。

**表 33: 溶媒种类信息详表**

| **变量** | **发生ADR (N=193)** | **未发生ADR (N=29937)** | **总计 (N=30130)** | **检验方法** | **P值** |
| --- | --- | --- | --- | --- | --- |
| 溶媒种类 |  |  |  | Pearson's Chi-squared test | 0.818 |
| 0.9%生理盐水 | 181 (93.78%) | 27971 (93.43%) | 28152 (93.44%) |  |  |
| 5%葡萄糖 | 12 (6.22%) | 1823 (6.09%) | 1835 (6.09%) |  |  |
| 其他 | 0 (0.00%) | 125 (0.42%) | 125 (0.41%) |  |  |
| 10%葡萄糖 | 0 (0.00%) | 18 (0.06%) | 18 (0.06%) |  |  |
| Missing | 0 | 0 | 0 |  |  |

### 9.5 溶媒剂量

  在使用复方苦参注射液的30130例患者中，ADR发生比例对溶媒剂量的统计结果详见表 34。

**表 34: 溶媒剂量信息详表**

| **溶媒剂量(ml)** | **发生ADR** | **未发生ADR** | **总计** |
| --- | --- | --- | --- |
| 0.9%生理盐水 | 发生ADR (N=181) | 未发生ADR (N=27971) | 总计 (N=28152) |
| 100 | 13 (7.18%) | 2524 (9.02%) | 2537 (9.01%) |
| 150 | 0 (0.00%) | 41 (0.15%) | 41 (0.15%) |
| 200 | 13 (7.18%) | 892 (3.19%) | 905 (3.21%) |
| 220 | 0 (0.00%) | 313 (1.12%) | 313 (1.11%) |
| 230 | 1 (0.55%) | 253 (0.90%) | 254 (0.90%) |
| 250 | 149 (82.32%) | 23402 (83.67%) | 23551 (83.66%) |
| 500 | 5 (2.76%) | 546 (1.95%) | 551 (1.96%) |
| Missing | 0 | 0 | 0 |
| 5%葡萄糖 | 发生ADR (N=12) | 未发生ADR (N=1823) | 总计 (N=1835) |
| 100 | 0 (0.00%) | 94 (5.16%) | 94 (5.12%) |
| 150 | 0 (0.00%) | 2 (0.11%) | 2 (0.11%) |
| 200 | 0 (0.00%) | 9 (0.49%) | 9 (0.49%) |
| 250 | 11 (91.67%) | 1676 (91.94%) | 1687 (91.93%) |
| 500 | 1 (8.33%) | 42 (2.30%) | 43 (2.34%) |
| Missing | 0 | 0 | 0 |

### 9.6 药物浓度

  在使用复方苦参注射液的30130例患者中，所用溶媒为0.9%生理盐水、5%葡萄糖、10%葡萄糖，其中使用10%葡萄糖溶媒的人群中无发生ADR患者。统计结果详见表 35。

**表 35: 药物浓度信息详表**

| **变量** | **发生ADR** | **未发生ADR** | **总计** |
| --- | --- | --- | --- |
| 药物浓度（ml/ml|溶媒：0.9%生理盐水) | 发生ADR (N=181) | 未发生ADR (N=27971) | 总计 (N=28152) |
| Mean (SD) | 0.07 (0.03) | 0.07 (0.03) | 0.07 (0.03) |
| Median (Q1, Q3) | 0.07 (0.06, 0.07) | 0.07 (0.06, 0.07) | 0.07 (0.06, 0.07) |
| Min - Max | 0.03 - 0.17 | 0.02 - 0.23 | 0.02 - 0.23 |
| Missing | 0 | 0 | 0 |
| 药物浓度（ml/ml|溶媒：5%葡萄糖) | 发生ADR (N=12) | 未发生ADR (N=1823) | 总计 (N=1835) |
| Mean (SD) | 0.07 (0.02) | 0.07 (0.03) | 0.07 (0.03) |
| Median (Q1, Q3) | 0.07 (0.07, 0.07) | 0.07 (0.06, 0.07) | 0.07 (0.06, 0.07) |
| Min - Max | 0.03 - 0.11 | 0.02 - 0.17 | 0.02 - 0.17 |
| Missing | 0 | 0 | 0 |

### 9.7 滴注时间

  发生ADR与未发生ADR人群的滴注时间占比不具有显著性差异，详见表 36。

**表 36: 滴注时间信息详表**

| **变量** | **发生ADR (N=193)** | **未发生ADR (N=29937)** | **总计 (N=30130)** | **检验方法** | **P值** |
| --- | --- | --- | --- | --- | --- |
| 滴注时间 |  |  |  | Pearson's Chi-squared test | 0.226 |
| 30min | 3 (1.55%) | 617 (2.06%) | 620 (2.06%) |  |  |
| 45min | 13 (6.74%) | 1120 (3.74%) | 1133 (3.76%) |  |  |
| 60min | 61 (31.61%) | 10169 (33.97%) | 10230 (33.95%) |  |  |
| 90min | 108 (55.96%) | 17137 (57.24%) | 17245 (57.24%) |  |  |
| 120min | 6 (3.11%) | 761 (2.54%) | 767 (2.55%) |  |  |
| 120min 以上 | 2 (1.04%) | 133 (0.44%) | 135 (0.45%) |  |  |
| Missing | 0 | 0 | 0 |  |  |

### 9.8 平均静滴速度

  全人群中，发生ADR与未发生ADR人群静滴速度使用比例具有显著性差异的是：31-45滴/min、46～60滴/min、61-90滴/min。组间比较详见表 37。

**表 37: 用药详情：平均静滴速度信息详表**

| **变量** | **发生ADR (N=193)** | **未发生ADR (N=29937)** | **总计 (N=30130)** | **检验方法** | **P值** |
| --- | --- | --- | --- | --- | --- |
| 61-90滴/min |  |  |  | Pearson's Chi-squared test | 0.034 |
| 是 | 142 (73.58%) | 23871 (79.74%) | 24013 (79.70%) |  |  |
| 否 | 51 (26.42%) | 6066 (20.26%) | 6117 (20.30%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 46-60滴/min |  |  |  | Pearson's Chi-squared test | 0.196 |
| 是 | 44 (22.80%) | 5725 (19.12%) | 5769 (19.15%) |  |  |
| 否 | 149 (77.20%) | 24212 (80.88%) | 24361 (80.85%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 31-45滴/min |  |  |  | Pearson's Chi-squared test | 0.009 |
| 是 | 15 (7.77%) | 1212 (4.05%) | 1227 (4.07%) |  |  |
| 否 | 178 (92.23%) | 28725 (95.95%) | 28903 (95.93%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 91-120滴/min |  |  |  | Fisher's Exact Test for Count Data | 0.693 |
| 是 | 2 (1.04%) | 269 (0.90%) | 271 (0.90%) |  |  |
| 否 | 191 (98.96%) | 29668 (99.10%) | 29859 (99.10%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 30滴/min内 |  |  |  | Fisher's Exact Test for Count Data | 0.773 |
| 是 | 2 (1.04%) | 467 (1.56%) | 469 (1.56%) |  |  |
| 否 | 191 (98.96%) | 29470 (98.44%) | 29661 (98.44%) |  |  |
| Missing | 0 | 0 | 0 |  |  |

### 9.9 配药至给药间隔时间

  发生ADR与未发生ADR人群的配药至给药间隔时间的使用比例不具有显著性差异，组间比较详见表 38。

**表 38: 配药至给药间隔时间信息详表**

| **变量** | **发生ADR (N=193)** | **未发生ADR (N=29937)** | **总计 (N=30130)** | **检验方法** | **P值** |
| --- | --- | --- | --- | --- | --- |
| 10(min) |  |  |  | Pearson's Chi-squared test | 0.158 |
| 是 | 183 (94.82%) | 28936 (96.66%) | 29119 (96.64%) |  |  |
| 否 | 10 (5.18%) | 1001 (3.34%) | 1011 (3.36%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 20(min) |  |  |  | Pearson's Chi-squared test | 0.072 |
| 是 | 29 (15.03%) | 6063 (20.25%) | 6092 (20.22%) |  |  |
| 否 | 164 (84.97%) | 23874 (79.75%) | 24038 (79.78%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 16(min) |  |  |  | Pearson's Chi-squared test | 0.687 |
| 是 | 6 (3.11%) | 1094 (3.65%) | 1100 (3.65%) |  |  |
| 否 | 187 (96.89%) | 28843 (96.35%) | 29030 (96.35%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 17(min) |  |  |  | Pearson's Chi-squared test | 0.790 |
| 是 | 6 (3.11%) | 1036 (3.46%) | 1042 (3.46%) |  |  |
| 否 | 187 (96.89%) | 28901 (96.54%) | 29088 (96.54%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 19(min) |  |  |  | Fisher's Exact Test for Count Data | 0.192 |
| 是 | 1 (0.52%) | 589 (1.97%) | 590 (1.96%) |  |  |
| 否 | 192 (99.48%) | 29348 (98.03%) | 29540 (98.04%) |  |  |
| Missing | 0 | 0 | 0 |  |  |

### 9.10 药物滴注开始到不良反应发生时间

  70例患者发生不良事件84例次，药物滴注开始到不良事件发生时间的统计结果详见详见表 39。

**表 39: 药物滴注开始到不良反应发生时间信息详表**

| **药物滴注开始到不良反应发生时间** | **频数** | **百分比** |
| --- | --- | --- |
| (0,5min] | 18 | 8.37% |
| (5min,30min] | 35 | 16.28% |
| (0.5h,1h] | 16 | 7.44% |
| (1h,5h] | 58 | 26.98% |
| (5h,24h] | 77 | 35.81% |
| >1d | 11 | 5.12% |

### 9.11 用药天数

  发生ADR与未发生ADR人群的用药天数不具有显著性差异，详见表 40。

**表 40: 用药天数信息详表**

| **变量** | **发生ADR (N=193)** | **未发生ADR (N=29937)** | **总计 (N=30130)** | **检验方法** | **P值** |
| --- | --- | --- | --- | --- | --- |
| 用药天数 |  |  |  | Wilcoxon rank sum tests | 0.067 |
| Mean (SD) | 9.42 (9.03) | 7.84 (8.03) | 7.85 (8.04) |  |  |
| Median (Q1, Q3) | 7.00 (3.00, 13.00) | 6.00 (3.00, 10.00) | 6.00 (3.00, 10.00) |  |  |
| Min - Max | 0.00 - 40.00 | 0.00 - 130.00 | 0.00 - 130.00 |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 平均秩 | 16204.927 | 15058.154 | 15065.5 |  |  |
| 正态性检验P值 | < 0.001 | < 0.001 |  |  |  |

## 10.合并用药详情

  全人群30130例患者中，有合并用药的患者共268772例，占比892.04%;AE人群4426例患者中，有合并用药的患者共4407例，占比99.57%;ADR人群193例患者中，有合并用药的患者共192例，占比99.48%。

### 10.1 合并用药类别

  全人群中，发生ADR的患者，西药:是189(97.93%)、否4(2.07%)，未发生ADR的患者，西药:是29227(97.63%)、否710(2.37%)，两组的发生比例不具有显著性差异，(p=>0.999)。发生ADR与未发生ADR患者的合并用药中，中药的使用比例具有显著性差异。详见表 41。

**表 41: 合并用药类别信息详表**

| **变量** | **发生ADR (N=193)** | **未发生ADR (N=29937)** | **总计 (N=30130)** | **检验方法** | **P值** |
| --- | --- | --- | --- | --- | --- |
| 西药 |  |  |  | Fisher's Exact Test for Count Data | > 0.999 |
| 是 | 189 (97.93%) | 29227 (97.63%) | 29416 (97.63%) |  |  |
| 否 | 4 (2.07%) | 710 (2.37%) | 714 (2.37%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 中药 |  |  |  | Pearson's Chi-squared test | 0.013 |
| 是 | 122 (63.21%) | 16235 (54.23%) | 16357 (54.29%) |  |  |
| 否 | 71 (36.79%) | 13702 (45.77%) | 13773 (45.71%) |  |  |
| Missing | 0 | 0 | 0 |  |  |

### 10.2 药物系统分类

  发生ADR与未发生ADR患者合并用药一级分类的使用比例具有显著性差异的为：激素及有关药物、诊断用药、中枢神经系统药物、抗微生物药物、呼吸系统药物、维生素类药物、水、电解质及酸碱平衡用药、抗变态反应药物、泌尿系统用药、延缓衰老药及某些老年病用药，详见表 42，表格中合并用药一级分类按发生ADR人群中的使用人数占比降序排列。

**表 42: 合并用药一级分类信息详表**

| **变量** | **发生ADR (N=193)** | **未发生ADR (N=29937)** | **总计 (N=30130)** | **检验方法** | **P值** |
| --- | --- | --- | --- | --- | --- |
| 消化系统药物 |  |  |  | Pearson's Chi-squared test | 0.340 |
| 是 | 161 (83.42%) | 24160 (80.70%) | 24321 (80.72%) |  |  |
| 否 | 32 (16.58%) | 5777 (19.30%) | 5809 (19.28%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 抗肿瘤药物 |  |  |  | Pearson's Chi-squared test | 0.349 |
| 是 | 123 (63.73%) | 18088 (60.42%) | 18211 (60.44%) |  |  |
| 否 | 70 (36.27%) | 11849 (39.58%) | 11919 (39.56%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 激素及有关药物 |  |  |  | Pearson's Chi-squared test | 0.001 |
| 是 | 126 (65.28%) | 15928 (53.21%) | 16054 (53.28%) |  |  |
| 否 | 67 (34.72%) | 14009 (46.79%) | 14076 (46.72%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 诊断用药 |  |  |  | Pearson's Chi-squared test | 0.027 |
| 是 | 99 (51.30%) | 12986 (43.38%) | 13085 (43.43%) |  |  |
| 否 | 94 (48.70%) | 16951 (56.62%) | 17045 (56.57%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 中枢神经系统药物 |  |  |  | Pearson's Chi-squared test | < 0.001 |
| 是 | 82 (42.49%) | 8682 (29.00%) | 8764 (29.09%) |  |  |
| 否 | 111 (57.51%) | 21255 (71.00%) | 21366 (70.91%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 影响血液及造血系统的药物 |  |  |  | Pearson's Chi-squared test | 0.808 |
| 是 | 77 (39.90%) | 12202 (40.76%) | 12279 (40.75%) |  |  |
| 否 | 116 (60.10%) | 17735 (59.24%) | 17851 (59.25%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 营养药 |  |  |  | Pearson's Chi-squared test | 0.257 |
| 是 | 52 (26.94%) | 7028 (23.48%) | 7080 (23.50%) |  |  |
| 否 | 141 (73.06%) | 22909 (76.52%) | 23050 (76.50%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 抗微生物药物 |  |  |  | Pearson's Chi-squared test | 0.034 |
| 是 | 53 (27.46%) | 6349 (21.21%) | 6402 (21.25%) |  |  |
| 否 | 140 (72.54%) | 23588 (78.79%) | 23728 (78.75%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 循环系统药物 |  |  |  | Pearson's Chi-squared test | 0.229 |
| 是 | 55 (28.50%) | 7408 (24.75%) | 7463 (24.77%) |  |  |
| 否 | 138 (71.50%) | 22529 (75.25%) | 22667 (75.23%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 呼吸系统药物 |  |  |  | Pearson's Chi-squared test | 0.012 |
| 是 | 43 (22.28%) | 4685 (15.65%) | 4728 (15.69%) |  |  |
| 否 | 150 (77.72%) | 25252 (84.35%) | 25402 (84.31%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 维生素类药物 |  |  |  | Pearson's Chi-squared test | 0.043 |
| 是 | 46 (23.83%) | 5447 (18.19%) | 5493 (18.23%) |  |  |
| 否 | 147 (76.17%) | 24490 (81.81%) | 24637 (81.77%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 水、电解质及酸碱平衡用药 |  |  |  | Pearson's Chi-squared test | 0.011 |
| 是 | 47 (24.35%) | 5196 (17.36%) | 5243 (17.40%) |  |  |
| 否 | 146 (75.65%) | 24741 (82.64%) | 24887 (82.60%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 抗变态反应药物 |  |  |  | Pearson's Chi-squared test | 0.009 |
| 是 | 59 (30.57%) | 6776 (22.63%) | 6835 (22.69%) |  |  |
| 否 | 134 (69.43%) | 23161 (77.37%) | 23295 (77.31%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 泌尿系统用药 |  |  |  | Pearson's Chi-squared test | 0.003 |
| 是 | 44 (22.80%) | 4489 (14.99%) | 4533 (15.04%) |  |  |
| 否 | 149 (77.20%) | 25448 (85.01%) | 25597 (84.96%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 影响免疫功能的药物 |  |  |  | Pearson's Chi-squared test | 0.108 |
| 是 | 55 (28.50%) | 10179 (34.00%) | 10234 (33.97%) |  |  |
| 否 | 138 (71.50%) | 19758 (66.00%) | 19896 (66.03%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 各临床科室备用药物 |  |  |  | Pearson's Chi-squared test | 0.313 |
| 是 | 37 (19.17%) | 4930 (16.47%) | 4967 (16.49%) |  |  |
| 否 | 156 (80.83%) | 25007 (83.53%) | 25163 (83.51%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 麻醉药及其辅助药物 |  |  |  | Pearson's Chi-squared test | 0.517 |
| 是 | 14 (7.25%) | 1835 (6.13%) | 1849 (6.14%) |  |  |
| 否 | 179 (92.75%) | 28102 (93.87%) | 28281 (93.86%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 植物神经系统药物 |  |  |  | Pearson's Chi-squared test | 0.170 |
| 是 | 17 (8.81%) | 1911 (6.38%) | 1928 (6.40%) |  |  |
| 否 | 176 (91.19%) | 28026 (93.62%) | 28202 (93.60%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 生物制品、生化药物和酶及辅酶类 |  |  |  | Pearson's Chi-squared test | 0.584 |
| 是 | 8 (4.15%) | 1499 (5.01%) | 1507 (5.00%) |  |  |
| 否 | 185 (95.85%) | 28438 (94.99%) | 28623 (95.00%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 其他用药 |  |  |  | Pearson's Chi-squared test | 0.155 |
| 是 | 7 (3.63%) | 1819 (6.08%) | 1826 (6.06%) |  |  |
| 否 | 186 (96.37%) | 28118 (93.92%) | 28304 (93.94%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 延缓衰老药及某些老年病用药 |  |  |  | Fisher's Exact Test for Count Data | 0.008 |
| 是 | 4 (2.07%) | 120 (0.40%) | 124 (0.41%) |  |  |
| 否 | 189 (97.93%) | 29817 (99.60%) | 30006 (99.59%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 生物制品、生化药物、酶及辅酶类 |  |  |  | Fisher's Exact Test for Count Data | 0.104 |
| 是 | 1 (0.52%) | 16 (0.05%) | 17 (0.06%) |  |  |
| 否 | 192 (99.48%) | 29921 (99.95%) | 30113 (99.94%) |  |  |
| Missing | 0 | 0 | 0 |  |  |

### 10.3 合并用药一级与二级分类例数与例次统计

**表 43: 合并用药一级、二级分类例数与例次信息详表**

| **一级分类名称** | **二级分类名称** | **全人群中使用例数** | **在全人群占比** | **AE人群中使用例数** | **在AE人群占比** | **ADR人群中使用例数** | **在ADR人群占比** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 消化系统药物:例数24321(80.72%) | 抗酸药及治疗消化性溃疡病药 | 21109 | 70.060% | 3510 | 79.304% | 132 | 68.394% |
| 止吐药 | 16874 | 56.004% | 2866 | 64.754% | 123 | 63.731% |
| 肝胆疾病辅助用药 | 9799 | 32.522% | 1691 | 38.206% | 66 | 34.197% |
| 泻药 | 1682 | 5.582% | 415 | 9.376% | 19 | 9.845% |
| 助消化药 | 1526 | 5.065% | 353 | 7.976% | 14 | 7.254% |
| 止泻药 | 754 | 2.502% | 208 | 4.700% | 10 | 5.181% |
| 胃肠解痉药 | 363 | 1.205% | 64 | 1.446% | 2 | 1.036% |
| 抗肿瘤药物:例数18211(60.44%) | 激素类 | 13562 | 45.012% | 2436 | 55.038% | 111 | 57.513% |
| 抗肿瘤药物-其他类 | 10996 | 36.495% | 1883 | 42.544% | 82 | 42.487% |
| 抗肿瘤植物药及中草药 | 8935 | 29.655% | 1594 | 36.014% | 54 | 27.979% |
| 抗代谢药 | 5840 | 19.383% | 1040 | 23.498% | 43 | 22.280% |
| 抗肿瘤抗生素 | 2233 | 7.411% | 429 | 9.693% | 16 | 8.290% |
| 烷化剂类 | 1883 | 6.250% | 357 | 8.066% | 11 | 5.699% |
| 激素及有关药物:例数16054(53.28%) | 肾上腺皮质激素类药 | 13279 | 44.072% | 2412 | 54.496% | 111 | 57.513% |
| 胰岛素及其他影响血糖的药物 | 2990 | 9.924% | 681 | 15.386% | 27 | 13.990% |
| 性激素及促性激素 | 2028 | 6.731% | 396 | 8.947% | 20 | 10.363% |
| 激素及有关药物-其他类 | 316 | 1.049% | 83 | 1.875% | 3 | 1.554% |
| 甲状腺激素类药及抗甲状腺药物 | 107 | 0.355% | 19 | 0.429% | 1 | 0.518% |
| 诊断用药:例数13085(43.43%) | 诊断用药-其他类 | 13086 | 43.432% | 2204 | 49.797% | 99 | 51.295% |
| 中枢神经系统药物:例数8764(29.09%) | 镇痛药 | 3794 | 12.592% | 976 | 22.052% | 44 | 22.798% |
| 解热镇痛抗炎药及抗痛风药 | 4192 | 13.913% | 1013 | 22.887% | 35 | 18.135% |
| 抗精神失常药 | 2022 | 6.711% | 436 | 9.851% | 14 | 7.254% |
| 中枢神经系统药物-其他类 | 858 | 2.848% | 145 | 3.276% | 9 | 4.663% |
| 镇静催眠药及抗惊厥药 | 272 | 0.903% | 46 | 1.039% | 2 | 1.036% |
| 抗癲痫药 | 118 | 0.392% | 33 | 0.746% | 1 | 0.518% |
| 抗震颤麻痹药 | 131 | 0.435% | 19 | 0.429% | 1 | 0.518% |
| 影响血液及造血系统的药物:例数12279(40.75%) | 促进白细胞增生药 | 5845 | 19.399% | 1233 | 27.858% | 36 | 18.653% |
| 抗凝血药 | 3805 | 12.629% | 528 | 11.930% | 23 | 11.917% |
| 抗贫血药 | 2592 | 8.603% | 454 | 10.258% | 17 | 8.808% |
| 促凝血药 | 1671 | 5.546% | 396 | 8.947% | 13 | 6.736% |
| 血浆及血浆代用品 | 831 | 2.758% | 244 | 5.513% | 9 | 4.663% |
| 抗血小板药物 | 356 | 1.182% | 64 | 1.446% | 3 | 1.554% |
| 营养药:例数7080(23.50%) | 营养药 | 7080 | 23.498% | 1501 | 33.913% | 52 | 26.943% |
| 抗微生物药物:例数6402(21.25%) | 抗生素 | 6568 | 21.799% | 1503 | 33.958% | 50 | 25.907% |
| 合成抗菌药 | 2288 | 7.594% | 599 | 13.534% | 22 | 11.399% |
| 抗真菌药 | 320 | 1.062% | 69 | 1.559% | 5 | 2.591% |
| 抗麻风病药及抗麻风病反应药 | 258 | 0.856% | 54 | 1.220% | 4 | 2.073% |
| 抗病毒药 | 266 | 0.883% | 59 | 1.333% | 2 | 1.036% |
| 循环系统药物:例数7463(24.77%) | 防治心绞痛药 | 4426 | 14.690% | 765 | 17.284% | 32 | 16.580% |
| 循环系统药物-其他类 | 2042 | 6.777% | 348 | 7.863% | 14 | 7.254% |
| 降血压药 | 1063 | 3.528% | 270 | 6.100% | 12 | 6.218% |
| 抗心律失常药 | 756 | 2.509% | 136 | 3.073% | 6 | 3.109% |
| 抗休克血管活性药 | 127 | 0.422% | 59 | 1.333% | 2 | 1.036% |
| 调节血脂药及抗动脉粥样硬化药 | 526 | 1.746% | 67 | 1.514% | 2 | 1.036% |
| 治疗慢性心功能不全的药物 | 246 | 0.816% | 69 | 1.559% | 2 | 1.036% |
| 周围血管扩张药 | 94 | 0.312% | 23 | 0.520% | 1 | 0.518% |
| 呼吸系统药物:例数4728(15.69%) | 祛痰药 | 3714 | 12.327% | 805 | 18.188% | 35 | 18.135% |
| 平喘药 | 2291 | 7.604% | 542 | 12.246% | 22 | 11.399% |
| 镇咳药 | 550 | 1.825% | 145 | 3.276% | 4 | 2.073% |
| 维生素类药物:例数5493(18.23%) | 维生素B属药物 | 3885 | 12.894% | 778 | 17.578% | 37 | 19.171% |
| 维生素C属药物及其他类 | 3710 | 12.313% | 697 | 15.748% | 22 | 11.399% |
| 水、电解质及酸碱平衡用药:例数5243(17.40%) | 电解质平衡调节药 | 3488 | 11.577% | 845 | 19.092% | 32 | 16.580% |
| 酸碱平衡调节药 | 2286 | 7.587% | 438 | 9.896% | 22 | 11.399% |
| 抗变态反应药物:例数6835(22.69%) | 抗组胺药 | 6835 | 22.685% | 1390 | 31.405% | 59 | 30.570% |
| 泌尿系统用药:例数4533(15.04%) | 利尿药 | 3236 | 10.740% | 874 | 19.747% | 34 | 17.617% |
| 脱水药 | 1576 | 5.231% | 360 | 8.134% | 13 | 6.736% |
| 影响免疫功能的药物:例数10234(33.97%) | 免疫增强剂 | 7599 | 25.221% | 1149 | 25.960% | 37 | 19.171% |
| 免疫抑制剂 | 2981 | 9.894% | 537 | 12.133% | 16 | 8.290% |
| 影响免疫功能的药物-其他类 | 433 | 1.437% | 90 | 2.033% | 5 | 2.591% |
| 各临床科室备用药物:例数4967(16.49%) | 眼科用药 | 4813 | 15.974% | 879 | 19.860% | 36 | 18.653% |
| 外科用药及消毒防腐收敛药 | 130 | 0.431% | 23 | 0.520% | 2 | 1.036% |
| 麻醉药及其辅助药物:例数1849(6.14%) | 局部麻醉用药 | 1685 | 5.592% | 329 | 7.433% | 14 | 7.254% |
| 全身麻醉用药 | 154 | 0.511% | 10 | 0.226% | 1 | 0.518% |
| 骨骼肌松弛药 | 99 | 0.329% | 4 | 0.090% | 1 | 0.518% |
| 植物神经系统药物:例数1928(6.40%) | 抗胆碱药 | 1169 | 3.880% | 229 | 5.174% | 12 | 6.218% |
| 抗肾上腺素药 | 637 | 2.114% | 129 | 2.915% | 4 | 2.073% |
| 拟肾上腺素药 | 162 | 0.538% | 26 | 0.587% | 2 | 1.036% |
| 生物制品、生化药物和酶及辅酶类:例数1507(5.00%) | 酶及辅酶类 | 1038 | 3.445% | 159 | 3.592% | 5 | 2.591% |
| 疫苗 | 375 | 1.245% | 98 | 2.214% | 2 | 1.036% |
| 免疫血清及血液制品 | 123 | 0.408% | 29 | 0.655% | 2 | 1.036% |
| 其他用药:例数1826(6.06%) | 诊断用药 | 13483 | 44.749% | 2268 | 51.243% | 100 | 51.813% |
| 抗肿瘤药物-抗代谢药 | 631 | 2.094% | 81 | 1.830% | 5 | 2.591% |
| 药用附加剂 | 396 | 1.314% | 73 | 1.649% | 1 | 0.518% |
| 延缓衰老药及某些老年病用药:例数124(0.41%) | 前列腺增生症用药 | 122 | 0.405% | 27 | 0.610% | 4 | 2.073% |
| 生物制品、生化药物、酶及辅酶类:例数17(0.06%) | 免疫血清及血液制品 | 123 | 0.408% | 29 | 0.655% | 2 | 1.036% |

### 10.4 发生与未发生ADR组间合并用药的二级分类统计检验

  发生ADR与未发生ADR患者所涉及合并用药二级分类的使用比例具有显著性差异的药物名称为：止吐药、诊断用药-其他类、肾上腺皮质激素类药、镇痛药、抗组胺药、利尿药、电解质平衡调节药、维生素b属药物、祛痰药、合成抗菌药、平喘药、酸碱平衡调节药、性激素及促性激素、降血压药、止泻药、前列腺增生症用药，详见表 44

**表 44: 合并用药二级分类信息详表**

表格按发生ADR人群的合并用药二级分类使用占比降序排列。

| **变量** | **发生ADR (N=193)** | **未发生ADR (N=29937)** | **总计 (N=30130)** | **检验方法** | **P值** |
| --- | --- | --- | --- | --- | --- |
| 止吐药 |  |  |  | Pearson's Chi-squared test | 0.030 |
| 是 | 123 (63.73%) | 16751 (55.95%) | 16874 (56.00%) |  |  |
| 否 | 70 (36.27%) | 13186 (44.05%) | 13256 (44.00%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 诊断用药-其他类 |  |  |  | Pearson's Chi-squared test | 0.027 |
| 是 | 99 (51.30%) | 12987 (43.38%) | 13086 (43.43%) |  |  |
| 否 | 94 (48.70%) | 16950 (56.62%) | 17044 (56.57%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 抗酸药及治疗消化性溃疡病药 |  |  |  | Pearson's Chi-squared test | 0.612 |
| 是 | 132 (68.39%) | 20977 (70.07%) | 21109 (70.06%) |  |  |
| 否 | 61 (31.61%) | 8960 (29.93%) | 9021 (29.94%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 肾上腺皮质激素类药 |  |  |  | Pearson's Chi-squared test | < 0.001 |
| 是 | 111 (57.51%) | 13168 (43.99%) | 13279 (44.07%) |  |  |
| 否 | 82 (42.49%) | 16769 (56.01%) | 16851 (55.93%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 抗肿瘤药物-其他类 |  |  |  | Pearson's Chi-squared test | 0.083 |
| 是 | 82 (42.49%) | 10914 (36.46%) | 10996 (36.50%) |  |  |
| 否 | 111 (57.51%) | 19023 (63.54%) | 19134 (63.50%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 肝胆疾病辅助用药 |  |  |  | Pearson's Chi-squared test | 0.618 |
| 是 | 66 (34.20%) | 9733 (32.51%) | 9799 (32.52%) |  |  |
| 否 | 127 (65.80%) | 20204 (67.49%) | 20331 (67.48%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 营养药 |  |  |  | Pearson's Chi-squared test | 0.257 |
| 是 | 52 (26.94%) | 7028 (23.48%) | 7080 (23.50%) |  |  |
| 否 | 141 (73.06%) | 22909 (76.52%) | 23050 (76.50%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 镇痛药 |  |  |  | Pearson's Chi-squared test | < 0.001 |
| 是 | 44 (22.80%) | 3750 (12.53%) | 3794 (12.59%) |  |  |
| 否 | 149 (77.20%) | 26187 (87.47%) | 26336 (87.41%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 抗组胺药 |  |  |  | Pearson's Chi-squared test | 0.009 |
| 是 | 59 (30.57%) | 6776 (22.63%) | 6835 (22.69%) |  |  |
| 否 | 134 (69.43%) | 23161 (77.37%) | 23295 (77.31%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 抗肿瘤植物药及中草药 |  |  |  | Pearson's Chi-squared test | 0.609 |
| 是 | 54 (27.98%) | 8881 (29.67%) | 8935 (29.65%) |  |  |
| 否 | 139 (72.02%) | 21056 (70.33%) | 21195 (70.35%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 抗生素 |  |  |  | Pearson's Chi-squared test | 0.198 |
| 是 | 35 (18.13%) | 4440 (14.83%) | 4475 (14.85%) |  |  |
| 否 | 158 (81.87%) | 25497 (85.17%) | 25655 (85.15%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 利尿药 |  |  |  | Pearson's Chi-squared test | 0.002 |
| 是 | 34 (17.62%) | 3202 (10.70%) | 3236 (10.74%) |  |  |
| 否 | 159 (82.38%) | 26735 (89.30%) | 26894 (89.26%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 促进白细胞增生药 |  |  |  | Pearson's Chi-squared test | 0.792 |
| 是 | 36 (18.65%) | 5809 (19.40%) | 5845 (19.40%) |  |  |
| 否 | 157 (81.35%) | 24128 (80.60%) | 24285 (80.60%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 抗代谢药 |  |  |  | Pearson's Chi-squared test | 0.391 |
| 是 | 38 (19.69%) | 5192 (17.34%) | 5230 (17.36%) |  |  |
| 否 | 155 (80.31%) | 24745 (82.66%) | 24900 (82.64%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 电解质平衡调节药 |  |  |  | Pearson's Chi-squared test | 0.029 |
| 是 | 32 (16.58%) | 3456 (11.54%) | 3488 (11.58%) |  |  |
| 否 | 161 (83.42%) | 26481 (88.46%) | 26642 (88.42%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 解热镇痛抗炎药及抗痛风药 |  |  |  | Pearson's Chi-squared test | 0.089 |
| 是 | 35 (18.13%) | 4157 (13.89%) | 4192 (13.91%) |  |  |
| 否 | 158 (81.87%) | 25780 (86.11%) | 25938 (86.09%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 维生素b属药物 |  |  |  | Pearson's Chi-squared test | 0.009 |
| 是 | 37 (19.17%) | 3848 (12.85%) | 3885 (12.89%) |  |  |
| 否 | 156 (80.83%) | 26089 (87.15%) | 26245 (87.11%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 免疫增强剂 |  |  |  | Pearson's Chi-squared test | 0.052 |
| 是 | 37 (19.17%) | 7562 (25.26%) | 7599 (25.22%) |  |  |
| 否 | 156 (80.83%) | 22375 (74.74%) | 22531 (74.78%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 眼科用药 |  |  |  | Pearson's Chi-squared test | 0.308 |
| 是 | 36 (18.65%) | 4777 (15.96%) | 4813 (15.97%) |  |  |
| 否 | 157 (81.35%) | 25160 (84.04%) | 25317 (84.03%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 防治心绞痛药 |  |  |  | Pearson's Chi-squared test | 0.457 |
| 是 | 32 (16.58%) | 4394 (14.68%) | 4426 (14.69%) |  |  |
| 否 | 161 (83.42%) | 25543 (85.32%) | 25704 (85.31%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 祛痰药 |  |  |  | Pearson's Chi-squared test | 0.014 |
| 是 | 35 (18.13%) | 3679 (12.29%) | 3714 (12.33%) |  |  |
| 否 | 158 (81.87%) | 26258 (87.71%) | 26416 (87.67%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 胰岛素及其他影响血糖的药物 |  |  |  | Pearson's Chi-squared test | 0.058 |
| 是 | 27 (13.99%) | 2963 (9.90%) | 2990 (9.92%) |  |  |
| 否 | 166 (86.01%) | 26974 (90.10%) | 27140 (90.08%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 抗凝血药 |  |  |  | Pearson's Chi-squared test | 0.765 |
| 是 | 23 (11.92%) | 3782 (12.63%) | 3805 (12.63%) |  |  |
| 否 | 170 (88.08%) | 26155 (87.37%) | 26325 (87.37%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 合成抗菌药 |  |  |  | Pearson's Chi-squared test | 0.045 |
| 是 | 22 (11.40%) | 2266 (7.57%) | 2288 (7.59%) |  |  |
| 否 | 171 (88.60%) | 27671 (92.43%) | 27842 (92.41%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 平喘药 |  |  |  | Pearson's Chi-squared test | 0.046 |
| 是 | 22 (11.40%) | 2269 (7.58%) | 2291 (7.60%) |  |  |
| 否 | 171 (88.60%) | 27668 (92.42%) | 27839 (92.40%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 维生素c属药物及其他类 |  |  |  | Pearson's Chi-squared test | 0.698 |
| 是 | 22 (11.40%) | 3688 (12.32%) | 3710 (12.31%) |  |  |
| 否 | 171 (88.60%) | 26249 (87.68%) | 26420 (87.69%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 酸碱平衡调节药 |  |  |  | Pearson's Chi-squared test | 0.045 |
| 是 | 22 (11.40%) | 2264 (7.56%) | 2286 (7.59%) |  |  |
| 否 | 171 (88.60%) | 27673 (92.44%) | 27844 (92.41%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 性激素及促性激素 |  |  |  | Pearson's Chi-squared test | 0.043 |
| 是 | 20 (10.36%) | 2008 (6.71%) | 2028 (6.73%) |  |  |
| 否 | 173 (89.64%) | 27929 (93.29%) | 28102 (93.27%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 抗贫血药 |  |  |  | Pearson's Chi-squared test | 0.919 |
| 是 | 17 (8.81%) | 2575 (8.60%) | 2592 (8.60%) |  |  |
| 否 | 176 (91.19%) | 27362 (91.40%) | 27538 (91.40%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 促凝血药 |  |  |  | Pearson's Chi-squared test | 0.469 |
| 是 | 13 (6.74%) | 1658 (5.54%) | 1671 (5.55%) |  |  |
| 否 | 180 (93.26%) | 28279 (94.46%) | 28459 (94.45%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 局部麻醉用药 |  |  |  | Pearson's Chi-squared test | 0.314 |
| 是 | 14 (7.25%) | 1671 (5.58%) | 1685 (5.59%) |  |  |
| 否 | 179 (92.75%) | 28266 (94.42%) | 28445 (94.41%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 免疫抑制剂 |  |  |  | Pearson's Chi-squared test | 0.454 |
| 是 | 16 (8.29%) | 2965 (9.90%) | 2981 (9.89%) |  |  |
| 否 | 177 (91.71%) | 26972 (90.10%) | 27149 (90.11%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 脱水药 |  |  |  | Pearson's Chi-squared test | 0.346 |
| 是 | 13 (6.74%) | 1563 (5.22%) | 1576 (5.23%) |  |  |
| 否 | 180 (93.26%) | 28374 (94.78%) | 28554 (94.77%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 抗精神失常药 |  |  |  | Pearson's Chi-squared test | 0.762 |
| 是 | 14 (7.25%) | 2008 (6.71%) | 2022 (6.71%) |  |  |
| 否 | 179 (92.75%) | 27929 (93.29%) | 28108 (93.29%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 抗肿瘤抗生素 |  |  |  | Pearson's Chi-squared test | 0.640 |
| 是 | 16 (8.29%) | 2217 (7.41%) | 2233 (7.41%) |  |  |
| 否 | 177 (91.71%) | 27720 (92.59%) | 27897 (92.59%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 循环系统药物-其他类 |  |  |  | Pearson's Chi-squared test | 0.792 |
| 是 | 14 (7.25%) | 2028 (6.77%) | 2042 (6.78%) |  |  |
| 否 | 179 (92.75%) | 27909 (93.23%) | 28088 (93.22%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 助消化药 |  |  |  | Pearson's Chi-squared test | 0.164 |
| 是 | 14 (7.25%) | 1512 (5.05%) | 1526 (5.06%) |  |  |
| 否 | 179 (92.75%) | 28425 (94.95%) | 28604 (94.94%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 降血压药 |  |  |  | Pearson's Chi-squared test | 0.042 |
| 是 | 12 (6.22%) | 1051 (3.51%) | 1063 (3.53%) |  |  |
| 否 | 181 (93.78%) | 28886 (96.49%) | 29067 (96.47%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 抗胆碱药 |  |  |  | Pearson's Chi-squared test | 0.092 |
| 是 | 12 (6.22%) | 1157 (3.86%) | 1169 (3.88%) |  |  |
| 否 | 181 (93.78%) | 28780 (96.14%) | 28961 (96.12%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 烷化剂类 |  |  |  | Pearson's Chi-squared test | 0.751 |
| 是 | 11 (5.70%) | 1872 (6.25%) | 1883 (6.25%) |  |  |
| 否 | 182 (94.30%) | 28065 (93.75%) | 28247 (93.75%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 止泻药 |  |  |  | Fisher's Exact Test for Count Data | 0.031 |
| 是 | 10 (5.18%) | 744 (2.49%) | 754 (2.50%) |  |  |
| 否 | 183 (94.82%) | 29193 (97.51%) | 29376 (97.50%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 泻药 |  |  |  | Pearson's Chi-squared test | 0.137 |
| 是 | 10 (5.18%) | 979 (3.27%) | 989 (3.28%) |  |  |
| 否 | 183 (94.82%) | 28958 (96.73%) | 29141 (96.72%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 血浆及血浆代用品 |  |  |  | Pearson's Chi-squared test | 0.105 |
| 是 | 9 (4.66%) | 822 (2.75%) | 831 (2.76%) |  |  |
| 否 | 184 (95.34%) | 29115 (97.25%) | 29299 (97.24%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 中枢神经系统药物-其他类 |  |  |  | Pearson's Chi-squared test | 0.128 |
| 是 | 9 (4.66%) | 849 (2.84%) | 858 (2.85%) |  |  |
| 否 | 184 (95.34%) | 29088 (97.16%) | 29272 (97.15%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 抗心律失常药 |  |  |  | Fisher's Exact Test for Count Data | 0.490 |
| 是 | 6 (3.11%) | 750 (2.51%) | 756 (2.51%) |  |  |
| 否 | 187 (96.89%) | 29187 (97.49%) | 29374 (97.49%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 抗真菌药 |  |  |  | Fisher's Exact Test for Count Data | 0.056 |
| 是 | 5 (2.59%) | 315 (1.05%) | 320 (1.06%) |  |  |
| 否 | 188 (97.41%) | 29622 (98.95%) | 29810 (98.94%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 抗肿瘤药物-抗代谢药 |  |  |  | Fisher's Exact Test for Count Data | 0.607 |
| 是 | 5 (2.59%) | 626 (2.09%) | 631 (2.09%) |  |  |
| 否 | 188 (97.41%) | 29311 (97.91%) | 29499 (97.91%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 酶及辅酶类 |  |  |  | Pearson's Chi-squared test | 0.515 |
| 是 | 5 (2.59%) | 1032 (3.45%) | 1037 (3.44%) |  |  |
| 否 | 188 (97.41%) | 28905 (96.55%) | 29093 (96.56%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 影响免疫功能的药物-其他类 |  |  |  | Fisher's Exact Test for Count Data | 0.207 |
| 是 | 5 (2.59%) | 428 (1.43%) | 433 (1.44%) |  |  |
| 否 | 188 (97.41%) | 29509 (98.57%) | 29697 (98.56%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 抗麻风病药及抗麻风病反应药 |  |  |  | Fisher's Exact Test for Count Data | 0.085 |
| 是 | 4 (2.07%) | 254 (0.85%) | 258 (0.86%) |  |  |
| 否 | 189 (97.93%) | 29683 (99.15%) | 29872 (99.14%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 抗肾上腺素药 |  |  |  | Fisher's Exact Test for Count Data | > 0.999 |
| 是 | 4 (2.07%) | 633 (2.11%) | 637 (2.11%) |  |  |
| 否 | 189 (97.93%) | 29304 (97.89%) | 29493 (97.89%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 前列腺增生症用药 |  |  |  | Fisher's Exact Test for Count Data | 0.008 |
| 是 | 4 (2.07%) | 118 (0.39%) | 122 (0.40%) |  |  |
| 否 | 189 (97.93%) | 29819 (99.61%) | 30008 (99.60%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 镇咳药 |  |  |  | Fisher's Exact Test for Count Data | 0.783 |
| 是 | 4 (2.07%) | 546 (1.82%) | 550 (1.83%) |  |  |
| 否 | 189 (97.93%) | 29391 (98.18%) | 29580 (98.17%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 激素及有关药物-其他类 |  |  |  | Fisher's Exact Test for Count Data | 0.460 |
| 是 | 3 (1.55%) | 313 (1.05%) | 316 (1.05%) |  |  |
| 否 | 190 (98.45%) | 29624 (98.95%) | 29814 (98.95%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 抗休克血管活性药 |  |  |  | Fisher's Exact Test for Count Data | 0.196 |
| 是 | 2 (1.04%) | 125 (0.42%) | 127 (0.42%) |  |  |
| 否 | 191 (98.96%) | 29812 (99.58%) | 30003 (99.58%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 抗血小板药物 |  |  |  | Fisher's Exact Test for Count Data | 0.500 |
| 是 | 3 (1.55%) | 353 (1.18%) | 356 (1.18%) |  |  |
| 否 | 190 (98.45%) | 29584 (98.82%) | 29774 (98.82%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 免疫血清及血液制品 |  |  |  | Fisher's Exact Test for Count Data | 0.186 |
| 是 | 2 (1.04%) | 121 (0.40%) | 123 (0.41%) |  |  |
| 否 | 191 (98.96%) | 29816 (99.60%) | 30007 (99.59%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 调节血脂药及抗动脉粥样硬化药 |  |  |  | Fisher's Exact Test for Count Data | 0.778 |
| 是 | 2 (1.04%) | 524 (1.75%) | 526 (1.75%) |  |  |
| 否 | 191 (98.96%) | 29413 (98.25%) | 29604 (98.25%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 抗病毒药 |  |  |  | Fisher's Exact Test for Count Data | 0.689 |
| 是 | 2 (1.04%) | 264 (0.88%) | 266 (0.88%) |  |  |
| 否 | 191 (98.96%) | 29673 (99.12%) | 29864 (99.12%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 拟肾上腺素药 |  |  |  | Fisher's Exact Test for Count Data | 0.278 |
| 是 | 2 (1.04%) | 160 (0.53%) | 162 (0.54%) |  |  |
| 否 | 191 (98.96%) | 29777 (99.47%) | 29968 (99.46%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 全身麻醉用药 |  |  |  | Fisher's Exact Test for Count Data | 0.629 |
| 是 | 1 (0.52%) | 153 (0.51%) | 154 (0.51%) |  |  |
| 否 | 192 (99.48%) | 29784 (99.49%) | 29976 (99.49%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 外科用药及消毒防腐收敛药 |  |  |  | Fisher's Exact Test for Count Data | 0.203 |
| 是 | 2 (1.04%) | 128 (0.43%) | 130 (0.43%) |  |  |
| 否 | 191 (98.96%) | 29809 (99.57%) | 30000 (99.57%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 胃肠解痉药 |  |  |  | Fisher's Exact Test for Count Data | > 0.999 |
| 是 | 2 (1.04%) | 361 (1.21%) | 363 (1.20%) |  |  |
| 否 | 191 (98.96%) | 29576 (98.79%) | 29767 (98.80%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 疫苗 |  |  |  | Fisher's Exact Test for Count Data | > 0.999 |
| 是 | 2 (1.04%) | 373 (1.25%) | 375 (1.24%) |  |  |
| 否 | 191 (98.96%) | 29564 (98.75%) | 29755 (98.76%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 镇静催眠药及抗惊厥药 |  |  |  | Fisher's Exact Test for Count Data | 0.694 |
| 是 | 2 (1.04%) | 270 (0.90%) | 272 (0.90%) |  |  |
| 否 | 191 (98.96%) | 29667 (99.10%) | 29858 (99.10%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 治疗慢性心功能不全的药物 |  |  |  | Fisher's Exact Test for Count Data | 0.673 |
| 是 | 2 (1.04%) | 244 (0.82%) | 246 (0.82%) |  |  |
| 否 | 191 (98.96%) | 29693 (99.18%) | 29884 (99.18%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 骨骼肌松弛药 |  |  |  | Fisher's Exact Test for Count Data | 0.471 |
| 是 | 1 (0.52%) | 98 (0.33%) | 99 (0.33%) |  |  |
| 否 | 192 (99.48%) | 29839 (99.67%) | 30031 (99.67%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 激素类 |  |  |  | Fisher's Exact Test for Count Data | > 0.999 |
| 是 | 1 (0.52%) | 274 (0.92%) | 275 (0.91%) |  |  |
| 否 | 192 (99.48%) | 29663 (99.08%) | 29855 (99.09%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 甲状腺激素类药及抗甲状腺药物 |  |  |  | Fisher's Exact Test for Count Data | 0.498 |
| 是 | 1 (0.52%) | 106 (0.35%) | 107 (0.36%) |  |  |
| 否 | 192 (99.48%) | 29831 (99.65%) | 30023 (99.64%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 抗癲痫药 |  |  |  | Fisher's Exact Test for Count Data | 0.532 |
| 是 | 1 (0.52%) | 117 (0.39%) | 118 (0.39%) |  |  |
| 否 | 192 (99.48%) | 29820 (99.61%) | 30012 (99.61%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 抗震颤麻痹药 |  |  |  | Fisher's Exact Test for Count Data | 0.570 |
| 是 | 1 (0.52%) | 130 (0.43%) | 131 (0.43%) |  |  |
| 否 | 192 (99.48%) | 29807 (99.57%) | 29999 (99.57%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 药用附加剂 |  |  |  | Fisher's Exact Test for Count Data | 0.526 |
| 是 | 1 (0.52%) | 395 (1.32%) | 396 (1.31%) |  |  |
| 否 | 192 (99.48%) | 29542 (98.68%) | 29734 (98.69%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 诊断用药 |  |  |  | Fisher's Exact Test for Count Data | 0.096 |
| 是 | 1 (0.52%) | 709 (2.37%) | 710 (2.36%) |  |  |
| 否 | 192 (99.48%) | 29228 (97.63%) | 29420 (97.64%) |  |  |
| Missing | 0 | 0 | 0 |  |  |
| 周围血管扩张药 |  |  |  | Fisher's Exact Test for Count Data | 0.454 |
| 是 | 1 (0.52%) | 93 (0.31%) | 94 (0.31%) |  |  |
| 否 | 192 (99.48%) | 29844 (99.69%) | 30036 (99.69%) |  |  |
| Missing | 0 | 0 | 0 |  |  |

## 11.ADR系统分类

#### 严重不良反应描述

| **受试者唯一编号** | **不良事件开始时间** | **不良事件终止时间** | **结局** | **对原疾病的影响** | **soc\_name** | **pt\_name** |
| --- | --- | --- | --- | --- | --- | --- |
| KS007-47-0098 | 2014-11-03-08-05 | 2014-11-03-10-05 | 好转 | 影响不明显 | 心脏器官疾病 | 心悸 |
| KS013-151-388 | 2015-07-30-10-05 | 2015-07-30-10-15 | 好转 | 影响不明显 | 呼吸系统、胸及纵隔疾病 | 呼吸困难 |
| KS013-151-388 | 2015-07-30-10-05 | 2015-07-30-10-15 | 好转 | 影响不明显 | 免疫系统疾病 | 超敏反应 |

### SOC分类统计

#### ADR人群各soc系统下例次统计

**表 45: ADR人群SOC系统名称统计详表**

| soc\_name | 例次 | 例次占比 | 例数 | 例数占比 |
| --- | --- | --- | --- | --- |
| 胃肠系统疾病 | 101 | 46.76% | 98 | 50.78% |
| 全身性疾病及给药部位各种反应 | 41 | 18.98% | 39 | 20.21% |
| 皮肤及皮下组织类疾病 | 19 | 8.80% | 17 | 8.81% |
| 各类神经系统疾病 | 12 | 5.56% | 12 | 6.22% |
| 呼吸系统、胸及纵隔疾病 | 12 | 5.56% | 12 | 6.22% |
| 感染及侵染类疾病 | 6 | 2.78% | 6 | 3.11% |
| 心脏器官疾病 | 6 | 2.78% | 6 | 3.11% |
| 各类损伤、中毒及操作并发症 | 4 | 1.85% | 4 | 2.07% |
| 免疫系统疾病 | 4 | 1.85% | 4 | 2.07% |
| 血管与淋巴管类疾病 | 3 | 1.39% | 3 | 1.55% |
| 各类检查 | 2 | 0.93% | 2 | 1.04% |
| 精神病类 | 2 | 0.93% | 2 | 1.04% |
| 代谢及营养类疾病 | 1 | 0.46% | 1 | 0.52% |
| 耳及迷路类疾病 | 1 | 0.46% | 1 | 0.52% |
| 各种肌肉骨骼及结缔组织疾病 | 1 | 0.46% | 1 | 0.52% |
| 肾脏及泌尿系统疾病 | 1 | 0.46% | 1 | 0.52% |

*注：例次占比=(soc\_name/216)×100%,例数占比=(soc系统例数/193)×100%。*

#### soc\_name–pt\_name统计详表

**表 46: SOC-PT系统名称统计详表**

| **soc系统分类** | **pt诊断名称** | **AE人群中发生例数** | **在AE人群占比** | **ADR人群中发生例数** | **在ADR人群占比** |
| --- | --- | --- | --- | --- | --- |
| 胃肠系统疾病:例数1662(26.47%) | 恶心 | 309 | 4.921% | 28 | 12.963% |
| 呕吐 | 355 | 5.654% | 28 | 12.963% |
| 胃肠疾病 | 307 | 4.889% | 27 | 12.500% |
| 腹痛 | 91 | 1.449% | 5 | 2.315% |
| 腹胀 | 96 | 1.529% | 4 | 1.852% |
| 腹泻 | 110 | 1.752% | 3 | 1.389% |
| 腹部不适 | 41 | 0.653% | 2 | 0.926% |
| 胃食管反流病 | 55 | 0.876% | 2 | 0.926% |
| 便秘 | 103 | 1.640% | 1 | 0.463% |
| 消化不良 | 24 | 0.382% | 1 | 0.463% |
| 全身性疾病及给药部位各种反应:例数837(13.33%) | 乏力 | 201 | 3.201% | 14 | 6.481% |
| 胸部不适 | 121 | 1.927% | 10 | 4.630% |
| 寒战 | 28 | 0.446% | 5 | 2.315% |
| 发热 | 155 | 2.469% | 4 | 1.852% |
| 高热 | 79 | 1.258% | 3 | 1.389% |
| 疼痛 | 228 | 3.631% | 3 | 1.389% |
| 胸痛 | 26 | 0.414% | 2 | 0.926% |
| 口渴 | 0 | 0.000% | 1 | 0.463% |
| 皮肤及皮下组织类疾病:例数98(1.56%) | 皮疹 | 18 | 0.287% | 10 | 4.630% |
| 瘙痒症 | 44 | 0.701% | 7 | 3.241% |
| 多汗 | 8 | 0.127% | 2 | 0.926% |
| 各类神经系统疾病:例数310(4.94%) | 头晕 | 85 | 1.354% | 10 | 4.630% |
| 头痛 | 36 | 0.573% | 2 | 0.926% |
| 呼吸系统、胸及纵隔疾病:例数510(8.12%) | 咳嗽 | 201 | 3.201% | 7 | 3.241% |
| 呼吸困难 | 85 | 1.354% | 2 | 0.926% |
| 咳痰 | 20 | 0.319% | 1 | 0.463% |
| 口咽不适感 | 9 | 0.143% | 1 | 0.463% |
| 口咽疼痛 | 28 | 0.446% | 1 | 0.463% |
| 感染及侵染类疾病:例数271(4.32%) | 感染性肺炎 | 128 | 2.039% | 2 | 0.926% |
| 尿路感染 | 23 | 0.366% | 2 | 0.926% |
| 鼻咽炎 | 23 | 0.366% | 1 | 0.463% |
| 上呼吸道感染 | 30 | 0.478% | 1 | 0.463% |
| 心脏器官疾病:例数127(2.02%) | 心悸 | 66 | 1.051% | 5 | 2.315% |
| 室上性心动过速 | 0 | 0.000% | 1 | 0.463% |
| 各类损伤、中毒及操作并发症:例数20(0.32%) | 输液相关反应 | 8 | 0.127% | 4 | 1.852% |
| 免疫系统疾病:例数9(0.14%) | 超敏反应 | 9 | 0.143% | 4 | 1.852% |
| 药物性超敏反应 | 3 | 0.048% | 1 | 0.463% |
| 血管与淋巴管类疾病:例数45(0.72%) | 潮红 | 5 | 0.080% | 3 | 1.389% |
| 各类检查:例数805(12.82%) | 白细胞计数降低 | 400 | 6.370% | 2 | 0.926% |
| 精神病类:例数28(0.45%) | 精神疲劳 | 1 | 0.016% | 1 | 0.463% |
| 意识模糊状态 | 8 | 0.127% | 1 | 0.463% |
| 代谢及营养类疾病:例数293(4.67%) | 摄食量减少 | 30 | 0.478% | 1 | 0.463% |
| 耳及迷路类疾病:例数4(0.06%) | 耳部不适 | 0 | 0.000% | 1 | 0.463% |
| 各种肌肉骨骼及结缔组织疾病:例数112(1.78%) | 肌无力 | 13 | 0.207% | 1 | 0.463% |
| 肾脏及泌尿系统疾病:例数56(0.89%) | 排尿迟缓 | 1 | 0.016% | 1 | 0.463% |

## 12.ADR转归/对原疾病的影响/不良事件与使用复方苦参注射液关联性评估

  下表统计216例次不良反应的

**表 47: ADR转归/对原疾病的影响/不良事件与使用复方苦参注射液关联性评**

| **变量** | **总计 (N=216)** |
| --- | --- |
| AE转归 |  |
| 好转 | 122 (56.48%) |
| 其他 | 1 (0.46%) |
| 痊愈 | 78 (36.11%) |
| 治疗中 | 15 (6.94%) |
| Missing | 0 |
| 对原疾病的影响 |  |
| 病程延长 | 2 (0.93%) |
| 病情加重 | 2 (0.93%) |
| 无影响 | 132 (61.11%) |
| 影响不明显 | 80 (37.04%) |
| Missing | 0 |
| 不良事件与使用复方苦参注射液关联性评估 |  |
| 很可能有关 | 30 (13.89%) |
| 可能有关 | 186 (86.11%) |
| 可能无关 | 0 (0.00%) |
| 无法评价 | 0 (0.00%) |
| Missing | 0 |